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Several Gram-negative bacteria modify their outer most surface structure, 
lipopolysaccharide (LPS), to evade immune surveillance and survive within the 
host. Many of these changes occur within the lipid A domain, a region that is 
recognized by the innate immune system via Toll-like receptor-4 (TLR4). One 
such pathogen, Porphyromonas gingivalis, orchestrates chronic inflammatory 
disease by disrupting immune homeostasis. P. gingivalis initially synthesizes a 
penta-acylated lipid A that functions as a weak TLR4 agonist but displays tetra-
acylated forms that are either immunologically silent or TLR4 antagonists. The 
impact of lipid A modifications on downstream signaling and antigen-specific 
immunity are unclear.  
 
TLR4 signals from the plasma membrane through a MyD88-dependent pathway 
and intracellularly through a TRIF-dependent pathway. Here we show that 
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expression of immunological silent or antagonistic lipid A enables P. gingivalis to 
evade TRIF-dependent signaling in dendritic cells (DCs). Evasion of TRIF 
signaling accelerated antigen degradation and impaired priming of pathogen-
specific T cells. In contrast, a P. gingivalis strain expressing agonist lipid A 
potently activated TRIF signaling and delayed antigen degradation, thereby 
preserving peptides for optimal T cell activation. We propose that lipid A 
modifications control the endocytic activity of DCs and the efficiency at which 
microbe-specific T cells are primed. 
 
We next investigated the impact of purified P. gingivalis LPS on innate signaling 
and antigen presentation. All P. gingivalis LPS species induced a program of DC 
maturation that allowed for constitutive antigen uptake and cross-presentation. 
This was independent of TLR4 agonist activity and required CD14, a protein that 
transports TLR4 to endosomes where TRIF signaling can occur. Agonist LPS 
induced signaling through both MyD88 and TRIF and elicited T cell priming. 
Antagonistic LPS potently accelerated CD14 endocytosis and induced TRIF-
biased signaling leading to comparable degree of cross-priming. Immunologically 
silent LPS promoted CD14 endocytosis but failed to activate signaling and 
induced T cell tolerance. Collectively, our results demonstrate that modification of 
lipid A structure enables Gram-negative bacteria to direct the host immune 
system towards tolerance or immunity. We propose that these findings can be 
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harnessed for therapeutic modulation of the immune system to treat a variety of 
immune-mediated diseases.   
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Chapter 1. Introduction 
The Architecture of the Mammalian Immune System 
A remarkable feature of the mammalian immune system is its capacity to mount 
responses to virtually any antigen that it may encounter. This property ensures 
host survival in the face of constant challenges imposed by rapidly evolving 
pathogens, genetically altered versions of self, and a variety of harmful 
substances. At the same time, immune responses must be carefully balanced to 
prevent unwanted reactions toward self-tissue, commensal organisms, and 
innocuous environmental antigens. Loss of the delicate balance between 
tolerance and immunity underlies the etiology of autoimmune, inflammatory, 
allergic, and neoplastic diseases.  
 
The mammalian immune system is comprised of two separate but interrelated 
arms—innate and adaptive immunity. The innate immune system recognizes 
conserved microbial structures and endogenous products of tissue damage 
through a limited set of germ-line encoded pattern recognition receptors (PRRs) 
(Takeuchi and Akira 2010). PRRs enable the innate immune system to 
distinguish between different classes of microorganisms such as viruses, 
bacteria, and fungi (Takeuchi and Akira 2010). They recognize molecules that 
are vital to the survival and replication of these microbes, and are therefore 




detection of microbial components, trigger rapid inflammatory responses for 
immediate control of infection. 
 
In contrast to germ-line encoded PRRs, the antigen recognition receptors of the 
adaptive immune system are randomly generated through the process of somatic 
recombination. The outcome of this process is a receptor repertoire capable of 
recognizing billions of different targets in a highly specific manner. What this 
means is that there is an extremely high probability that the adaptive immune 
system will be able to recognize an antigen from any given infectious agent that it 
may encounter in the future. Unlike innate immunity, which is present at birth and 
constitutively active, the adaptive immune system takes time to develop. Primary 
immune responses against pathogens typically develop 4-7 days after the initial 
exposure. Fortunately, the adaptive immune system is equipped with memory. 
Immunological memory enables immune responses to occur more rapidly upon 
secondary exposure to that same pathogen, and often confers lifetime protection. 
Thus, the hallmarks of the adaptive immune system are diversity, specificity, and 
memory. 
 
Adaptive immunity is based on two main types of lymphocytes, T cells and 
antibody-producing B cells. Each has its own specialized type of receptor that 
enables recognition of specific antigens: T-cell receptors (TCR) and B-cell 




in adaptive immunity. BCRs recognize portions of extracellular molecules that 
typically retain their native, three-dimensional conformations. In contrast, TCRs 
have evolved to recognize the products of partially degraded antigens generated 
by intracellular proteolysis. Specifically, they recognize peptides derived from 
antigens inside cells that have been bound to major histocompatibility complex 
(MHC) molecules, which enables their transport from intracellular locations up to 
the cell surface. There are two classes of MHC molecules, which differ in the 
source of the peptides they capture and transport to the cell surface. Proteins 
synthesized in the cytosol and degraded by the proteasome are the major source 
of peptides for MHC-I molecules. MHC-II molecules bind peptides derived from 
extracellular proteins that are located within endocytic compartments. These 
peptides are generated by the action of vacuolar proteolytic enzymes. Antigen-
specific activation of T cells is facilitated by co-receptors that distinguish between 
the two classes of MHC molecules. T cells with specificity for MHC-I molecules 
express the co-receptor CD8 and mount cytotoxic immune responses upon 
encountering their cognate ligand. T cells with specificity for MHC-II molecules 
express the co-receptor CD4 and form helper T cells.  
 
Despite the breadth and specificity of the adaptive immune system, the initiation 
of T cell immunity is rather demanding. Although somatic recombination 
generates a vastly diverse T cell repertoire, the number of T cells that recognize 




numbers of T cells that have never before encountered their cognate peptide-
MHC ligand to find the infected cells in the body. These naïve T cells need to be 
activated and greatly expanded before they can reach a critical mass to function 
effectively. Because TCRs are randomly generated and not hard-wired to 
discriminate between self and non-self, the T cells need to be instructed on the 
origin of the presented peptide to respond appropriately. To solve these 
problems, the immune system makes use of specialized antigen presenting cells 
(APCs) called dendritic cells (DCs) (Figure 1). Located in peripheral tissue, DCs 
capture and process antigens, and display high levels of peptide-MHC 
complexes at their cell surface (Banchereau and Steinman 1998). They 
upregulate co-stimulatory molecules and migrate to T cell areas of lymphoid 
organs, where naïve T cells are concentrated. Here, they locate and activate rare 
T cell clones. All of these activities can be induced upon engagement of PRRs by 
microbial components, and DCs integrate these context-dependent cues to 
properly educate T cells (Ralph M. Steinman and Banchereau 2007). Not only do 
DCs initiate immunity to harmful agents, they also tolerize T cells to self- and 













































Figure 1. DCs bridge innate and adaptive immunity.  
The innate immune system recognizes conserved microbial structures through a 
relatively limited set of germ-line encoded PRRs. The antigen-recognition 
receptors of the adaptive immune system are generated through somatic 
recombination and are capable of recognizing billions of different targets. B cells 
secrete antibodies that can bind and neutralize pathogens before they enter 
cells, providing prophylactic immunity. T cells recognize peptides derived from 
antigens inside cells that are bound to host MHC molecules and are uniquely 
equipped to provide therapeutic immunity after infection has occurred. The 
frequency of T cells that recognize any given antigen is low, and these cells need 
to be expanded and educated on the origin of the antigen they recognize before 
they can function effectively. DCs sample peripheral tissues, surveying the 
environment for pathogens with a collection of PRRs. Upon microbial detection, 
they migrate to lymph nodes where naïve T cells are concentrated, and select 
rare T cell clones for expansion. They use the information they obtained through 
PRRs to properly educate T cells. Moreover, they also tolerize T cells to antigens 
that are innate to the body. In this way, DCs bridge innate and adaptive 




Innate Immunity and Pattern Recognition 
The PRRs of the innate immune system are structural diverse proteins that are 
grouped functionally by their ability to detect conserved microbial structures or 
microbe-associated molecular patterns (MAMPs) (Iwasaki and Medzhitov 2015). 
To date, six families of PRRs have been identified based on common structural 
and functional domains: Toll-like receptors (TLRs), C-type lectin receptors 
(CLRs), RIG-I-like receptors (RLRs), AIM-like receptors (ALRs), Nod-like 
receptors (NLRs), and OAS-like receptors (OLRs) (Iwasaki and Medzhitov 2015). 
These families can be further divided into membrane-bound receptors (TLRs, 
CLRs) and cytosolic sensors (RLRs, ALRs, NLRs, and OLRs) based upon their 
subcellular locations (Brubaker et al. 2015). The molecules recognized by PRRs 
are diverse and include complex polysaccharides, glycolipids, lipoproteins, and 
nucleic acids.  
 
Toll-like Receptors  
TLRs are type I transmembrane proteins that contain three distinct structural 
domains: (1) a ligand binding ectodomain containing the leucine-rich repeat 
(LRR) motif, (2) a transmembrane domain, and (3) a cytosolic Toll/IL-1 receptor 
(TIR) domain that binds downstream adaptor proteins to mediate signaling (Taro 
Kawai and Akira 2010). To date, 13 mammalian TLRs have been identified (10 in 
humans and 12 in mice), allowing for the detection of a variety of microbial 




cellular localization. Certain TLRs (TLR1, -2,- 4, -5, -6, and -10) primarily localize 
to the plasma membrane where they recognize microbial surface structures.  
Other TLRs (TLR3, 7-9, 11-13) are located almost exclusively in intracellular 
compartments, including endosomes and lysosomes, where they sense microbial 
nucleic acids and components of intracellular parasites (Brubaker et al. 2015; 
Takeuchi and Akira 2010). Although TLRs recognize discrete microbial patterns, 
these receptors share a common structural framework in their ligand binding 
domains. These domains all adopt a horseshoe-shaped structure (Botos, Segal, 
and Davies 2011). Upon ligand binding, two extracellular domains form an “m”-
shaped dimer, triggering downstream signal transduction (Botos, Segal, and 
Davies 2011). Thus, ligand-induced dimerization represents a common means of 
activating TLR signaling.  
 
Following activation, TLR signaling is propagated through the recruitment of one 
or more TIR-domain containing adaptor proteins to the cytosolic TIR domain of 
TLRs. In most cases (with the exception of TLR3), a sorting adaptor called 
TIRAP senses dimerized TLRs through interactions between the TIR domains 
present in each of these proteins. These TIR-TIR interactions promote the 
assembly of a higher-order structure called the myddosome, which consists of 
the signaling adaptor MyD88 and several IRAK family kinases (Lin, Lo, and Wu 
2010). The myddosome initiates signaling events that activate mitogen activated 




NF-kB (Kagan, Magupalli, and Wu 2014). This leads to the production of 
cytokines that promote inflammation and chemokines that recruit immune cells. 
TLR3 and TLR4 are capable of recruiting another sorting adaptor, TRAM, and 
the signaling adaptor TRIF, to induce downstream activation of the transcription 
factor IRF3 and the expression of expression of type I interferon (IFNβ) (Kagan et 
al. 2008). 
 
Toll-like Receptor-4  
As the prototype of the mammalian TLR family, TLR4 detects lipopolysaccharide 
(LPS), the major outer membrane component of Gram-negative bacteria 
(Poltorak et al. 1998; Tan and Kagan 2017). TLR4 is unique among TLRs in that 
it requires an accessory molecule, MD-2, to capture its ligand. MD-2 is a 
secreted protein that associates with the extracellular domain of TLR4 (Shimazu 
et al. 1999). It is the principal LPS binding component of the TLR4/MD-2 complex 
and is required to dimerize TLR4 and initiate signaling (Shimazu et al. 1999). 
Two key accessory molecules, LPS binding protein (LBP) and CD14, make LPS 
transfer to TLR4/MD-2 as efficient as possible (Gioannini et al. 2004a). The LPS 
transfer cascade begins with LBP, which extracts LPS monomers from the 
bacterial membrane or soluble micelles and transfers them to CD14. 
Subsequently, CD14 delivers LPS to TLR4-bound MD-2, an event that dimerizes 
the TLR4 complex and initiates a MyD88-dependent signaling pathway from the 




cytokine production (Horng et al. 2002). CD14 also coordinates the endocytosis 
of the activated TLR4 complex (i.e. dimerized) (Tan et al. 2015a; Zanoni et al. 
2011).  From endosomes, TLR4 engages a second signaling adaptor, TRIF, 
leading to the activation of the transcription factor IRF3 and the expression of 
type I interferon (IFNβ) (Kagan et al. 2008). 
 
TLR4 activation elicits a robust inflammatory response that is crucial for 
pathogen clearance. This inflammatory response can be severe, resulting in 
tissue damage, organ failure, and lethal septic shock (Beutler 2009). Severe 
reactions to LPS have been attributed to activation of the pro-inflammatory 
MyD88-dependent signaling pathway. Activation of the TRIF pathway is not 
associated with lethality but is necessary for the initiation of adaptive immune 
responses (Mata-Haro et al. 2007). For example, TRIF deficiency in mice 
substantially impairs T cell priming, whereas MyD88 deficiency has little effect on 
this process (Mata-Haro et al. 2007; Gandhapudi, Chilton, and Mitchell 2013). 
This impairment is partly due to the fact that TRIF is required for activation of 
IRF3 and downstream IFNβ production, which is crucial for the T cell adjuvant 
activity of several TLR agonists, including TLR4 (Kolb et al. 2014; Le Bon et al. 
2006). These findings highlight the importance of the endosome-specific 




CD14   
CD14 was originally identified as a high-affinity LPS-binding protein that 
sensitizes mammalian cells to low doses of LPS (Frey et al. 1992). It is 
expressed on the surface of myeloid cells, where it is anchored to the plasma 
membrane via a C-terminal glycosylphosphatidylinositol (GPI) tail (Haziot et al. 
1988). A soluble form of CD14 that lacks its GPI membrane anchor is secreted 
into serum and confers LPS responsiveness to CD14-negative cells (Frey et al. 
1992). The importance of CD14 in LPS sensing is underscored by the finding that 
CD14-deficient mice are resistant to doses of LPS that are lethal to wild-type 
mice (Haziot et al. 1996).  
 
CD14 mediates efficient LPS transfer to TLR4/MD-2 and is necessary for 
MyD88-dependent signaling at low doses of LPS (Zanoni et al. 2011; Moore et 
al. 2000). CD14 also controls the LPS-induced endocytosis of TLR4, a process 
that is necessary for TRIF-mediated signal transduction (Zanoni et al. 2011). 
Notably, only cells that express membrane CD14 are capable of promoting TLR4 
endocytosis in response to LPS, regardless of the presence or absence of 
soluble CD14 (Zanoni et al. 2011). Thus, while diverse cell types are responsive 




TLR4-independent responses to LPS 
Perhaps the most notable feature of LPS-induced TLR4 endocytosis is that it 
does not depend on TLR4 signal transduction (Tan and Kagan 2014). Cells 
lacking both MyD88 and TRIF retain the capacity to internalize TLR4 in response 
to LPS, as do signaling deficient TLR4 mutants (Zanoni et al. 2011). Mutational 
analysis revealed that the cytosolic tail of TLR4 was also dispensable for 
endocytosis, indicating that TLR4 is selected as cargo for CD14-dependent 
endocytosis entirely through extracellular interactions (Tan et al. 2015a). Indeed, 
MD-2 was subsequently identified as the cargo selection agent for TLR4 
endocytosis (Tan et al. 2015a). Mechanistically, MD-2 bound to and dimerized 
TLR4 to promote its entry into the cell (Tan et al. 2015a). These studies revealed 
that receptor proximal events play a dominant role in controlling TLR4 signaling 
from both the cell surface and endosomal compartment (Figure 2A). 
 
Notably, CD14 is not immobile at the plasma membrane but rather, undergoes a 
constitutive rate of endocytosis that is accelerated upon LPS binding (Figure 2A) 
(Tan et al. 2015a) . The constitutive endocytosis pathway is not associated with 
inflammation. Dimerization of TLR4 by MD-2 converts the normally silent entry 
route taken by CD14, into an inflammatory endocytosis pathway that transports 
TLR4 to endosomes (Tan et al. 2015a). CD14-dependent endocytosis results in 
the internalization of TLR4, CD14, and LPS (Kagan et al. 2008; Zanoni et al. 




and TLR4-deficient mice, indicating that TLR4 is merely cargo for an LPS-
inducible event mediated by CD14 (Zanoni et al. 2009; Latz et al. 2002). 
Consistent with this, CD14 also promotes the endocytosis of modified host lipids 
(oxPAPC) independent of TLR4 (Zanoni et al. 2017).  
 
Recent studies have revealed additional TLR4-independent responses to LPS 
that occur selectively in DCs. In DCs, LPS induces the expression of several 
genes that are not expressed in macrophages, including IL-2, Nur77, and 
mPGES-1 (Zanoni et al. 2012).  The products of these genes regulate processes 
that distinguish DC and macrophage functions, namely the activation of naïve of 
T cells. Their expression is dependent on NF-kB and the calcium-regulated 
transcription factors of the NFAT family (Zanoni et al. 2009). Whereas TLR4 can 
induce NF-kB activation, it cannot activate NFAT or induce calcium fluxes 
(Zanoni et al. 2009). The latter two activities are dependent on CD14, and occur 
normally in TLR4-deficient DCs (Zanoni et al. 2009). Thus, CD14 activates a set 
of responses that are required to promote the expression of genes that control 

















































































Figure 2. Receptor proximal activities control TLR4 signaling. 
Although TLR4 is required for transcriptional responses to LPS, its signaling 
functions are controlled by receptor proximal events mediated by CD14 and MD-
2 (Tan et al. 2015a). First, CD14 delivers LPS to TLR4/MD-2. MD-2 is the 
principal LPS binding component of the TLR4/MD-2 complex, and it mediates 
TLR4 dimerization, to initiate MyD88 signaling from the plasma membrane 
(Shimazu et al. 1999; Viriyakosol et al. 2001). The endocytosis of TLR4, which is 
required for TRIF signaling, is controlled by CD14 (Zanoni et al. 2011). Notably, 
CD14 is on a constitutive endocytosis pathway that is accelerated by LPS, a 
process that proceeds independently of TLR4 (Tan et al. 2015a). Thus, TLR4 is 
merely cargo for an LPS-inducible event mediated by CD14. Dimerization of 
TLR4 by MD-2 promotes its selection as cargo for endocytosis, and converts the 
silent entry route taken by CD14, into an inflammatory endocytosis pathway (Tan 




P. gingivalis mediated periodontal disease as a paradigm for microbiota-
driven immune dysfunction  
Recent studies have emphasized the importance of the microbiome in health and 
disease, revealing a critical role for commensal bacteria in the development and 
homeostasis of the mammalian immune system. Adverse alterations in microbial 
communities (dysbiosis) are emerging as potential triggers for systemic and 
mucosal inflammatory disorders including inflammatory bowel disease, 
rheumatoid arthritis, diabetes, and periodontal disease (Round and Palm 2018; 
Darveau 2010). Periodontal disease is a microbiota-driven chronic inflammatory 
disease that leads to the destruction of tooth-supporting tissue and exerts an 
adverse impact on systemic health (Darveau 2010; Pihlstrom, Michalowicz, and 
Johnson 2005; Hajishengallis 2015). Reports from the Centers for Disease 
Control and Prevention estimate that nearly half (47.2%) of American adults aged 
30 years and older have some form of periodontal disease making it a significant 
public health concern (Eke et al. 2012). The financial burden of oral disease is 
estimated to be in excess of $100 billion annually (Eke et al. 2012). Periodontal 
disease is initiated and propagated by dysbiosis of the oral microbiota, which 
includes an overall increase in the subgingival microbial load and altered 
composition (Pihlstrom, Michalowicz, and Johnson 2005). It is believed that 





Animal models support a role for infection with periodontal pathogens as a trigger 
for dysbiosis, with Porphyromonas gingivalis being a well-documented example 
(Hajishengallis et al. 2011). P. gingivalis is regarded as a keystone pathogen, a 
low abundance organism that can orchestrate inflammatory disease by disrupting 
immune homeostasis (Hajishengallis, Darveau, and Curtis 2012). This leads to 
remodeling of the normally benign commensal microbiota into a dysbiotic one 
(Hajishengallis, Darveau, and Curtis 2012). In mice, P. gingivalis subverts host 
immune defenses promoting its own survival and the outgrowth of a disease-
provoking commensal flora that drive inflammatory oral bone destruction 
(Hajishengallis et al. 2011). Notably, P. gingivalis fails to induce disease in the 
absence of the commensal flora (Hajishengallis et al. 2011). Thus, although P. 
gingivalis is necessary to precipitate disease, immunopathology is ultimately 
driven by aberrant immune responses toward an altered community of 
commensal bacteria (Hajishengallis et al. 2011). In addition to local 
immunopathology, clinical and experimental evidence implicate P. gingivalis as a 
risk factor for a number of systemic diseases characterized by misdirected 
immune responses, including diabetes, rheumatoid arthritis, atherosclerosis, and 
certain cancers (Hajishengallis 2015; Ahn, Segers, and Hayes 2012; Gao et al. 
2016; Hayashi et al. 2012; Slocum et al. 2014; Hayashi et al. 2011a). These 
diseases are driven by imbalances in the effector and regulatory arms of the 






Alterations in bacterial communities have been documented in nearly all known 
immune-mediated disorders (Round and Palm 2018). Yet, a cogent hypothesis 
for how resident microbes might increase the risk for aberrant immune responses 
has not been put forth. Recent studies have shown that DCs isolated from P. 
gingivalis infected mice constitutively prime T cells of irrelevant specificity (Mizraji 
et al. 2017). P. gingivalis lipid A structures are similar to those observed in 
Bacteroides doreii, an intestinal commensal recently linked to the onset of 
allergic and autoimmune disease in children (Vatanen et al. 2016). These 
observations suggest that the lipid A species expressed by these organisms may 






The Outer Membrane of Gram-negative Bacteria  
The outer membrane (OM) of Gram-negative bacteria is an asymmetric bilayer 
with the inner leaflet composed of phospholipids and the outer leaflet composed 
of lipopolysaccharide (LPS) (Figure 3)  (Raetz and Whitfield 2002). As an 
integral membrane component, LPS contributes to structural integrity, assists in 
OM protein folding, and provides a selective permeability barrier that shields 
Gram-negative bacteria from their unpredictable and often hostile surroundings 
(Raetz et al. 2007). In light of these important functions, it is not surprising that 
LPS is essential for the growth and survival of nearly all Gram-negative 
organisms (Raetz and Whitfield 2002). LPS is typically comprised of three 
domains: lipid A, the core oligosaccharide, and the O antigen (Figure 3) (Raetz 
and Whitfield 2002). Lipid A is the structurally conserved region that is required 
for microbial viability (Raetz et al. 2007). It serves to anchor LPS to the OM and 
is recognized by the innate immune system via TLR4/MD-2.  
 
Like most OM components, lipid A is assembled at the cytoplasmic face of the 
inner membrane (IM) and must be transported across the IM and through the 
periplasmic space to reach the cell surface (Raetz et al. 2007). It is initially 
synthesized as a β-1’,6-linked disaccharide of glucosamine that is both 
phosphorylated and fatty acylated (Needham and Trent 2013). In the case of 
Escherichia coli LPS, the lipid A backbone consists of two phosphorylated 




Kagan 2014) (Figure 3). This configuration optimally activates TLR4/MD-2, 
provoking a robust inflammatory response that is crucial for clearance of infection 
but can be potent enough to induce lethal endotoxic shock (Beutler 2009). 
  
As lipid A is required for bacterial growth, the genes involved in its biosynthesis 
are highly conserved among Gram-negative bacteria, and most organisms 
produce lipid A molecules resembling that of E. coli (Raetz and Whitfield 2002). 
However, the structure of lipid A can be extensively modified during and after 
transit to the cell surface (Raetz et al. 2007). This is achieved through the use of 
diverse lipid A modification enzymes that add or remove chemical moieties to the 
molecule. Alterations to lipid A structure are observed with respect to acyl chain 
length, number, and positioning, as well as the number and position of phosphate 
groups (Clett Erridge, Bennett-Guerrero, and Poxton 2002).  Such modifications 
can weaken or abolish TLR4 signaling and can influence preferential usage of 
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Figure 3. The cell envelope of Gram-negative bacteria. 
Top panel: The cell envelope of Gram-negative bacteria is comprised of an inner 
and outer membrane separated by an intervening periplasmic space containing 
peptidoglycan. Both leaflets of the IM are composed of phospholipids. The OM is 
an asymmetric bilayer with phospholipids confined to the inner leaflet and LPS 
anchored to the outer leaflet. LPS is comprised of three domains: the lipid A 
anchor, the core oligosaccharide, and the O antigen (Raetz and Whitfield 2002). 
The enzymes involved in the constitutive pathway for lipid A biosynthesis are 
conserved among Gram-negative organisms and are confined to the cytoplasmic 
face of the IM. Lipid A modification enzymes vary among different species of 
bacteria and are typically located on the periplasmic face of the IM or within the 





Lipid A modifications promote survival in the host 
Modification of lipid A is a common virulence strategy employed by pathogenic 
bacteria to evade innate immune responses and persist within the host (Raetz et 
al. 2007). Many innate immune effectors that target lipid A, such as cationic 
antimicrobial peptide (CAMPs) and complement proteins, rely on charge-
dependent binding (Giangrande et al. 2013). By changing the overall charge of 
the bacterial surface, through removal of lipid A phosphate groups or the addition 
of chemical moieties that mask the negative charge, resistance to these effectors 
increases. Second, changes in the structure of lipid A directly impact recognition 
by the TLR4/MD-2 complex (Maeshima and Fernandez 2013). Unmodified E. coli 
lipid A, which contains six acyl chains and two phosphates groups, is optimally 
detected by TLR4/MD-2. Bacteria can remove acyl chains and phosphate groups 
to weaken or abolish TLR4 signaling. Lastly, lipid A modifications can alter outer 
membrane permeability, rendering bacteria resistant to harsh pH and antibiotics, 
as well as other stressors (Li et al. 2012).  
 
In many cases, lipid A modifications are only necessary for a particular stage of 
the bacterial life cycle, and the enzymes responsible for these modifications are 
induced or repressed in response to specific growth conditions (Raetz et al. 
2007). This is particularly true for bacteria that are transmitted through 
environmental reservoirs or those that are capable of colonizing multiple hosts 




occur constitutively in organisms that stably colonize a singular ecological niche 
(Coats et al. 2009; T. W. Cullen et al. 2015; Thomas W. Cullen et al. 2011). 
Below we discuss several examples that illustrate this point.  
Evasion of host immunity by Yersinia pestis  
Yersinia pestis is the causative of agent of bubonic plague, a disease that killed a 
third of the European population in the 14th century (Raoult et al. 2000). Y. pestis 
is a zoonotic bacterium that is transmitted to humans when they are bitten by 
fleas that have fed on an infected animal (Chouikha and Hinnebusch 2012). In 
the gut of the flea, Y. pestis grows at a temperature between 21-27 °C and 
produces a hexa-acylated lipid A that is structurally similar to E. coli lipid A 
(Figure 4A) (Rebeil et al. 2006). When transmitted to the human host, the 
bacterium senses a shift in temperature (from 21-27 °C to 37 °C) and 
synthesizes a tetra-acylated lipid A that functions as a TLR4 antagonist (Figure 
4B) (Rebeil et al. 2006). Expression of the tetra-acylated form of lipid A is 
believed to allow this pathogen to proliferate undetected in the bloodstream 
during the initial stages of infection (Telepnev et al. 2009; Needham and Trent 
2013). Genetically modified strains that produce hexa-acylated lipid A at 37 °C 
potently stimulate TLR4 signaling in reporter cell lines and fail to establish 
systemic infection in mice (Montminy et al. 2006). Notably, the protective effect 




as the engineered strain retained the capacity to kill TLR4-deficient mice, as well 



































































































Figure 4. Evasion of host immunity by Yersinia pestis  
(A) When residing in the gut of the flea vector, the plague bacillus Y. pestis 
produces an endotoxic hexa-acylated lipid A (Montminy et al. 2006). (B) Upon 
transmission to the human host, the bacterium senses a change in temperature 




Evasion of host immunity by Helicobacter pylori  
The caustic environment of the human stomach is the sole niche for Helicobacter 
pylori, an organism that colonizes half the world’s population and can persist for 
decades within a single host (Hooi et al. 2017). Infection manifests itself in a 
variety of clinical outcomes ranging from mild gastritis to severe diseases, 
including peptic ulcers and gastric cancer (Kim et al. 2011). Like most Gram-
negative bacteria, H. pylori initially synthesizes a bis-phosphorylated, hexa-
acylated lipid A but through the constitutive action of several lipid A modification 
enzymes, a tetra-acylated form lacking the 4’-phosphate group and substituted at 
the C-1 position with phosphoethanolamine is displayed at the cell surface 
(Figure 5A) (Cullen et al. 2011). These enzymes include the deacylase LpxR 
and the lipid A 1- and 4’-phosphatases, LpxE and LpxF, respectively (Cullen et 
al. 2011). Removal of the lipid A phosphates by LpxE and LpxF reduces the 
negative charge on the bacterial membrane and inhibits charge-dependent 
binding of CAMPs, which are present at high levels in the gastric mucosa (Cullen 
et al. 2011). The reduced acylation and phosphorylation of lipid A also facilitate 
evasion of TLR4 signaling. When LpxE and LpxF are inactivated through 
mutagenesis, H. pylori produces a hexa-acylated, bis-phosphorylated lipid A that 
functions as a potent TLR4 agonist (Figure 5B) (Cullen et al. 2011). The mutant 
strain exhibits increased sensitivity to CAMPS, and is unable to colonize the 
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Figure 5. Evasion of host immunity by Helicobacter pylori.  
(A) H. pylori constitutively modifies lipid A to a form that resists killing by CAMPs 
and evades TLR4 signaling. The modified molecule is tetra-acylated substituted 
at the C-1 position with phosphoethanolamine and is silent at TLR4. (B) Deletion 
of LpxE and LpxF results in a mutant that produces a hexa-acylated, bis-




Evasion of host immunity by Porphyromonas gingivalis 
The gingival crevice is the sole niche for Porphyromonas gingivalis, and the 
bacterium is so well adapted to this environment it is colonizes nearly ~50% of 
the population and can persist for long periods of time before (and after) 
expressing pathogenicity. To maintain its subgingival lifestyle and remain 
undetected, P. gingivalis employs two constitutive lipid A mediated evasion 
strategies: repulsion of CAMPs and evasion of TLR4 signaling. P. gingivalis 
initially synthesizes a penta-acylated, bis-phosphorylated lipid A  (Figure 6A) but 
displays a tetra-acylated molecule lacking both phosphate groups at the bacterial 
surface (Figure 6B). This lipid A is immunologically silent at the TLR4 complex 
and renders P. gingivalis resistant to killing by CAMPs.  The striking difference 
between the originally synthesized lipid A and the surface exposed molecule is 
due to the constitutive action of several lipid A modification enzymes, which 
include an unidentified deacylase and the lipid A 1- and 4’-phosphatases, LpxE 
and LpxF, respectively. In the presence of excess hemin, the activity of the 1-
phosphatase is suppressed, resulting in the expression of a tetra-acylated, 
mono-phosphorylated lipid A that functions as TLR4 antagonist (Figure 6C). It 
has been postulated that hemin-dependent regulation of lipid A 1-
dephosphorylation can shift P. gingivalis lipid A activity from TLR4 evasive to 
TLR4 suppressive, potentially altering critical interactions between this 





The use of P. gingivalis lipid A mutants has shed led light on the role of defined 
lipid A structures in the induction of local and systemic immunopathology. 
Genetic deletion of the 1-phosphatase activity (PG1773) results in a strain of P. 
gingivalis that expresses tetra-acylated, mono-phosphorylated lipid A and 
behaves as a “locked” TLR4 antagonist (Slocum et al. 2014; Coats et al. 2009). A 
mutant lacking 4’-phosphatase activity (PG1587) expresses mono- and di-
phosphorylated, penta-acylated lipid A structures and behaves as a “locked” 
TLR4 agonist (Slocum et al. 2014; Coats et al. 2009).  In a rabbit model of 
periodontitis, both lipid A phosphatase activities were required for colonization of 
the oral mucosa (Zenobia et al. 2014), indicating that dephosphorylation of lipid A 
is critical for survival within the host. Despite colonization defects, infection with 
the lipid A mutant strains still induced dysbiosis of the oral microbiota and 
inflammatory periodontal bone loss (Zenobia et al. 2014). One interpretation of 
such a result is that live bacteria are not necessary to precipitate oral disease. 
Indeed, treatment with LPS purified from wild-type P. gingivalis or the lipid A 
mutant strains was sufficient to trigger changes to the composition of the oral 
microbiota and induce periodontal bone loss (Zenobia et al. 2014). Notably, each 
LPS preparation induced distinct shifts in microbial species (Zenobia et al. 2014). 
These results suggest that P. gingivalis LPS contains unique properties that 
disrupt immune homeostasis and that minor alterations to lipid A structure can 




wild-type P. gingivalis and the lipid A mutant strains induced oral bone loss in 
infected, atherosclerosis-prone, apoliprotein E (ApoE)-deficient mice (Slocum et 
al. 2014). However, ApoE-deficient mice infected with the agonist strain exhibited 
diminished vascular inflammation as compared to mice infected with the wild-
type P. gingivalis or the antagonistic strain (Slocum et al. 2014). The expression 
of agonistic lipid A was associated with increased sensitivity to killing by CAMPs 
and impaired intracellular survival in macrophages, suggesting that survival 
within immune cells is required for pathogen-accelerated atherosclerosis (Slocum 
et al. 2014).  Collectively, these results demonstrate that the modifications on 
lipid A enable P. gingivalis to resist killing by innate immune effectors, 








































































































































Figure 6. Evasion of host immunity by Porphorymonas gingivalis.  
Colonizing only one ecological niche, P. gingivalis constitutively modifies lipid A 
to a form that resists CAMPs and evades TLR4 signaling. P. gingivalis lipid A is 
first synthesized as a penta-acylated, bis-phosphorylated species by the de novo 
pathway (A), but through the action of LpxE and LpxF a tetra-acylated form 
lacking both phosphate groups is displayed at the cell surface (B). The non-
phosphorylated lipid A is immunologically silent at the TLR4 complex. When 
grown in the presence of excess heme, the activity of LpxE is suppressed and a 
tetra-acylated, mono-phosphorylated TLR4 antagonist is observed (C). Genetic 
deletion of LpxE results in a P. gingivalis strain that exclusively expresses 
antagonist lipid A. A mutant lacking LpxF expresses a mixture of di- and mono-







Evasion of host immunity by Bacteroides thetaiotaomicron  
Similar to host-adapted pathogens, commensal bacteria of the mammalian 
intestine constitutively alter their lipid A structure and such modifications are 
critical for long term colonization (T. W. Cullen et al. 2015). Bacteroides spp are 
the most numerically prominent members of the mammalian intestinal microbiota, 
which serves as their singular environmental niche (Coats et al. 2011). 
Bacteroides encode the LpxF phosphatase and produce penta-acylated, mono-
phosphorylated lipid A (Figure 7A) (T. W. Cullen et al. 2015). Production of 
mono-phosphorylated lipid A renders this phylum resistant to high levels of 
inflammation-associated anti-microbial peptides (Cullen et al. 2015) . Deletion of 
LpxF in B. thetaiotaomicron resulted in the expression of a bis-phosphorylated, 
penta-acylated lipid A (Figure 7B). LpxF mutants were still capable of host 
colonization but were rapidly displaced from the microbiota during inflammation 
triggered by pathogen infection. These examples illustrate that the tendency to 
alter lipid A structure is a common feature of Gram-negative bacteria that 







































































Figure 7. Evasion of host immunity by the intestinal symbiont Bacteroides 
thetaioataomicron. 
The mammalian intestine is the sole ecological niche for the ubiquitous symbiont 
B. thetaiotaomicron. (A) To establish a permanent residence, B. thetaiotamicron 
utilizes LpxF to constitutively modify lipid A to a penta-acylated, mono-
phosphorylated form that resists high levels of inflammation-associated 
antimicrobial peptides. (B) An LpxF deletion mutant synthesizes penta-acylated, 
bis-phosphorylated lipid A and is rapidly displaced from the microbiota during 




The structural basis of LPS recognition by the TLR4/MD-2 complex 
The structural basis of LPS recognition by the TLR4/MD-2 complex has provided 
important insight into the diverse bioactivities of modified lipid A structures 
(Figure 8A). In the absence of LPS, MD-2 forms a heterodimer with the 
extracellular domain of TLR4 (Kim et al. 2007; Park et al. 2009). MD-2 is a β-cup 
folded protein composed of two anti-parallel β sheets that form a hydrophobic 
pocket which accommodates five of the six acyl chains of lipid A (Kim et al. 
2007). The sixth acyl chain extends outside the MD-2 cavity and interacts with 
hydrophobic residues in the extracellular domain of TLR4 from an adjacent 
TLR4/MD-2 complex (herein referred to as TLR4*), prompting the formation of 
the “m” shaped TLR4/MD-2/LPS dimer (2:2:2) (Kim et al. 2007) (Figure 8A).  
LPS-induced dimerization of the extracellular TLR4 domains triggers recruitment 
of adaptor proteins to the intracellular TIR domains and initiates signaling. Thus, 
MD-2 activates TLR4 signaling by inducing receptor dimerization. Lipid A variants 
with less than six acyl chains are weak inducers of TLR4 dimerization (Tan et al. 
2015). In addition to acyl chain number, the positioning and length of the acyl 
chains can substantially impact lipid A bioactivity (Erridge, Bennett-Guerrero, and 
Poxton 2002). TLR4/MD-2 is optimally activated by lipid A molecules that 
resemble that of E. coli, which contains six asymmetrically arranged lipid chains 





The presence of two phosphate groups on lipid A is also critical for activation of 
the TLR4/MD-2 complex (Rietschel et al. 1994, 1993). The lipid A phosphates 
interact with positively charged lysine and arginine residues at the mouth of the 
MD-2 cavity (Park et al. 2009). These molecular interactions are necessary for 
proper orientation of the lipid A molecule within the MD-2 cavity and facilitate 
optimal receptor activation (Park et al. 2009). Removal of either phosphate group 
from hexa-acylated lipid A results in ~100 fold decrease in endotoxic activity 
(Rietschel et al. 1994). The 1-phosphate is of particular importance, as it forms 
hydrophilic interactions with positively charged residues in the extracellular 
domain of TLR4* facilitating receptor dimerization (Park et al. 2009). Penta-
acylated mono-phosphorylated lipid A bearing a 1-phosphate is substantially 
more stimulatory than penta-acylated lipid A bearing a 4’-phosphate (Coats et al. 
2011). The significance of phosphate groups is further underscored by the finding 
that dephosphorylated lipid A variants from several species of Gram-negative 
bacteria are immunologically silent or inert with respect to TLR4 activation (Coats 




























Figure 8. Recognition of hexa-acylated E. coli lipid A by the TLR4/MD-2 
complex.  
Lipid A is an amphipathic molecule comprised of negatively charged phosphate 
groups (red circles) and hydrophobic fatty acyl chains. High affinity binding 
between lipid A and MD-2 is facilitated by the optimized distribution of 
hydrophobic residues within the LPS-binding pocket, which accommodates five 
of the six acyl chains. Charged residues at the opening of the MD-2 cavity 
(indicated by cloud labeled +) interact with the phosphate groups on lipid A. In 
the absence of lipid A, MD-2 forms a heterodimer with the extracellular domain of 
TLR4. Upon ligand binding, the TLR4/MD-2/LPS complex dimerizes. The lipid A 
molecule engages the TLR4 molecule in the second complex (TLR4*) at two 
main interfaces. The first is mediated by hydrophobic interactions between the 
sixth acyl chain and uncharged amino acid residues in the extracellular domain of 
TLR4*. The second is mediated by interactions between the negatively-charged 
1-phosphate (1-PO4) on lipid A and positively-charged amino acid residues 




Several synthetic and naturally occurring lipid A variants have been shown to 
function as TLR4 antagonists. One such molecule is lipid IVa (Figure 9A), a 
tetra-acylated intermediate in the lipid A biosynthesis pathway (Ohto et al. 2007). 
The crystal structure of lipid IVa in complex with human TLR4/MD-2 revealed that 
all four acyl chains are buried deep inside the MD-2 pocket (Kim et al. 2007). The 
acyl chain that normally sits outside of the MD-2 cavity and interacts with TLR4* 
is absent, precluding TLR4 dimerization. Occupation of the MD-2 cavity by lipid 
IVa prevents binding of agonistic lipid A structures and inhibits TLR4 activation. 
Competitive inhibition of the LPS binding site at MD-2 is a common mechanism 
of action employed by all known TLR4 antagonists including the synthetic TLR4 
antagonist Eritoran  (Figure 9B), the antagonistic LPS produced by P. gingivalis 
(Figure 9C), and Rhodobacter sphaeroides LPS (Figure 9D) (Coats et al. 2005; 















































































































Figure 9. The structure of synthetic and naturally occurring TLR4 
antagonists.  
The chemical structure of the TLR4 antagonists lipid IVa (A), Eritoran (B), P. 
gingivalis lipid A (C), and Rhodobacter spheroids lipid A (D).  Competitive 
inhibition of the LPS-binding site at MD-2 represents a common mechanism of 




Whereas hexa-acylated lipid A acts as a potent agonist for both mouse and 
human TLR4/MD-2, certain lipid A variants exhibit species-specific activity. Lipid 
IVa acts an antagonist for human TLR4/MD-2 but exhibits weak agonist activity 
for mouse and horse TLR4/MD-2 (Ohto et al. 2012). Species-specific responses 
to lipid IVa have been attributed to differences in amino acid residues in both 
TLR4 and MD-2.  Like lipid IVa, Eritoran has four acyl chains and two phosphate 
groups, yet functions as a TLR4 antagonist for both mouse and human 
TLR4/MD-2.  
 
Detoxified lipid A derivatives as a therapeutic tool for immune system 
modulation 
Through chemical or biological modifications to lipid A structure, the therapeutic 
efficacy of this LPS derivative can harnessed while limiting its toxicity. One such 
molecule is the FDA-approved adjuvant monophosphoryl lipid A (MPLA) (Figure 
10A) (Mata-Haro et al. 2007). MPLA was generated through chemical 
detoxification of Salmonella minessota LPS (Figure 10B) and contains 3-O-
deacyl-4’-monophosphoryl lipid A as the major species (Qureshi, Takayama, and 
Ribi 1982). The resulting derivative is 1,000 times less toxic than the parental 
LPS species, but is as potent in inducing T cell clonal expansion in vivo 
(Thompson et al. 2005).  MPLA has gained worldwide acceptance as a vaccine 
adjuvant and is a component of the commercially available human papilloma 





MPLA was selected for and not designed on a rational basis as its chemical 
synthesis pre-dated the discovery of TLRs. Efforts to understand the adjuvant 
activity of this detoxified lipid A derivative have focused on interactions with 
TLR4/MD-2. They revealed that MPLA is a weak inducer of TLR4/MD-2 
dimerization and MyD88-dependent signaling when compared to canonical lipid 
A (Casella and Mitchell 2013). As a result, downstream activation of NF-
kB/MAPK and pro-inflammatory cytokine production are all reduced. However, it 
retains TRIF-dependent responses, which are crucial for T cell priming (Mata-
Haro et al. 2007; Gandhapudi, Chilton, and Mitchell 2013). Indeed, its ability to 
function as an effective adjuvant is heavily dependent on TRIF-mediated IFN 
induction (Kolb et al. 2014).  Apart from MPLA, a variety of naturally occurring 
lipid A variants from mucosal niche bacteria that are weak TLR4 agonists retain T 
cell adjuvant activity in vivo (Darveau and Chilton 2013), suggesting that 
recognition of a common pattern in structurally diverse LPS molecules is 
sufficient to engage DC function. Overall, the evidence indicates that something 
more complicated than strength of signal is at play. Notably, the critical role of 
CD14 has largely been ignored. While numerous studies have established that 
alteration of lipid A structure dampens innate immunity, the impact of lipid A 














































































Figure 10. Chemical structure of the FDA-approved adjuvant 
monophosphoryl lipid A.  
MPLA (A)  was generated through chemical detoxification of S. Minnesota lipid A 








Dendritic Cells  
DC Maturation  
Resident DCs are present in most tissues, and are particularly abundant at 
barrier surfaces of the body, the primary sites of microbial encounters 
(Banchereau and Steinman 1998). They derive from bone marrow precursors 
that migrate into the bloodstream and seed peripheral tissues. In the absence of 
inflammatory signals,  “resting” or “immature” DCs continuously sample their 
microenvironment taking up extracellular material through a variety of endocytic 
mechanisms including phagocytosis, macropinocytosis, and receptor-mediated 
endocytosis (Banchereau and Steinman 1998). Internalized antigens are 
processed into peptides that associate intracellularly with MHC-I or MHC-II 
molecules. Peptide-MHC complexes are then transported to the cell surface 
where they can be recognized by T cells.  
 
DCs are equipped with an array of PRRs that survey the environment for the 
presence of microbial components. Upon PRR engagement, DCs undergo a 
differentiation process termed maturation, which greatly enhances their capacity 
for antigen processing and presentation, and equips them with the ability to prime 
naïve T cells (Figure 11). Maturation is accompanied by profound changes in 
protein expression, both at the cell membrane and as secreted mediators (Reis e 




activation, including: 1) an enhanced capacity to form and transport peptide-MHC 
complexes to the cell surface (Inaba et al. 2000; Pierre et al. 1997; Turley et al. 
2000) 2) increased expression of co-stimulatory molecules (e.g. CD86, CD80, 
CD40) that amplify T cell receptor signaling (Tseng et al. 2001; Caux et al. 1994, 
28; Inaba et al. 1994) 3) the secretion of immunostimulatory cytokines that 
influence T cell proliferation and effector function (Ebner et al. 2001, 12; 
Langenkamp et al. 2000) 4) an increase in the expression of chemokine 
receptors that direct migration of DCs to lymphoid organs (CCR7), where they 
interact with T cells to bring about clonal selection (Randolph et al. 1999).  
 
Maturation is also accompanied by profound changes to cellular morphology and 
the DC cytoskeleton (Figure 11). Immature DCs extend and retract sheet-like 
processes in many directions from the cell body. These processes, called 
lamellipodia, give immature DCs a characteristic “veiled” morphology (Hoefsmit, 
Duijvestijn, and Kamperdijk 1982). During maturation, DCs develop dendritic 
processes and a hallmark probing morphology (Banchereau and Steinman 
1998). These changes to the actin cytoskeleton coincide with a greatly 
diminished capacity to take up antigens (Garrett et al. 2000). Loss of antigen 
sampling functions is one of several mechanisms to prevent immunogenic 
responses to self-antigens from being launched during infection (Ralph Marvin 
Steinman and Nussenzweig 2002). Maturation also results in the redistribution of 




distribution, whereas mature DCs sequester lysosomes into perinuclear clusters 
(Alloatti et al. 2015).  
 
A key concept in DC biology is their ability to mature along different lines 
according to the type of microbial stimulus they encounter (Ralph M. Steinman 
and Banchereau 2007). The maturation pathway determines the immunogenic 
properties of the DC, and plays a key role in instructing lymphocyte function.  For 
example, depending on the pathogen they encounter, DCs can prime 
qualitatively different types of effector CD4 T cell responses such as Th1, Th2, or 
Th17 cells (L. Steinman 2007; Kapsenberg 2003; Gutcher and Becher 2007). 
Th1 cells secrete the signature cytokine IFNγ and are crucial for immunity 
against intracellular bacteria, whereas Th17 cells produce IL-17 and confer 
resistance to extracellular bacteria and fungi (Gutcher and Becher 2007; 
Kapsenberg 2003). The subset of CD4 T cell that develops appears to be 
dependent upon the local cytokine milieu (Kapsenberg 2003). It should be noted 
that many studies implicating a major role for cytokines in the polarization of T 
cell subsets used plate bound CD3 to engage the TCR rather than antigen and 
bona fide APCs. These studies do not provide any insight into the role of antigen 


































































Figure 11. Phenotypic and functional changes that accompany DC 
maturation.  
Immature DCs are present in peripheral tissue where they constitutively sample 
their microenvironment through a variety of endocytic mechanisms. Engagement 
of PRRs by microbes or their components initiates a program of DC maturation 
that dramatically alters cellular phenotype and function. The arrows indicate 





The Endosomal System  
Endocytosis is a fundamental process for all eukaryotic cells, and is necessary 
for a variety of cellular functions, including nutrient acquisition, recycling of 
plasma membrane components, and host defense. Four primary endocytic 
pathways serve as regulated portals of entry for extracellular material: clathrin- or 
receptor-mediated endocytosis (RME), macropinocytosis, phagocytosis, and 
caveolae-mediated endocytosis (Conner and Schmid 2003). The endocytic 
pathway that is utilized depends on the receptors that are engaged and the size 
of the cargo. RME mediates the uptake of soluble proteins, hormones, 
metabolites, and certain viruses. RME is employed by diverse cell types and 
participates in the regulation of a variety of cellular processes, including signal 
transduction. Like RME, phagocytosis is a receptor-mediated process, only it 
mediates internalization of large solid particles, and is restricted to a subset of 
motile cells of the hematopoietic lineage including neutrophils, macrophages, and 
DCs (Flannagan, Jaumouillé, and Grinstein 2012). Macropinocytosis is a non-
specific form of bulk fluid phase uptake. In contrast to RME, phagocytosis and 
macropinocytosis are actin-dependent processes controlled by the Rho family of 
GTPases (Hall and Nobes 2000). Regardless of the mode of uptake, cargo-
containing vesicles are ultimately met with the same fate. Below we focus our 





After particle uptake, phagosomes migrate along microtubules undergoing a 
series of fusion and fission events with endosomal compartments that eventually 
culminate in the proteolytic degradation of internalized material within lysosomes, 
a process known as phagosome maturation (Vieira, Botelho, and Grinstein 
2002). Phagosome maturation is accompanied by a gradual decrease in luminal 
pH, which drops from ~pH 5.5 in nascent phagosomes to ~pH 4.5 in lysosomes 
(Trombetta et al. 2003). Hydrolytic enzymes in endosomes and lysosomes are 
activated by low pH, which ensures that their activities are restricted to distinct 
stages of the endocytic pathway (Trombetta and Mellman 2005). Unlike 
macrophages and neutrophils, which rapidly deliver internalized cargo to 
lysosomes for degradation, DCs have developed a specialized endocytic 
pathway that serves to prevent complete degradation of cargo antigens so that 
they may be presented by MHC molecules (Savina and Amigorena 2007). For 
example, DCs express lower levels of lysosomal proteases when compared to 
macrophages (Delamarre et al. 2005). DCs also contain an incompletely 
assembled V-ATPase, the main proton pump transporter in lysosomes, resulting 
in slow acidification and delayed activation of acid sensitive proteases (Savina et 
al. 2006). NADPH oxidase 2 (NOX2) is rapidly recruited to DC phagosomes, 
which slows down acidification by consuming protons (Savina et al. 2006, 2). 




DCs can delay fusion of phagosomes with lysosomes to preserve antigens for 
presentation (Alloatti et al. 2015).  
MHC-I restricted antigen presentation the Classical Pathway 
The MHC-I antigen presentation pathway plays a critical role in alerting the 
immune system to the presence of infected and transformed cells. MHC-I 
molecules are expressed on the surface of all nucleated cells. Their function is to 
display peptides derived from proteins synthesized within the cell. Normally, 
these peptides derive from a cell’s own proteins. A viral or intra-cellular bacterial 
infection leads to the presentation of microbial peptides on MHC-I. Cytotoxic CD8 
T cells specific for these peptides can then identify and kill infected cells. 
Similarly, tumor cells expressing altered self-peptides can be targeted for 
destruction by antigen-specific CD8 T cells. Harnessing this capacity of the 
immune system is a major goal of modern day cancer immunotherapy. In 
addition to its role in immunity, constitutive expression of MHC-I is an integral 
component of maintaining tolerance to self-tissue. For example, MHC-I 
molecules engage inhibitory receptors on natural killer (NK) cells, preventing their 
cytotoxic activity (Kärre 2002). The formation and surface delivery of peptide-
MHC-I complexes is therefore crucial for host cell survival.  
 
The folding and assembly of MHC-I molecules occurs in the lumen of the 




(HC) translocates into the ER lumen and associates with a chaperone protein, 
calnexin, which maintains the MHC-I molecule in a partially folded state. When 
this complex binds β2-microglobulin (β2m), the partially folded HC- β2m 
heterodimer dissociates from calnexin and interacts with a set of proteins 
collectively known as the peptide-loading complex (PLC). The PLC is comprised 
of the transporter associated with antigen presentation (TAP), ERp57, 
calreticulin, and tapasin. It coordinates peptide translocation into the ER, 
trimming, and loading onto nascent HC- β2m complexes. The peptides derive 
from cytosolic proteins that are degraded by the proteasome and transported into 
the lumen of the ER via TAP. The HC- β2m complex is released from the PLC 
and exits the ER only upon peptide binding, which completes the folding of the 
MHC-I molecule. Fully assembled MHC-I molecules are transported to the ER-
Golgi intermediate compartment (ERGIC) where quality control (QC) 
mechanisms ensure that bound peptides are of high affinity. Finally, peptide-
MHC-I complexes that have passed QC traffic through the Golgi apparatus to the 
cell surface where they can be recognized by CD8 T cells. Because MHC-I 
molecules cannot leave the ER unless they bind high-affinity peptides, their 









































Figure 12. The classical pathway of MHC-I presentation. 
(A) Newly synthesized MHC-I HC polypeptide translocates into the ER lumen via 
the Sec61 complex. (B) Its first interaction is with the chaperone protein calnexin 
followed by assembly with β2m. (C) The partially folded HC- β2m heterodimer is 
unstable at this stage and is recruited by calreticulin to the PLC to complete its 
folding. Association with ERp57, calreticulin, and tapasin stabilize the empty 
MHC-I molecule and favor a conformation that is receptive to high-affinity peptide 
binding. Within the PLC, TAP translocates cytosolic peptides generated by the 
proteasome into the ER lumen. The peptides derive from endogenous proteins 
(i.e. proteins that are translated in the cytosol), which includes cellular proteins or 
viral proteins when cells are infected with virus. In the ER lumen, the peptides 
are further trimmed by ER aminopeptidases (ERAP) to accommodate the peptide 
length preferred by MHC-I (8-10 amino acids). (D) Peptide binding completes the 
folding of MHC-I, and the peptide-MHC-I complex is released from PLC. (E) 
Assembled MHC-I molecules are transported to the ER-Golgi intermediate 
compartment (ERGIC) for QC. (F) Peptide-MHC-I complexes that have passed 
QC traffic through the Golgi apparatus to the cell surface where they can be 





In most cell types, MHC-I molecules are exclusively loaded with endogenous 
peptides during their biosynthesis in the ER. DCs are uniquely equipped to adapt 
this pathway to present peptides derived from extracellular sources on MHC-I. 
This process, termed cross-presentation, is crucial for mounting cytotoxic 
immune responses to tumors and pathogens, as well as for maintaining tolerance 
to self (Bevan 1976). Why is cross-presentation a specialized function of DCs? 
One reason relates to the spatial challenge imposed by this process (Blander 
2018). Cross-presentation involves loading MHC-I molecules with peptides 
derived from extracellular cargo such as soluble proteins, microbes, and infected, 
transformed, or dying cells (Figure 13) (Blander 2018). Endosomes and 
phagosomes containing these cargoes are physically separated from the ER, 
where the machinery for assembling peptide-MHC-I complexes resides. As a 
consequence, cross-presentation requires deliberate rewiring of vesicular 
trafficking patterns and organelle communication (Blander 2018).  To accomplish 
this task, DCs have developed a myriad of adaptations to control their endocytic 
pathways. In DCs, a vesicular trafficking pathway emerging from ERGIC supplies 
endosomes and phagosomes with the necessary machinery for loading MHC-I 
molecules with high affinity peptides (Cebrian et al. 2011). This pathway operates 
constitutively and is orchestrated by the SNARE protein Sec22b (Cebrian et al. 
2011). In addition, DCs have developed adaptations that allow enhanced antigen 




Lastly, efficient cross-presentation requires maintenance of an alkaline pH (~7-



































Figure 13. Cross-presentation: the spatial challenge.  
Cross-presentation involves loading MHC-I molecules with peptides derived from 
extracellular sources, such as soluble proteins, bacteria, viruses, and dying cells. 
These cargoes are internalized through either endocytosis or phagocytosis. 
Endosomes and phagosomes are physically separated from the ER, where 
MHC-I molecules are synthesized, folded, and loaded with peptides. The 
classical pathway of MHC-I presentation takes place in all nucleated cells, 





The Sub-Cellular Pathways of Cross-presentation  
Different pathways of cross-presentation have been described, including the 
cytosolic and vacuolar pathways (Figure 14) (Joffre et al. 2012). These pathways 
differ in the site of antigen processing irrespective of the location of MHC-I 
loading. In the cytosolic pathway, internalized proteins are exported to the cytosol 
and degraded by the proteasome. The resulting peptides can be transported 
back into endosomes or phagosomes via TAP for loading onto vacuolar MHC-I 
molecules. Alternatively, peptides could be transported into the ER via TAP and 
loaded onto ER-resident MHC-I molecules, as occurs in the classical pathway for 
endogenous antigens. In the vacuolar pathway, antigens are degraded by 
endosomal or phagosomal proteases, in particular cathepsin S. The resulting 
peptides are loaded onto vacuole resident MHC-I molecules independently of 
proteasomal degradation and TAP activity. The combined activity of these two 


























Figure 14.  The vacuolar and cytosolic pathways for generating cross-
presented peptides. 
The schematic depicts processing of antigen following phagocytosis of a 
bacterium. Sec22b delivers the MHC-I PLC to the emergent cross-presentation 
compartment (Cebrian et al. 2011, 22). Cross-presented peptides are generated 
by one of two pathways. In the vacuolar pathway (black) peptides are generated 
within the phagosome by vacuolar proteases (cathepsin S) independently of the 
proteasome. In the cytosolic pathway (red), the Sec 61 complex transports 
bacterial polypeptides into the cytosol for proteasome-mediated degradation. The 
resultant peptides are imported back into the phagosome via TAP, and trimmed 
by insulin-regulated aminopeptidase (IRAP). The cytosolic pathway is sensitive to 




TLRs control phagosome maturation and antigen presentation on MHC-I 
and MHC-II  
Within endocytic compartments, antigens are processed and presented on MHC 
molecules for recognition by naïve CD4 or CD8 T cells. By internalizing 
extracellular components, DCs execute a critical function in the immune system:  
the induction of tolerance to self or immunity to pathogens (Steinman 2003). 
However, the same endocytic pathways used to take up apoptotic cells and 
normal by-products of tissue turnover, are also used in the uptake of microbial 
pathogens. With this comes the necessity for immunosurveillance of the 
endocytic pathway, so that the internalization of microbial antigens is met with 
vigorous immune responses (Blander 2007). TLRs are located on the plasma 
membrane and within endosomal compartments, and are thus ideally positioned 
to carry out this function.  
 
The immunological outcome of naïve T cell activation depends on the 
biochemical nature of the cargo and the receptors and signal transduction 
pathways engaged during DC internalization (Blander 2007). Even though all 
cargoes are delivered into the same intracellular compartments where antigen 
processing and presentation take place, only cargoes containing TLR ligands 
significantly remodel phagosomes for efficient antigen presentation by MHC 




maturation and antigen presentation in a phagosome autonomous manner 
(Blander and Medzhitov 2006). This means that the maturation fate of individual 
phagosomes is dependent on the cargo within that phagosome, and not by cargo 
in other phagosomes within the same cell. Peptides derived from cargoes that 
engage TLRs are loaded onto MHC-II molecules and trafficked to the cell surface 
for recognition by CD4 T cells (Figure 15). When phagosomes from within the 
same cell do not engage TLRs, MHC-II molecules are targeted for degradation 
by ubiquitination (Figure 15). Phagosome autonomous control of antigen 
presentation provides an additional layer of self non-self discrimination. This 
might be important during the course of an infection when DCs take up both 
apoptotic and microbial cells. By reading the contents of their phagosomes, DCs 
can preferentially select microbial antigens for presentation by MHC-II during 
simultaneous uptake of self and non-self components (Blander and Medzhitov 
2006). TLR mediated control of peptide-MHC-II complex formation is dependent 
on the downstream signaling adapter MyD88.  
 
Whereas MHC-II molecules are abundant in a variety of endocytic 
compartments, MHC-I molecules are not normally present in phagosomes of 
immature DCs (Alloatti et al. 2015; Nair-Gupta et al. 2014). As a consequence, 
resting DCs cannot efficiently cross-present antigens, despite the fact that all the 




delivered to phagosomes via Sec22b (Cebrian et al. 2011). Phagosomes that 
engage TLR signaling recruit MHC-I molecules from the endosomal recycling 
compartment (ERC), enabling cross-presentation of microbial peptides during 
infection (Figure 15) (Nair-Gupta et al. 2014). ERC-derived MHC-I molecules are 
delivered to phagosomes containing microbial cargo (E. coli or LPS-coated 
beads) in a TLR4/MyD88-dependent manner, without a requirement for TRIF 
(Nair-Gupta et al. 2014). Thus, two pathways of vesicular traffic converge to form 
the ideal cross-presentation compartment. The constitutive pathway emerging 
from ERGIC supplies the necessary machinery for loading MHC-I molecules with 
high affinity peptides, while the ERC pathway delivers MHC-I molecules under 
the guidance of TLR signals (Nair-Gupta et al. 2014). Delivery of rate limiting 
MHC-I molecules is critical for the positive edge that TLR signals impart on 
cross-presentation (Blander 2018; Nair-Gupta et al. 2014). Thus, in addition to 
inducing the expression of co-stimulatory molecules (signal 2), TLRs control 







































Figure 15. TLRs control peptide-MHC complex formation in a phagosome 
autonomous manner.  
The figure depicts events that occur 0-5 hr after phagocytosis of bacteria or 
apoptotic cells by DCs.  Sec22b delivers the PLC to both phagosomes. ERC 
stores of MHC-I molecules are recruited to phagosomes carrying microbial 
components in a TLR/MyD88-dependent manner (Nair-Gupta et al. 2014). 
Microbial peptides are presented on the cell surface to CD8 T cells.  Apoptotic 
cells do not engage TLR signaling and fail to recruitment rate limiting MHC-I 
molecules. Peptide-MHC-II complexes from the apoptotic cell phagosome are 
ubiquitinated and degraded in lysosomes (ten Broeke, Wubbolts, and Stoorvogel 
2013). MHC-II peptides from phagosomes containing bacteria are routed to the 




Regulation of Cross-Presentation During DC Maturation  
Although the effects of TLR engagement on antigen presentation are phagosome 
autonomous at first, a more global increase is seen after prolong exposure to 
microbial ligands. Numerous studies have shown that cross-presentation is 
temporally regulated during DC maturation (Alloatti et al. 2016). The efficiency of 
cross-presentation is enhanced during LPS-induced DC maturation and then 
down-modulated in fully mature cells (Gil-Torregrosa et al. 2004). Early following 
LPS exposure (0-5 hr), cross-presentation is enhanced in an 
endosome/phagosome autonomous manner through selective recruitment of 
MHC-I molecules  (Figure 16) (Blander 2016; Burgdorf et al. 2008). In maturing 
DCs (12-20 hr), the efficiency of cross-presentation is more generally increased 
both in vitro and in vivo  (Figure 16) (Alloatti et al. 2015). This increase occurs 
despite an overall reduction in antigen uptake and cannot be attributed to 
differences in antigen export to the cytosol (Alloatti et al. 2015). The mechanism 
here is a strong and selective delay in the fusion between phagosomes and 
lysosomes. The GTPase Rab34 mediated peri-nuclear clustering of lysosomes 
and delayed motility of phagosomes along microtubules to prevent their fusion 
with lysosomes (Alloatti et al. 2015). This delay prevented phagosomal 
acidification and spared antigens from excessive proteolytic degradation with the 
end effect of increasing the efficiency of cross-presentation (Alloatti et al. 2015).  




TLR ligands (24-40h) likely due to the fact that fully mature DCs lose their 
antigen sampling capacity and rapidly acidify endosomal compartments (Blander 
2018). Temporal control of cross-presentation is thought to ensure maximal T cell 
priming during the initial phases of infection while minimizing the risk of 
generating responses to self-antigens after prolonged microbial exposures 
(Corridoni and Simmons 2017). Most of what is known regarding the regulation of 
cross-presentation during DC maturation comes from studies employing E. coli 
LPS as the maturation stimulus (Alloatti et al. 2016). Importantly, how 
modifications to LPS structure influences cross-presentation has not been 
investigated. Additionally, whether LPS molecules from distinct species of 


















































Figure 16. Temporal control of antigen presentation during DC maturation. 
When DCs are exposed to TLR ligands for extended periods of time ( >6 hr) the 
phagosomes no longer behave autonomously. That is, cross-presentation is 
more generally increased. During this intermediate phase of DC maturation 
which lasts up to 24 hr, the efficiency of cross-presentation is still increased. This 
is attributed to a spatial and temporal delay in phagosome maturation, which 
spares internalized antigens from excessive proteolysis. This intermediate phase 




Cross-tolerance versus Cross-priming 
Cross-presentation can lead to CD8 T cell activation (cross-priming), to prime 
immune responses against pathogens and tumors, or inactivation (cross-
tolerance), to maintain tolerance to self- and innocuous environmental antigens 
(Heath and Carbone 2001). Successful priming of naïve CD8 T cells by DCs 
requires that DCs sense microbial components or endogenous danger signals 
through PRRs, prior to or concurrent with antigen presentation. It was initially 
believed that cross-presentation by immature or resting DCs leads to CD8 T cell 
tolerance (Blankenstein 2002). A problem with this assumption was that 
immature DCs could not efficiently present antigens, suggesting that alternative 
maturation signals were required for T cell tolerance. Indeed, it appears that DCs 
that have undergone ‘homeostatic’ maturation are responsible for inducing 
tolerance, although the signals that promote this developmental program remain 
unknown (Ardouin et al. 2016). Nevertheless, recent studies have demonstrated 
that both homeostatic and immunogenic DC maturation (induced by TLR ligands) 
involve broad and largely concordant changes in gene expression (Ardouin et al. 
2016). In these studies, differentially expressed genes were largely restricted to a 
small set of interferon-inducible targets, which were expressed at higher levels in 
immunogenic DCs (Ardouin et al. 2016). This is interesting given that TLRs 
induce interferon expression only when signaling from intracellular 




tolerogenic DCs is largely unknown. Such molecules may have therapeutic utility 





Hypothesis and specific aims  
P. gingivalis lipid A species have been designated as TLR4 antagonists, weak 
agonists, or immunologically silent (Reife et al. 2006; Coats et al. 2011, 2009), 
but how these lipid A species influence the activation of downstream signaling 
pathways is not well-defined. Moreover, we lack a clear understanding of how P. 
gingivalis expression of divergent lipid A structures impacts the development of 
adaptive immune responses, which are critical for maintaining immune 
homeostasis. DCs and their blood monocyte precursors play a particularly 
important role in bridging the innate and adaptive arms of the immune system 
during Gram-negative bacterial infection (Cheong et al. 2010; León, López-
Bravo, and Ardavín 2007; Randolph et al. 1999; van Helden et al. 2010). TLR4 
activation in these cells induces a distinct maturation phenotype that promotes 
their mobilization to immune T cell areas for initiation of antigen-specific 
immunity, a process that is critically dependent upon TRIF signaling (Cheong et 
al. 2010; T. Kawai et al. 2001; van Helden et al. 2010). In preliminary studies, 
using P. gingivalis strains expressing defined lipid A species we demonstrated 
that the expression of immune evasive lipid A species 
(antagonist/immunologically silent) enables this bacterium to evade TRIF-
dependent expression of IFNβ in DCs. Based on these preliminary results, we 
hypothesize that P. gingivalis disrupts DC maturation, mobilization, and the 
development of antigen-specific immune responses through the expression of 




our studies on cross-presentation and the initiation of CD8 T cell immune 














































Figure 17. P. gingivalis disrupts DC maturation, mobilization, and the 
development of antigen-specific immune responses through expression of 
immune evasive lipid A species.  
In Aim 1, we determine how alterations to lipid A structure influence its detection 
by the TLR4 complex and the activation of downstream signaling pathways in 
DCs. In Aim 2, we determine the impact of lipid A modifications on DC maturation 
and the activation of antigen-specific CD8 T cell responses. In Aim 3, we 






Chapter 2. Materials and Methods 
Antibodies and Reagents  
 






rabbit IgG (H+L) 
Rabbit  N/A Invitrogen FC 
Alexa647 goat anti-
rabbit IgG (H+L) 
Rabbit  N/A Invitrogen FC 
B7-H4 (B7S1) Mouse  HMH4-5G1 BioLegend FC 
CCR7 Mouse  4B12 eBioscience FC 
CD115 (CSF-1R) Mouse  AFS98 BioLegend FC 
CD11b Mouse  M1/70 eBioscience FC 
CD11c Mouse  N418 eBioscience FC 
CD14 Mouse  Sa2-8 BioLegend FC 
CD19 Mouse  eBio1D3 eBioscience FC 
CD205 Mouse  205yekta eBioscience FC 
CD206 (MMR) Mouse  MR6F3 Thermo-Fisher 
Scientific 
FC 
CD209a/DC-SIGN Mouse  MMD3 eBioscience FC 
CD3ε Mouse  145-2C11 eBioscience FC 
CD40 Mouse  1C10, 
HM40-3 
eBioscience FC 
CD45 Mouse  30-F11 BD 
Pharmingen 
FC 
CD45R (B220) Mouse  RA3-6B2 eBioscience FC 
CD49b Mouse  DX5 eBioscience FC 
CD62L Mouse  MEL-14 BioLegend FC 
CD69 Mouse  H1.2F3 eBioscience FC 
CD80 Mouse  16-10A1 eBioscience FC 
CD86 Mouse  GL-1 eBioscience FC 
CD8a Mouse  53-6.7 eBioscience FC 
F4/80 Mouse  BM8 eBioscience FC 
Fc Block (anti-
CD16/32) 
Mouse 93 eBioscience FC 




MHC-I Mouse  AF6-
88.5.5.3 
eBioscience FC 
MHC-II (I-A/I-E) Mouse  M5/114.15.
2 
eBioscience FC 
NK1.1 Mouse  PK136 eBioscience FC 
PD-L1 (CD274) Mouse 10F.9G2 BioLegend FC 








TCRβ chain Mouse H57-597 BioLegend FC 
TLR2 Mouse 6C2, mT2.7 eBioscience FC  
TLR4 (CD284) Mouse  SA15-21 BioLegend FC 
TLR4/MD-2 
(monomer) 
Mouse  MTS510 BioLegend FC 
Biotin anti-mouse 
IFNβ 
Mouse  MIB-5E9.1 BioLegend ELISA 
Purified anti-mouse 
IFNβ 
Mouse  Poly5192 BioLegend ELISA 
p44/42 MAPK 
(Erk1/2) 





Mouse  9106S Cell Signaling 
Technologies 
WB 





Mouse  9255S Cell Signaling 
Technologies 
WB 
IRF3 (D83B9) Mouse  4302S Cell Signaling 
Technologies 
WB 










Mouse 9211S Cell Signaling 
Technologies 
WB 
P-NF-kB p65 (S536) Mouse  3033S Cell Signaling 
Technologies 
WB 












Table 1. List of Antibodies.  
Primary (1°) and secondary (2°) antibodies used in the experiments described 
throughout this thesis. Species reactivity, vendor, application, and clone or 





Reagent Catalogue # Vendor Application  
2-Mercaptoethanol 
(55 mM) 
21985-023 Gibco  Cell culture 
HEPES (1M) 15630-080 Gibco Cell culture 
ISQAVHAAHAEINE
AGR peptide (OVA 
323-339; OT-II  
peptide) 
vac-isq Invivogen Cell culture  
Non-essential 
amino acids (100x) 








(OVA 257-264; OT-I 
peptide) 
vac-sin Invivogen Cell culture  
Sodium pyruvate 
(100 mM) 
11360-070 Gibco Cell culture 
Recombinant 
murine GM-CSF 
315-03 Peprotech Cell culture  





Cell separation  





Cell separation  
Polybead Amino 3.0 
µm microspheres 
17145 Polysciences Covalent OVA 
coupling  









C36950 Invitrogen FC 
Normal Rat Serum 13551 Stemcell 
Technologies 
FC 




NHS Ester Scientific labeling  










Lucifer Yellow CH, 
potassium salt  
L1177  Invitrogen Macropinocytosis 
probe 
Carboxyl latex 3.0 
µm microspheres 





Table 2. List of Reagents.  
List of select reagents used for the experiments described in this thesis. Vendor, 






Mice and Cells 
C57BL/6J (WT; Jax #000664), Cd14-/- (Jax #003726), Tlr4-/- (Jax #007227), Tlr2-/- 
(Jax #004650), Trif-/- (Jax #005037), Myd88-/- (Jax #009088) and OT-I (Jax 
#00383) mice were purchased from Jackson Laboratories (Bar Harbor, ME). Ifnb-
/- and OT-II mice were a generous gift from Dr. Alexander Poltorak. Mice were 
housed under specific-pathogen free conditions and used at 6-10 weeks of age. 
All animal procedures were approved by the Tufts University School of Medicine 
Institutional Animal Care and Use Committee.  
 
To generate monocyte-derived DCs, single cell suspensions of red blood cell 
depleted bone marrow cells were cultured in RPMI 1640 (Corning) containing 
10% fetal bovine serum (FBS; Hyclone), 100 IU/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine, 1x non-essential amino acids, 1x sodium 
pyruvate, 50 µM β-mercaptoethanol, 10 mM HEPES (all from Invitrogen), and 20 
ng/ml recombinant mouse GM-CSF (Peprotech). After 8 days, non-adherent cells 
were collected and used for experiments. For all experiments, DC purity was 
greater than 90% as assessed by flow cytometry. Maturation was induced by 16-
18 hr treatment with LPS (100 ng/ml) or bacteria (MOI 10) unless otherwise 
stated. CD8+ T cells specific for the SIINFEKL peptide presented by the H-2Kb 
MHC-I molecule were isolated from spleens and lymph nodes of OT-I mice by 
negative selection (Stemcell Technologies) according to the manufacturer’s 




maintained in RPMI 1640 containing 10% FBS, 2 mm L-glutamine, 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 50 µM β-mercaptoethanol, 10 mM HEPES, 
and 0.4 mg/ml G418 (Sigma-Aldrich).   
 
Bacteria and LPS preparations  
Porphyromonas gingivalis lipid A phosphatase mutants were generated by gene 
deletion in the parental strain 381 (ATCC BAA-1703) and have been previously 
characterized (Table 3) (Slocum et al. 2014). Frozen stocks of wild-type P. 
gingivalis and the isogenic mutant strains were streaked onto blood agar plates 
(BD BBL) and grown anaerobically at 37 ̊C for 3–5 d. Plate-grown organisms 
were used to inoculate liquid cultures of brain heart infusion broth (BD BBL) 
supplemented with yeast extract (0.5%; BD BBL), hemin (10 µg/ml; Sigma-
Aldrich), and menadione (1 µg/ml; Sigma-Aldrich). Erythromycin (5 µg/ml; Sigma-
Aldrich) was added according to the selection requirements of the strain. A 5 ml 
liquid culture was grown to saturation overnight and then diluted 1:10 in BHI 
broth (5 ml into 45 ml). Stationary phase cultures (18-24 hr) were harvested by 
centrifugation (7,000 x g, 8 min), washed three times in PBS, and resuspended 
at an OD660 of 1.0 (~1 x 109 CFU/ml) prior to use. Heat-killed E. coli was used as 
a control for bacterial stimulation to avoid artifacts due to bacterial replication (P. 
gingivalis is an obligate anaerobe). E. coli  was grown at 37 ̊C in LB broth under 
standard conditions. Overnight cultures were harvested by centrifugation, 




bacteria were washed three times with PBS prior to use. Live P. gingivalis was 
used for all experiments, with the exception of antigen-presentation assays 
where bacteria were coated with OVA. For these experiments, stationary phase 
liquid cultures were harvested by centrifugation, resuspended in PBS at an OD660 
of 1.0 and heat-killed for 15 min at 65 ̊C. Heat-killed P. gingivalis strains (109/ml) 
were washed twice with PBS and coated with 2 mg/ml of OVA overnight at 4 C 
on a rotating wheel. Bacteria were washed three times with PBS and stained with 
a 1/750 dilution of a polyclonal rabbit anti-OVA antibody followed by an 
Alexafluor647-conjugated anti-rabbit IgG. OVA coating was assessed by flow 
cytometry. 
 
Ultra-pure E. coli 0111:B4 LPS was purchased from Invivogen. LPS from P. 
gingivalis strains and Bacteroides thetaioataomicron VPI-5482 were isolated by 
Dr. Stephen R. Coats in the Darveau laboratory at the University of Washington 






Strain  Gene 
Deletion  
Nomenclature  
in these studies  

































Table 3. P. gingivalis lipid A phosphatase mutant strains.  
P. gingivalis lipid A mutant strains were previously described (Slocum et al. 
2014). Note that the nomenclature was changed for these studies to reflect the 




MALDI-TOF MS analyses  
MALDI-TOF MS analyses were performed by Dr. Stephen R. Coats in the 
Darveau laboratory at the University of Washington Seattle, WA. To generate 
lipid A, dried LPS samples were suspended in 10 mM sodium acetate (pH 4.5) 
containing 1% (wt/vol) sodium dodecyl sulfate. The solution was heated at 100°C 
for 1 h, followed by lyophilization overnight. The resulting lipid A pellets were 
washed once in ice-cold 95% ethanol containing 0.02 N HCl and three times in 
95% ethanol. The lipid A samples were then subjected to a final Bligh-Dyer 
extraction, which consisted of 1,160 µl of a chloroform-methanol-water mixture 
(1:1:0.9 [vol/vol/vol]) to remove residual carbohydrate contaminants. For matrix-
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-
TOF MS) analyses, lipid A samples were dissolved in 10 µl of a mixture of 5-
chloro-2-mercaptobenzothiazole (20 mg/ml) in 1:1 (vol/vol) chloroform-methanol, 
and 0.5 µl of each sample was analyzed in both positive- and negative-ion 
modes on an AutoFlex Analyzer (Bruker Daltonics). Data were acquired with a 
50-Hz repletion rate, and up to 3,000 shots were accumulated for each spectrum. 
Instrument calibration and all other tuning parameters were optimized using HP 
Calmix (Sigma-Aldrich). Data were acquired and processed using FlexAnalysis 








Phagocytic uptake efficiency was analyzed by the methods of Hoffmann et al 
(Hoffmann et al. 2016). Briefly, 3 µm amine-modified beads (Polysciences) were 
washed twice in PBS and activated with 8% (vol/vol) glutaraldehyde in PBS for 4 
hr at room temperature with gentle end-to-end mixing. Subsequently, beads were 
washed in PBS and covalently coupled to 0.5 mg/ml OVA and 0.1 mg/ml Alexa 
Fluor 647 overnight at 4°C on a rotating wheel. Beads were quenched with 0.5 M 
glycine in PBS for 30 min and washed twice in PBS prior to use. DCs were 
treated as indicated for 16-18 hr then collected from culture dishes, washed twice 
in PBS, and resuspended in CO2-independent medium (Invitrogen) at a density 
of 2×107 cells/ml. Phagocytic binding of OVA- and Alexa647-coated beads 
(bbOVA-Alexa647) to the cell suspension was performed for 15 min on ice at a 
bead:cell ratio of 15:1. Unbound beads were removed by three washes in cold 
PBS in a pre-chilled centrifuge. Cells were then incubated at 37°C in complete 
medium for different periods of chase. Phagocytic uptake was stopped by the 
addition of ice-cold PBS. To distinguish bound from internalized beads, cells 
were labeled with a polyclonal rabbit anti-OVA primary antibody followed by a 
goat anti-rabbit Alexa488 secondary. Samples were acquired on an LSR II 
cytometer and the percentage of cells with internalized beads was calculated for 





To assess phagocytic activity, DCs were treated as indicated for 16-18 hr then 
collected from culture dishes, washed twice in PBS, and resuspended in CO2-
independent medium at a density of 2×107 cells/ml. Cells were incubated with 
bbOVA-Alexa647 for 15 min at 37°C at a bead:cell ratio of 5:1. Phagocytosis was 
stopped by the addition of ice-cold PBS and external beads were removed 
following three rounds of FCS flotation. The number of internalized beads was 
determined by flow cytometry using a bead standard. Results are presented as 
phagocytic activity relative to unstimulated DCs.  
 
Binding and internalization of fluorescently labeled P. gingivalis strains was 
determined as previously described (G. Papadopoulos et al. 2017). Briefly, broth 
grown P. gingivalis strains were labeled with 0.01 mg/ml FITC-NHS Ester in PBS 
at room temperature for 30 min on a rotating wheel. Bacteria were washed three 
times with PBS to remove unreacted dye and then added to DCs (MOI=10). At 
the indicated times, phagocytosis was stopped by addition of ice-cold PBS and 
unbound bacteria were removed by washing. Cells were then analyzed by flow 
cytometry to determine bacterial uptake. To distinguish between bound and 
internalized bacteria, 2% Trypan Blue (Merck) was added to samples before 
acquisition to quench extracellular fluorescence. These experiments revealed 
comparable binding and uptake of P. gingivalis strains by DCs. Similar results 







DCs were treated with media alone, bacteria (MOI 10) or LPS (100 ng/ml) for 16-
18 hr. At this time, cells were collected, washed twice in PBS, and resuspended 
in CO2-independent medium at a density of 2×107 cells/ml. DCs were pulsed with 
latex beads covalently coupled to OVA (bead to cell ratio 5:1) for 10 minutes at 
37°C. Ice-cold PBS was added to stop internalization, followed by three rounds of 
FCS flotation to remove beads that were not internalized. Cells were 
resuspended in complete medium and incubated at 37°C. Aliquots of cell 
suspension were collected 0’, 30’, 90’, and 120’ min after bead pulsing and lysed 
in buffer containing protease inhibitors (Roche) overnight at 4°C in a 96-well V-
bottom conical plate. Beads were stained with a polyclonal anti-OVA ab followed 
by an Alexafluor647 conjugated secondary ab and fluorescence was analyzed by 
flow cytometry. Percent degradation was calculated by determining the amount 
of remaining OVA on beads (MFI) relative to time 0’. 
 
Endocytosis and Macropinocytosis Assays  
To assess macropinocytosis, DCs were incubated with Lucifer Yellow CH (1 
mg/ml), a fluorescent and cell impermeable fluid phase tracer, for 15 min at 37°C. 
Where indicated, incubations were performed in the presence of various doses of 
LPS. Cells were washed with cold PBS and analyzed by flow cytometry. Cell-




untreated cell populations to determine changes from steady state levels of 
macropinocytosis. Results are expressed as percent change in activity relative to 
immature or unstimulated cells. The endocytic activity of DCs was determined by 
measuring uptake of DQ-OVA (25 µg/ml) using the same protocol. 
 
Cross-presentation Assays 
DCs were pulsed with graded doses of soluble OVA (0.25, 0.5, or 1 mg/ml), 3 µm 
latex beads (Polysciences) coated with different ratios of OVA and BSA (25%, 
50%, or 100%), or the control SIINFEKL peptide (0.01 ng/ml). After 1 hr, cells 
were washed three times with PBS containing 0.1% BSA and co-cultured with 
purified CellTrace Violet labeled CD8+ OT-I T cells (1x104 DCs: 5 x104 T cells). 
After 3 days, the absolute number of proliferating T cells was determined by flow 
cytometry using a bead standard. Alternatively, T cell activation was determined 
after 18 hr of co-culture by assessing surface expression of CD69 by flow 
cytometry or IL-2 and IFNγ secretion into culture supernatants by ELISA. Where 
indicated, antigen presentation was evaluated in the continuous presence of a 
limiting dose of soluble OVA (40 µg/ml).  
 
Immunoblotting  
Cells were subjected to the indicated treatments and lysed in RIPA buffer 
(Thermo-Fisher Scientific) containing a protease/phosphatase inhibitor cocktail 




indicated primary antibodies using standard conditions. Membranes were probed 
with species specific secondary antibodies conjugated to near IR fluorescent 
dyes (Licor) and protein expression was quantified using an Odyssey CLx imager 
(Licor). All protein blots shown were representative data from at least three 
independent experiments. For in-cell western assays, DCs were plated in black-
walled 96 well plates (1x104 cells/well) and stimulated as indicated. At various 
times, supernatants were decanted and cells were fixed with 4% 
paraformaldehyde at room temperature for 5 minutes. Cells were washed, 
permeabilized, and labeled with primary antibodies overnight at 4°C on an orbital 
shaker. Incubations with near-IR-conjugated secondary antibodies were 
performed at room temperature for 1 hr. Plates were washed thoroughly and 
dried. Fluorescence was analyzed using the Odyssey CLx imager and 
manufacturer recommended settings. Protein expression was normalized to actin 
for each well.  
 
mRNA Isolation and Real-Time qPCR  
Total RNA was isolated with the RNeasy Plus kit (Qiagen) and contaminating 
gDNA was depleted using the provided columns. Single strand cDNA was 
synthesized using the High-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Gene expression analyses were performed using validated Taqman 




were calculated using actb as the endogenous control. Graphs show the mean 
and SD of triplicate samples from one of three independent experiments.  
 
Flow Cytometry  
DCs were treated as indicated in figure legends at 37°C. Cells were then washed 
with 1 ml cold PBS containing 0.5% BSA (PBS/BSA) and incubated with Fc block 
(anti-mouse CD16/32) or 2% rat serum for 15 min at 4°C to block non-specific 
binding of antibodies. Incubations with fluorochrome-conjugated antibodies were 
performed on ice for 30 min in the dark.  Cells were stained with the appropriate 
fluorochrome-conjugated antibodies for 30 min on ice in the dark. The stained 
cells were washed twice and resuspended in PBS/BSA for flow cytometry 
analysis using a BD LSRI II. For CD14 and TLR4 endocytosis assays, surface 
receptor expression (MFI) was recorded for unstimulated and stimulated cells. 
The percentage of surface receptor staining at each time point was plotted to 
reflect the efficiency of receptor endocytosis. For measuring the extent of 
TLR4/MD-2 dimerization, the percentage of TLR4/MD-2 dimer was calculated 
using loss of TLR4/MD-2 monomer staining as the readout. Flow cytometry 
graphs shown in the results section were representative data from at least three 







Acute Peritonitis  
C57BL/6 mice were injected i.p. with 5x107 CFU of wild-type P. gingivalis and the 
lipid A mutant strains in 500µL of PBS or PBS alone as a control (3-4 
mice/group). After 6 or 24h, mice were euthanized and peritoneal exudate fluid 
was harvested by lavage for bacterial CFU enumeration by plating or cell 
analysis by flow cytometry. Cells were stained with one of three antibody 
cocktails: Panel #1 contained anti-mouse antibodies for identification of myeloid 
cell subsets including CD45 BV650 (pan-leukocyte), CD11b APC (myeloid), 
F4/80 PE (macrophage), CD11c PE-Cy7 (DC), Ly6G FITC (neutrophil), MHC-II 
eFluor450 (APCs), and ZombieUV for dead cell discrimination. Panel #2 
contained antibodies for identification of lymphocyte cell subsets including CD45 
BV650 (pan-leukocyte), CD3 FITC (T cells), CD49d (NK cells), CD19 (B cells), 
and ZombieUV for dead cell discrimination. Panel #3 contained antibodies to 
asses myeloid cell activation including CD40 FITC, CD80 PE, CD86 PE-Cy7, 
MHCII eFluor450 and CD11b APC. Counting beads were added before sample 
acquisition on BD LSRII for determination of absolute cell counts. 
 
DC Mobilization  
C57BL/6 mice (n=3) were infected with wild-type P. gingivalis and the lipid A 
mutant strains (108 CFU in 100 uL PBS) by subcutaneous injection at the nape of 
the neck. Mice treated with PBS alone served as vehicle controls.  After 24 hr, 




sacrificed and skin-draining lymph  nodes (inguinal, brachial, axial) and spleens 
were harvested for analysis of DC numbers by flow cytometry analysis. DCs 
were identified as MHC-IIhighCD11c+CD19-CD3-.  
 
Statistical Analysis  
Data were analyzed by one or two-way ANOVA with Bonferroni’s posttest. A p 





Chapter 3. Phenotypic and functional characterization of monocyte-derived 
dendritic cells  
Introduction 
In this brief chapter, we characterize the cells and detail methods that will be 
used throughout this thesis. We also examine the phenotyptic and functional 
changes that accompany E. coli LPS-induced DC maturation, which serves as a 
foundation for the comparisons made throughout our studies.  
 
LPS transforms immature DCs into potent effectors of immunity 
Of the known DC subsets, the expression of CD14 is limited to monocyte-derived 
DCs (moDCs) (Sallusto and Lanzavecchia 2010). In response to LPS or Gram-
negative bacteria, moDCs become the dominant cell type for the induction of T 
cell immunity and can be distinguished from other APCs in lymph nodes by their 
selective expression of DC-SIGN (Cheong et al. 2010). To generate equivalent 
cells for study, we cultured mouse bone marrow precursors in the presence of 
recombinant GM-CSF (20 ng/ml). After 8 days, we recovered non-adherent cells 
for phenotypic analysis. The resulting population expressed the integrin family 
members CD11b and CD11c, as well as MHC-II, CD14, TLR4/MD-2, TLR2, and 
DC-SIGN, consistent with the phenotype of moDCs in vivo (Figure 18A).  
 
Resting or immature DCs extend and retract sheet-like processes in many 




responsible for the characteristic morphology of immature DCs (Figure 18C). 
Immature DCs expressed low levels of the co-stimulatory molecules CD40, 
CD80, and CD86 (Figure 18B). Following treatment with E. coli LPS (100 ng/ml; 
16-18 hr), surface expression of co-stimulatory molecules, MHC complexes, and 
the lymph node homing chemokine receptor CCR7, were significantly increased 
(Figure 18B). LPS-treated cells developed a probing or dendritic morphology, 
the hallmark of mature DCs (Figure 18C,D). These cytoskeletal changes were 
evident at the single cell level by microscopy (Figure 18C) and when examining 
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Figure 18. Phenotypic characterization of monocyte-derived DCs generated 
from mouse bone marrow precursors.  
(A) Red blood cell depleted mouse bone marrow cells were cultured for 8 days in 
the presence of 20 ng/ml GM-CSF. Non-adherent cells were harvested for 
phenotypic analysis. Surface expression of CD11c, DC-SIGN, CD11b, TLR2, 
CD14, and TLR4/MD-2 was analyzed by flow cytometry. (B) Surface expression 
of CD40, CD80, CD86, MHC-I, MHC-II, & CCR7 on immature (i.e. media treated) 
and E. coli LPS  (100 ng/ml; 16-18h) stimulated DCs as assessed by flow 
cytometry. (C) Immature and E. coli LPS treated DCs were fixed, labeled for F-
actin (Green) and DNA (Blue), and analyzed by confocal microscopy. Shown are 
maximum projections of representative cells. Note the cytoskeletal changes that 
accompany E. coli LPS-induced DC maturation, namely the development of a 
probing morphology that is the hallmark of DCs. (D) Light scattering properties of 
immature and E. coli LPS treated DCs (100 ng/ml; 16-18hr) as determined by 










To test the functional capacity of the resulting cells, we used the mixed leukocyte 
reaction (MLR), an example of the immune-stimulating function of DCs. In these 
and all T cell proliferation assays, we used CellTrace Violet (CTV) labeled T cells 
and monitored expansion of dividing cells as in Figure 19. DCs matured with 
LPS stimulated a strong MLR, whereas immature cells were weak or inactive 
(Figure 20A). Similarly, only LPS-treated cells could efficiently present peptides 
derived from the model protein ovalbumin (OVA) on MHC-I or MHC-II to TCR 
transgenic T cells (Figure 20B). Therefore, in vitro generated DCs were both 
phenotypically and functionally similar to moDCs in vivo, including the capacity 
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Figure 19. Gating strategy for the analysis of T cell proliferation in the DC:T 
cell co-culture system.  
(A) Cells were initially gated according to light scattering properties typical of 
lymphocytes to exclude cell debris. (B) The resulting population was further 
gated on cells expressing the T cell co-receptors CD4 or CD8. (C) Dead cells 
were excluded from analysis using a fixable viability dye unless otherwise noted. 
(D) The percentage of proliferating T cells was then determined by CellTrace 
Violet dilution. To obtain absolute cell numbers, we included counting beads 



































































































Figure 20. LPS treatment induces the functional maturation of DCs.  
(A) Primary MLR; Immature or E. coli LPS treated (100 ng/ml;16-18hr) C57BL/6J 
DCs were added to CellTrace Violet (CTV) labeled T cells isolated from DBA 
mice (DC:T cell ratio of 1:5 or 1:10) and cultured for 5 days prior to flow 
cytometry analysis for CD8 and CTV dilution. Gates indicate the percentage of 
proliferating T cells. (B) TCR transgenic T cells were used to evaluate the 
presentation of exogenous protein antigens on MHC-I and MHC-II by immature 
and E. coli LPS treated DC. DCs were pulsed with graded doses of OVA protein 
for 60 min, washed three times, and then co-cultured with CTV labeled T cells 
purified from OT-I (OVA-specific CD8+) or OT-II (OVA-specific CD4+) mice. 
Antigen presentation was evaluated using T cell activation by upregulation of 





Chapter Summary  
In this chapter, we demonstrated that DCs differentiated from mouse bone 
marrow precursors express DC-SIGN and express the necessary PRRs for 
efficient recognition of LPS, including CD14, MD-2, and TLR4. Immature DCs 
could not efficiently process and present peptides derived from extracellular 
proteins on MHC-I or MHC-II molecules, and were poor stimulators of primary 
allogeneic T cells responses in the MLR. TLR4 engagement in these cells 
transformed immature DCs into potent effectors of immunity. The functional 
maturation of DCs was accompanied by profound changes to cellular 
morphology and membrane protein expression, many of which relate to T cell 
activation. One question that will be addressed in our work is whether these 





Chapter 4. Lipid A modifications regulate innate and adaptive immune 
responses to LPS   
Introduction 
There is tremendous diversity in lipid A structure with respect to acyl chain length 
and number, as well as the number and position of phosphate groups, and all of 
these factors can influence strength of signaling and preferential adapter usage 
(Maeshima and Fernandez 2013). P. gingivalis lipid A species have been 
designated as TLR4 antagonists, weak agonists, or immunologically silent on the 
basis of their activity in transfected cells (Reife et al. 2006; Coats et al. 2011, 
2009), but how these lipid A species influence the activation of downstream 
signaling pathways is not well-defined. It is also important to note that the 
aforementioned studies employed cells expressing TLR4/MD-2 alone, which 
cannot conduct TRIF signaling. Moreover, we lack a clear understanding of how 
these modified lipid A structures influence the development of adaptive immune 
responses. 
   
In this chapter, we utilized purified LPS preparations from P. gingivalis strains 
expressing defined lipid A moieties to understand how structural changes to the 
LPS molecule influence its detection by the TLR4 complex and the activation of 
downstream signaling pathways in DCs. Special emphasis is placed on receptor 
proximal events that control TLR4 signaling from the plasma membrane and 




and inflammatory cytokine secretion in response to these LPS variants. We then 
use these variants to understand how innate signaling shapes cross-presentation 
and the initiation of CD8 T cell immunity.  
 
Characterization of P. gingivalis lipid A phosphatase mutants and their 
purified LPS preparations   
P. gingivalis initially synthesizes a penta-acylated lipid A that is phosphorylated at 
the 1- and 4’-positions of the di-glucosamine backbone (Jain and Darveau 2010).  
Heterogeneity arises from the activity of lipid A modification enzymes, which 
include an unidentified deacylase and the lipid A 1-and 4’-phosphatases (Coats 
et al. 2009). These enzymes operate constitutively in wild type strain P. gingivalis 
381 resulting in the expression of a non-phosphorylated, tetra-acylated lipid A 
that is immunologically silent at the TLR4 complex (Figure 21A,D). To determine 
the impact of specific lipid A structures on immune activation, we constructed 
genetically modified strains of P. gingivalis that lack either lipid A 1- or 4’-
phosphatase activity resulting in the expression of defined lipid A moieties that do 
not vary in response to growth conditions (Slocum et al. 2014). These mutants 
have been extensively characterized and tested in in vivo models of local and 
systemic inflammation (Slocum et al. 2014; Zenobia et al. 2014; George 
Papadopoulos et al. 2014). We did not detect differences in growth kinetics, 
expression of membrane bound virulence factors, or general morphology 




et al. 2014). A mutant lacking 1-phosphatase activity synthesizes a tetra-acylated 
and mono-phosphorylated lipid A that functions as TLR4 antagonist (Figure 
21B,E). Antagonist refers to the ability of this variant to potently inhibit binding 
and cytokine production by stronger TLR4 agonists (Coats et al. 2007). However, 
it is not devoid of biological activity. Contrary to the species-specific activity of 
similar structures (Ohto et al. 2012), this variant acts as a weak TLR4 agonist for 
both mouse and human TLR4/MD-2 (Darveau et al. 2004). Deletion of 4’-
phosphatase activity resulted in a strain that produces a mixture of mono- and di-
phosphorylated, penta-acylated lipid A species that function as weak TLR4 
agonists (Figure 21C,F,G). For clarity, the wild-type strain, which is selectively 
enriched in tetra-acylated, non-phosphorylated lipid A, will herein be referred to 
as P. gingivalis-NP (Pg-NP). The lipid A phosphatase mutant strains will be 
referred to as P. gingivalis-4P (Pg-4P), and P. gingivalis-5P (Pg-5P), to indicate 
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Figure 21. P. gingivalis utilizes endogenous lipid A 1- and 4’-phosphatase 
activities to modify LPS structure.  
Lipid A isolated from P. gingivalis wild-type strain Pg-NP (A) or the lipid A mutant 
strains Pg-4P (B) and Pg-5P  (C) were examined by MALDI-TOF MS. Arrows 
indicate the major lipid A species expressed by each strain. (D-G) The lipid A 
structures examined in this study have been identified in P. gingivalis as 
previously described. In the case of E. coli LPS, the lipid A backbone consists of 





We used a cell-based reporter assay to confirm the predicted activity of lipid A 
structures on TLR4 activation. HEK 293 cells expressing recombinant human 
CD14/TLR4/MD-2 and an NF-kB/AP-1 dependent reporter construct were 
stimulated with graded doses of LPS purified from P. gingivalis strains (Figure 
22A). Hexa-acylated E. coli LPS was used as a control to indicate maximal 
stimulation. As expected, LPS purified from Pg-4P (4P-LPS) and Pg-5P (5P-LPS) 
both induced dose-dependent increases in TLR4 activation, and were weak 
agonists when compared to E. coli LPS. LPS purified from Pg-NP (NP-LPS) did 
not induce substantial reporter activity, consistent with a TLR4 silent phenotype.  
 
A reduction in acyl chain number would be expected to decrease the efficiency of 
TLR4/MD-2 dimerization and diminish transcriptional responses to LPS(Clett 
Erridge, Bennett-Guerrero, and Poxton 2002). However, 4P-LPS and 5P-LPS 
induced similar levels of TLR4 activation at high doses of LPS, whereas 4P-LPS 
was a superior agonist at low and intermediates doses (Figure 22A).  
 
Native P. gingivalis LPS also contains TLR2 activity, which is common among 
host-adapted Gram-negative organisms, including phylogenetically related 
Bacteroides spp, (Mancuso et al. 2005; C. Erridge 2004; Coats et al. 2009). LPS 
preparations from all three P. gingivalis strains similarly activated NF-kB 
dependent reporter activity in HEK293 expressing recombinant murine TLR2/1 




























































Figure 22. P. gingivalis evades TLR4 signaling via expression of modified 
lipid A.  
(A) HEK cells expressing human CD14/TLR4/MD-2 and an NF-kB reporter 
construct (secreted embryonic alkaline phosphate; SEAP) were stimulated with 
the increasing concentrations of LPS isolated from E. coli or P. gingivalis strains 
overnight. Supernatants were harvested and assayed for SEAP activity. Results 
are expressed as relative fluorescence units (RFU). (B) TLR2/1 and an NF-kB 
reporter construct (luciferase) were treated with LPS isolated from P. gingivalis 
strains overnight. Fold NF-kB activation indicates inducible firefly luciferase 
activity over the media control. Error bars represent the mean ± SD of triplicate 






Recognition of P. gingivalis LPS variants by the TLR4 complex and 
activation of downstream signaling pathways in DCs 
Efficient detection of extracellular LPS begins with CD14. LPS binding by CD14 
accelerates the constitutive endocytosis rate of this receptor, resulting in a 
transient decrease in cell surface expression (Tan et al. 2015). Because LPS 
must interact directly with CD14 to promote its endocytosis, loss of surface 
expression serves as a measure of LPS binding (Tan et al. 2015). To determine 
whether modification of lipid A structure influences detection by CD14, we treated 
DCs with LPS from P. gingivalis or E. coli and monitored CD14 endocytosis by 
flow cytometry (Figure 23A). Consistent with previous work, E. coli LPS induced 
the rapid endocytosis of CD14, resulting in a transient decrease in surface 
expression that was restored after 90 min (Tan et al. 2015). Both NP-LPS and 
5P-LPS accelerated CD14 endocytosis as efficiently as E. coli LPS, indicating 
that CD14 does not discriminate between these variants. We observed a two fold 
increase in the efficiency of CD14 endocytosis following treatment of cells with 
4P-LPS, as compared to all other LPS variants. Therefore, 4P-LPS binds to 
CD14 with higher affinity than other LPS variants and potently accelerates the 
CD14-dependent endocytosis pathway. Enhanced binding to CD14 probably 
results in more efficient transfer to TLR4/MD-2, which can explain the superior 




(Gioannini et al. 2004b). These results show that all P. gingivalis LPS species are 
detected by CD14 and promote its endocytosis, and that modification of lipid A 
can influence the efficiency of this interaction.  
 
LPS sensing rapidly mobilizes the DC cytoskeleton to enhance fluid phase 
antigen capture, or macropinocytosis, and this response requires both CD14 and 
TLR4 (Zanoni et al. 2011; West et al. 2004). Therefore, LPS-induced 
macropinocytosis was examined using Lucifer Yellow (LY), a fluorescent and cell 
impermeable fluid phase tracer (Figure 23B). Consistent with CD14 endocytosis 
assays, NP-LPS and 5P-LPS stimulated the uptake of LY comparably to E. coli 
LPS. The superior ability of 4P-LPS to accelerate the CD14-dependent 
endocytosis pathway was reflected by enhanced LY capture. Both CD14 and 
TLR4 were required for LPS-induced macropinocytosis in all cases. Comparable 
results were obtained using fluorescently labeled dextrans (data not shown). 
Thus, all LPS variants engage TLR4 and are similarly dependent on this receptor 
for their functional activity.   
 
Although LPS-induced macropinocytosis required CD14 and TLR4, it did not 
correlate with transcriptional activity. For instance, NP-LPS, which did not 
stimulate TLR4-dependent transcriptional responses in DCs (see below) or 
transfected cells, retained the ability to promote macropinocytosis. This result 




molecules is sufficient to engage DC functions, regardless of TLR4 agonist 
activity. To further explore this possibility, we examined processing of the model 
antigen ovalbumin (OVA) (Figure 23C). We used a self-quenched conjugate of 
OVA (DQ OVA) that becomes fluorescent upon proteolytic cleavage. Treatment 
with each of the LPS variants enhanced OVA endocytosis and processing of the 
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Figure 23. Recognition of structurally diverse LPS molecules by CD14 
promotes endocytosis and enhances antigen capture.  
(A) DCs were treated with P. gingivalis LPS species or E. coli  LPS (1 µg/ml) for 
0, 30, 60, or 90 min. Surface staining of CD14 was measured by flow cytometry.  
Line graphs represent the mean fluorescence intensity (MFI) of CD14 surface 
staining at each time point, as compared to staining pre-stimulation. (B) LPS-
induced macropinocytosis was assessed in WT, Cd14-/-, and Tlr4-/- DCs by flow 
cytometry using Lucifer Yellow (LY; 1 mg/ml) as the fluid-phase tracer. Cells 
were incubated with LY for 15 min in the presence or absence of the indicated 
LPS variants (100 ng/ml or 1 µg/ml). Cell-associated fluorescence intensity was 
then compared between LPS-treated and untreated cell populations to determine 
changes from steady state levels of macropinocytosis. (C) WT DCs were treated 
P. gingivalis LPS species or E. coli LPS (100 ng/ml or 1 µg/ml) in the presence of 
DQ-OVA (40 µg/ml) for 15 min. OVA uptake and processing were assessed by 
flow cytometry and are expressed as percent activity relative to untreated 
controls. Error bars represent the mean ± SD of triplicate samples from one 
representative of three independent experiments. *p <0.05; compared to similarly 
treated WT DCs by ANOVA with Bonferroni’s posttest. # p <0.05; compared to all 







LPS binding to MD-2 promotes TLR4 dimerization at the plasma membrane, a 
process that is necessary to initiate MyD88-dependent signaling (Saitoh et al. 
2004). To determine the impact of LPS structure on TLR4 dimerization, we 
utilized a flow cytometry based assay that exploits the binding characteristics of 
the MTS510 antibody (Akashi et al. 2000), which detects only TLR4/MD-2 
monomers (Figure 24A). Because this antibody recognizes monomeric 
TLR4/MD2 at the plasma membrane, loss of surface staining indicates receptor 
dimerization induced by LPS (Akashi et al. 2000; Tan et al. 2015). To 
complement this assay, we also examined Il6 mRNA induction as a read out for 
MyD88-dependent signaling from the plasma membrane (Figure 24B). When 
compared to E. coli LPS, 5P-LPS was a weaker inducer of TLR4/MD-2 
dimerization and Il6 mRNA induction. Interestingly, despite its high affinity for 
CD14, 4P-LPS triggered less efficient TLR4 dimerization and elicited lower Il6 
mRNA levels when compared to 5P-LPS. Thus, although 4P-LPS can out-
compete other species for binding to the TLR4 complex, it cannot efficiently 
cross-link TLR4. These properties explain the ability of this variant to function as 
both a weak TLR4 agonist and potent antagonist and are consistent with the 
finding that MD-2 represents the principal site of LPS antagonism (Coats et al. 
2005). Whereas NP-LPS and 5P-LPS were similarly recognized by CD14, NP-
LPS failed to dimerize TLR4 and induce gene expression. Overall, these results 




status in determining the agonistic activity of lipid A to the TLR4/MD-2 complex 
(Erridge, Bennett-Guerrero, and Poxton 2002; Park et al. 2009). Furthermore, the 
data indicate that the presence of a phosphate group on lipid A is critical for 
TLR4 dimerization and that P. gingivalis evades TLR4 signaling by 
dephosphorylating LPS. 
 
Native P. gingivalis LPS contains TLR2 activity, which contributes to MyD88-
dependent inflammatory gene expression (Ogawa et al. 2002; Triantafilou et al. 
2007, 2). Consistent with this, we observed low levels of Il6 mRNA induction in 
WT and Tlr4-/- DCs treated with NP-LPS (Figure 24B). TLR4-independent 
responses to 4P-LPS and 5P-LPS were also noted. To ensure that TLR2 
signaling was not a confounding factor in our interpretation of results, we 
examined LPS-induced gene expression in TLR2-deficient DCs (Figure 24C). 
We observed a similar trend in Il6 mRNA levels in WT and Tlr2-/- DCs treated 
with the different LPS variants (NP-LPS < 4P-LPS < 5P-LPS < E. coli LPS). 
Notably, NP-LPS was unable to induce Il6 expression in Tlr2-/- DCs, attesting to 
the fact this variant is transcriptionally silent at TLR4. As expected, LPS-induced 
Il6 expression was abolished in MyD88-deficient DCs for all variants tested 






































































































































































Figure 24. Modification of LPS structure impairs TLR4/MD-2 dimerization 
and MyD88-dependent signaling from the plasma membrane.  
(A) WT DCs were treated with P. gingivalis LPS species or E. coli LPS (1µg/ml) 
for 0, 30, 60, or 90 min and TLR4/MD-2 dimerization was assessed by flow 
cytometry. Percent dimerization was calculated by assessing TLR4/MD-2 
monomer staining (MFI) at each time point as compared to staining pre-
stimulation. Data represent the mean ± SD of triplicate cultures from one 
representative of three independent experiments. ***p <0.001; Two-way ANOVA 
with repeated measures with Bonferroni’s post-test. WT (B, D), Tlr4-/- (B), Tlr2-/- 
(C), and MyD88-/- (D) DCs were treated with 10, 100, or 1000 ng/ml of P. 
gingivalis LPS species or E. coli LPS for 2 hr. Relative Il6 mRNA expression was 
measured by qPCR. Results are expressed as fold change over media control. 
Data represent the mean ± SD of triplicate cultures from one representative of 
three independent experiments. *p <0.05; **p <0.01; ***p <0.001; NS, not 






In addition to initiating signaling from the plasma membrane, dimerization of 
TLR4 by MD-2 selects TLR4 as cargo for inflammatory endocytosis (Tan et al. 
2015). To determine the impact of LPS structure on TLR4 endocytosis, we 
utilized a flow cytometry based assay that uses loss of cell surface expression as 
a readout for endocytosis (Figure 25A) (Zanoni et al. 2011; Tan et al. 2015; 
Zanoni et al. 2017; Rajaiah et al. 2015). TLR4 surface levels were monitored 
using the Sa15-21 antibody, which recognizes TLR4 regardless of allosteric 
changes triggered by LPS binding. To supplement this approach, we also 
examined ifnb mRNA induction as a read out for TRIF-mediated signaling from 
endosomes (Figure 25B). E. coli LPS induced the rapid endocytosis of TLR4 
and robust ifnb mRNA induction in DCs. TLR4 endocytosis proceeded less 
efficiently in cells treated with 5P-LPS, and this coincided with a reduction in ifnb 
mRNA levels. Consistent with the inability of NP-LPS to cross-link TLR4, this 
variant failed to induce TLR4 endocytosis and ifnb mRNA expression. Addition of 
a phosphate group to this structure, through the use of 4P-LPS, restored TLR4 
endocytosis and ifnb expression. Thus, P. gingivalis evades TLR4 dimerization 
and prevents inflammatory endocytosis via dephosphorylation of LPS. DCs 
treated with 4P-LPS expressed significantly higher levels of ifnb mRNA at low 
and intermediate doses of LPS when compared to cells treated with 5P-LPS. 
These results are concordant with observations in transfected cells (Figure 22A) 
and indicate that the increased activity of 4P-LPS (at low doses) reflects 




explained by enhanced binding of this variant to CD14, which was required for 
LPS-induced TLR4 endocytosis (Figure 26A) and TRIF-mediated gene 
expression (Figure 26B), as previously shown (Zanoni et al. 2011, 14). 
Preferential signaling from endosomes is a possibility supported by the finding 
that MyD88-dependent signaling from the plasma membrane is not required for 
LPS-induced TLR4 endocytosis (Zanoni et al. 2011, 14) or TRIF-mediated ifnb 
expression (Figure 26C).  Similar results have been obtained with MPLA, which 
preferentially activates TRIF-dependent gene expression when compared to its 































































































Figure 25. A dephosphorylated LPS variant prevents inflammatory 
endocytosis and evades TRIF-dependent signaling from endosomes.  
(A) DCs were treated with P. gingivalis LPS species or E. coli LPS (1 µg/ml). Cell 
surface levels of TLR4 were measured by flow cytometry after 0, 30, 60, or 90 
min.  Line graphs represent the mean fluorescence intensity (MFI) of TLR4 
surface staining at each time point, as compared to staining pre-stimulation. 
Results are expressed as fold change over media control. Data represent the 
mean ± SD of triplicate cultures from one representative of three independent 
experiments. ***p <0.001 by Two-way ANOVA with repeated measures with 
Bonferroni’s post-test. (B) WT and Tlr4-/- DCs were treated with P. gingivalis LPS 
species or E. coli LPS at a concentration of 10, 100, or 1000 ng/ml for 2h. 
Relative Ifnb mRNA expression was measured by qPCR. Results are expressed 
as fold change over media control. Data represent the mean ± SD of triplicate 
cultures from one representative of three independent experiments. ***p <0.001 









































































































































Figure 26. CD14 controls the LPS-induced endocytosis of TLR4.  
(A) WT and Cd14-/- DCs were treated with P. gingivalis LPS species or E. coli 
LPS (1 µg/ml) for the indicated times. TLR4 endocytosis was determined by flow 
cytometry. (B) WT and Cd14-/- DCs were treated with P. gingivalis LPS species 
or E. coli LPS at a concentration of 10, 100, or 1000 ng/ml for 2h. Relative Ifnb 
mRNA expression was measured by qPCR. Results are expressed as fold 
change over media control. (C) WT and MyD88-/- DCs were treated with P. 
gingivalis LPS species or E. coli LPS at a concentration of 10, 100, or 1000 ng/ml 
for 2h. Relative Ifnb mRNA expression was measured by qPCR. Results are 
expressed as fold change over media control. Data represent the mean ± SD of 




Collectively, our results demonstrate that modification of LPS structure influences 
the strength of TLR4 signaling and preferential adapter usage by altering 
interactions with the TLR4 complex. Both NP- and 5P-LPS are similarly 
recognized by CD14 and promote its endocytosis. The activities of these variants 
are discriminated by MD-2, based upon their capacity to dimerize this receptor. 
NP-LPS fails to dimerize TLR4 and prevents its selection as cargo for 
inflammatory endocytosis, thus evading signaling from both the plasma 
membrane and endosomes. Although 4P-LPS is less efficient in inducing TLR4 
dimerization and MyD88-dependent signaling when compared to 5P-LPS, it 
binds CD14 with higher affinity and comparably activates endosomal TLR4 
signaling. Regardless of transcriptional activity, all LPS variants were capable of 
triggering critical changes to DC function, including enhanced antigen capture 
and processing.  
 
Alteration of lipid A structure modulates LPS-induced DC maturation  
To determine the impact of lipid A structure on phenotypic correlates of DC 
maturation, we treated DCs with P. gingivalis LPS species or E. coli LPS (100 
ng/ml; 16-18 hr) and assessed surface expression of molecules involved in T cell 
activation (Figure 27A). Treatment with E. coli LPS induced the classical 
features of DC maturation including increased expression of peptide-MHC 
complexes (MHC-I, MHC-II), co-stimulatory molecules (CD40, CD80, CD86), and 




LPS also induced the expression of the co-inhibitory molecules B7-H4 and PDL-
1. In contrast, treatment with NP-LPS failed to induce the expression of all 
markers tested. Both 4P-LPS and 5P-LPS were poor inducers of maturation 
molecules when compared to E. coli LPS, consistent with their weak 
transcriptional activity. As an additional control, we included LPS from the human 
gut commensal Bacteroides thetaioataomicron (Bt-LPS), since it contains a 
penta-acylated and mono-phosphorylated lipid A that is structurally similar to that 
produced by P. gingivalis. Mono-phosphorylated Bt-LPS differs from its 
counterpart in P. gingivalis LPS only in the positioning of the phosphate group 
(Figure 27B). Bt-LPS contains predominantly a lipid A 1-phosphate, whereas 5P-
LPS contains predominantly a lipid A 4’-phosphate.  This structural difference 
confers these LPS variants with markedly distinct abilities to promote pro-
inflammatory TLR4 responses (Coats, Berezow et al 2011). Accordingly, Bt-LPS 
was superior in its ability to induce the expression of maturation molecules when 
compared to P. gingivalis LPS. However, the maturation phenotype induced by 
























































































































































Figure 27. Alteration of lipid A structure modulates LPS-induced co-
stimulatory molecule expression.  
(A) DCs were treated, or not, with LPS from P. gingivalis, B. thetaiotaomicron or 
E. coli (100 ng/ml) for 16-18 hr. Cell surface expression of co-stimulatory 
molecules (CD40, CD80, CD86), co-inhibitory molecules (B7-H4, PD-L1), MHC 
complexes (MHC-I, MHC-II), and CCR7 were examined by flow cytometry. 
Histogram overlays are shown for each marker. A dashed line was drawn 
arbitrarily for reference. Results are representative of three independent 
experiments. (B) Structure of penta-acylated, mono-phosphorylated lipid A 






Maturing DCs secrete immunomodulatory cytokines that can influence T cell 
activation and effector function, including IL-6 and IL-12p70 (Mellman and 
Steinman 2001). We next compared production of these cytokines among LPS 
treated DCs (100 ng/ml)  (Figure 28A&B). E. coli LPS induced robust production 
of IL-6 and IL-12p70 when compared to all other variants, whereas Bt-LPS was 
significantly more stimulatory than P. gingivalis LPS species. Low but detectable 
levels of IL-6 were observed in response to 4P-LPS and 5P-LPS. No cytokines 
were detected in cells treated with NP-LPS or LPS treated Tlr4-/- DCs. A similar 
trend in results was obtained at a higher dose of LPS (1 µg/ml) (Figure 28C&D). 
In agreement with transcriptional data, these results demonstrate that P. 
gingivalis evades TLR4-dependent pro-inflammatory cytokine production and the 































































































































































Figure 28. Modification of lipid A structure attenuates LPS-induced 
inflammatory cytokine production.  
DCs were treated with LPS from P. gingivalis, B. thetaiotaomicron or E. coli (100 
ng/ml) for 16-18 hr. Secretion of IL-6 (A) and IL-12p70 (B) into cell culture 
supernatants was measured by ELISA. In (C) and (D) a dose of 1 µg/ml was 
used for all LPS species except E. coli  (100 ng/ml).  Data represent the mean ± 
SD of triplicate cultures from one representative of three independent 
experiments. *p <0.05; **p <0.01; ***p <0.001; #p <0.001 E. coli LPS versus all 





DC maturation is typically accompanied by profound changes to cellular 
morphology. This transformation was apparent for E. coli LPS treated DCs when 
light scattering properties were assessed by flow cytometry (Figure 29A). Such 
changes were not observed when DCs were treated with P. gingivalis LPS 
species. When other microbial ligands were tested, including CpG DNA (TLR9) 
and the synthetic lipopeptide Pam3CysK4 (TLR2), morphological changes and 
increased expression of maturation markers were both observed (Figure 29B). 
Overall, these data indicate that P. gingivalis LPS species are generally poor 
inducers of phenotypic maturation markers, even when compared to structurally 
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 Figure 29.  Comparison of morphological changes that accompany DC 
maturation induced by microbial ligands. 
(A) DCs were treated with the indicated LPS variants (100 ng/ml), CpG (1µM), 
Pam3CysK4 (1µg/ml), or media alone for 16 hr. Light scattering properties were 
analyzed by flow cytometry. (B) DCs treated with E. coli LPS (100 ng/ml), CpG 
(1µM), Pam3CysK4 (1µg/ml), or media alone for 16 hr were analyzed for surface 
expression of CD40, CD80, CD86, MHC-II, and CCR7 by flow cytometry. Results 
are presented as histogram overlays (dashed lines drawn arbitrarily for 






The CD14-dependent endocytosis pathway is required for LPS-induced 
cross-presentation  
To determine whether modification of lipid A structure influences cross-
presentation, we treated DCs with P. gingivalis LPS species or E. coli LPS (100 
ng/ml) for 16-18 hr. Cells were washed thoroughly and pulsed with graded doses 
of soluble OVA (sOVA) or bead bound OVA (bbOVA) for 1 hr. The logic behind 
using sOVA and bbOVA is that they are taken up by two different routes, 
endocytosis and phagocytosis, respectively. We assessed cross-presentation to 
TCR transgenic CD8+ OT-I T cells, which recognize the SIINFEKL peptide from 
OVA presented by the H-2Kb MHC-I molecule. The pre-processed SIINFEKL 
peptide was used as a control for cross-presentation, and was presented with 
equal efficiency by resting and LPS-treated DCs (Figure 30A). Consistent with 
prior studies, E. coli LPS-treated DCs cross-presented both sOVA (Figure 30B) 
and bbOVA (Figure 30C) more efficiently than untreated cells (Alloatti et al. 
2015). DCs treated with NP-, 4P-, and 5P-LPS cross-presented sOVA and 
bbOVA as efficiently as E. coli LPS-treated DCs. Equivalent results were 
obtained with Bt-LPS, indicating that outcomes were not a microbe specific 
anomaly. Therefore, LPS treated DCs cross-present endosomal and phagosomal 
antigens more efficiently than untreated DCs, a difference that is independent of 
lipid A structure. Thus, contrary to LPS-induced co-stimulatory molecule 
expression and inflammatory cytokine production, enhanced cross-presentation 




responses. Together with data in previous sections, these results demonstrate 
that LPS induces the functional maturation of DCs, which includes enhanced 
antigen capture, processing, and presentation on MHC-I molecules, independent 









































































Figure 30. LPS treatment enhances cross-presentation of peptides derived 
from endosomal and phagosomal antigens regardless of lipid A structure.  
DCs were treated with media alone or LPS from P. gingivalis, B. thetaiotaomicron 
or E. coli (100 ng/ml) for 16-18 hr. Cells were pulsed with SIINFEKL peptide 
(0.01 ng/ml) (A), sOVA (B), or bbOVA (C) for 1hr and then co-cultured with CTV-
labeled OT-I T cells. The frequency of proliferating T cells was assessed by flow 
cytometry after 72 hr. Data represent the mean ± SD of triplicate samples from 






Our results indicate that a common pathway activated by structurally diverse LPS 
variants enhances cross-presentation and that this pathway is independent of 
host-mediated transcriptional responses. To regulate the presentation of 
internalized antigens on MHC-I molecules, LPS might need to be recruited to the 
appropriate compartment. The CD14-dependent endocytosis pathway mediates 
LPS internalization, proceeds independently of TLR4 signaling, and was 
commonly activated by all LPS variants (Zanoni et al. 2011; Latz et al. 2002). 
Thus, we postulated that CD14 would be critical for LPS-induced cross-
presentation. To address this, we treated WT and Cd14-/- DCs with E. coli LPS 
and assessed cross-presentation of OVA to OT-I cells (Figure 31A). In contrast 
to results obtained in WT cells, LPS treatment failed to increase the efficiency of 
cross-presentation in Cd14-/- DCs for both endosomal and phagosomal antigens. 
Given that CD14 is necessary for LPS-induced macropinocytosis, it was possible 
that differences in cross-presentation were due to inefficient uptake during 
antigen pulsing. However, the continuous presence of soluble OVA in culture 
could not restore cross-presentation deficits in Cd14-/- DC, in response to either 
E. coli or P. gingivalis LPS species (Figure S5A).  Under these conditions, Cd14-/- 
DCs were as defective as Tlr4-/- DCs in their ability to induce OT-I proliferation 
(Figure 31B). Cd14-/- and Tlr4-/- DCs activated OT-I cells similarly to WT DCs 
when provided with SIINFEKL, excluding a general inability to present peptide 
(Figure 31C). The requirement for CD14 could not be attributed to events 




these were not necessary for enhanced cross-presentation. Moreover, CD14 
deficiency reduced but did not abolish LPS-induced TLR4 signaling from the 
plasma membrane, as assessed by transcriptional upregulation of Il1b (Figure 
31D). These results demonstrate that TLR4-dependent transcriptional responses 
are neither necessary nor sufficient to promote cross-presentation. These 
collective findings demonstrate that CD14 is required for the LPS-induced 
increase in the efficiency of cross-presentation and suggest that the need for this 
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Figure 31. The CD14 dependent endocytosis pathway is required for LPS-
induced cross-presentation.  
(A) Cross-presentation of SIINFEKL from soluble or bead-bound OVA by resting 
and E. coli LPS-treated WT or Cd14-/- DCs. DCs were treated with media alone 
or E. coli LPS (100 ng/ml) for 16-18 hr and then pulsed with graded doses of 
sOVA or bbOVA for 1hr prior to co-culture with CTV labeled OT-I T cells. The 
frequency of proliferating T cells was assessed by flow cytometry after 72 hr. 
Results are representative of two similar experiments.   (B) WT, Cd14-/-, and Tlr4-
/- DCs were treated with the indicated LPS species (100 ng/ml; 16-18hr) and then 
co-cultured with CTV-labeled OT-I T cells in the presence of soluble OVA (40 
µg/ml). The absolute number of live proliferating T cells was determined by flow 
cytometry after 72 hr. Data represent the mean ± SD of triplicate samples from 
one of two similar experiments. (C) WT, Tlr4-/-, and Cd14-/- DCs were pulsed with 
SIINFEKL peptide (0.01 ng/ml) and then co-cultured with CTV-labeled OT-I T 
cells. The absolute number of proliferating T cells was determined by flow 
cytometry after 72 hr. Results are representative of two similar experiments. (D) 
WT, Cd14-/-, and Tlr4-/- DCs were stimulated with 10, 100, or 1000 ng/ml of E. coli 
LPS for 2 hr. Il1b mRNA expression was examined by qPCR. Data represent the 









If the requirement for CD14 in cross-presentation is due to its role in LPS 
endocytosis, then alternative means of delivering LPS to intracellular 
compartments should bypass the need for this PRR. This was tested using whole 
E. coli as a source of LPS. Treatment with E. coli restored cross-presentation of 
sOVA and bbOVA in Cd14-/- DCs to near WT levels (Figure 32A), and this was 
TLR4-dependent (Figure 32B,C). We conclude that the CD14 endocytosis 
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Figure 32. The requirement for CD14 in LPS-induced cross-presentation 
can be bypassed with phagocytic cargo.  
(A) Cross-presentation of SIINFEKL from sOVA and bbOVA by resting and E. 
coli treated WT or Cd14-/- DCs. DCs were treated with media alone or E. coli 
(MOI 10) for 16-18 hr and then pulsed with graded doses of sOVA or bbOVA for 
1hr before addition of CTV labeled OT-I T cells. The frequency of proliferating T 
cells was assessed by flow cytometry after 72 hr. (B&C) Cross-presentation of 
sOVA by resting or E. coli treated WT, Cd14-/-, or Tlr4-/- DCs. DCs were treated 
with media alone or E. coli (MOI 10) for 16-18 hr and then pulsed with graded 
doses of sOVA for 1 hr before addition of CTV labeled OT-I T cells. The 
frequency (B) and absolute number (C) of proliferating T cells was determined by 
flow cytometry after 72 hr. Data represent the mean ± SD of triplicate samples 





LPS structure regulates DC mediated cross-priming 
The activation of CD8 T cells by cross-presented peptides requires additional 
signals that collectively provide co-stimulation. To determine whether 
modification of LPS structure influences T cell priming, we measured T cell 
expansion and production of the effector cytokines IL-2 and IFNγ. Immature DCs 
poorly stimulated OT-I proliferation and cytokine secretion in response to bbOVA 
(Figure 33A-C), consistent with the finding that cross-presentation is inefficient in 
these cells. Moreover, despite the fact that immature DCs present the pre-
processed SIINFEKL peptide as efficiently as LPS-treated cells, they did not 
provide the necessary signals for robust T cell activation and proliferation (Figure 
33D-F). In fact, the majority of activated T cells in these cultures died (Figure 
33G). In contrast, DCs treated with E. coli LPS were potent stimulators of OT-I 
expansion and cytokine secretion with each source of antigen tested. The dose 
response curve to induce OT-I proliferation in response to bbOVA was 
comparable in DCs treated with 4P-LPS, 5P-LPS, and E. coli LPS. However, T 
cells activated by DCs treated with 4P-LPS and 5P-LPS secreted significantly 
lower levels of IFNγ and IL-2. When compared to all other LPS variants, DCs 
treated with NP-LPS were markedly impaired in their ability to prime T cells, as 
indicated by a reduction in the number of live proliferating T cells and diminished 
cytokine production. Comparable results were obtained with regards to T cell 
proliferation when DCs were pulsed with sOVA (Figure 33H). Cytokine secretion 




shown). These results demonstrate that modification of LPS structure controls 
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Figure 33. LPS structure regulates CD8 T cell activation by cross-presented 
peptides.  
Cross-presentation of bbOVA (A-C), the SIINFEKL peptide (D-G), or sOVA (H) 
by immature and LPS-treated DCs. DCs treated with LPS from P. gingivalis or E. 
coli (100 ng/ml; 16-18 hr) or media alone were pulsed with sOVA, bbOVA, or the 
SIINFEKL peptide (0.01 ng/ml) for 1 hr and then co-cultured with CTV-labeled 
OT-I T cells. (A, D, H) The absolute number of live proliferating T cells was 
determined by flow cytometry after 72 hr. IL-2 (B, E) and IFNγ (C, F) secretion by 
OT-I cells in 18 hr culture supernatants was measured by ELISA. Data represent 
the mean ± SD of triplicate samples from one representative of three 
independent experiments. *p <0.05, **p <0.01, ***p <0.0001; # **p <0.01 NP-LPS 
versus all other LPS variants by two-way ANOVA with Bonferroni’s post-test. (G) 
Top panel: Light scattering properties of OT-I cells co-cultured with immature 
DCs, peptide-pulsed immature DCs, and peptide-pulsed LPS-treated DCs for 72 
hr. Lower panel: T cell proliferation and viability analysis in the indicated co-
cultures. Shown are representative scatter plots for CTV dilution versus Live 





Because NP-LPS enhanced the efficiency of cross-presentation comparably to 
other LPS variants but failed to induce robust proliferative responses, we 
hypothesized that DCs treated with this species promote T cell tolerance, a 
process that is characterized by proliferation followed by cell death (Kurts et al. 
1997). To address this possibility, we examined the fate of activated T cells in the 
co-culture system (Figure 34A-E). The frequency of proliferating T cells was low 
in cultures containing immature DCs. Even at high doses of antigen, a substantial 
portion of T cells in these cultures die without engaging in a productive encounter 
with their cognate peptide-MHC-I ligand (R1; Figure 34A,B). LPS treatment 
enhanced cross-presentation, such that ~80-90% of T cells were activated at the 
lowest dose of antigen, regardless of lipid A structure. In cultures containing DCs 
treated with 4P-LPS, 5P-LPS, and E. coli LPS, T cell activation led to proliferation 
and increased survival (R2; Figure 34A,C). When DCs were treated with NP-
LPS, the majority of activated T cells when through several rounds of proliferation 
followed by cell death (R3; Figure 34A,C,D). When both live and dead T cells 
were taken into account (R2+R3), the percentage (Figure 34D) and absolute 
number (Figure 34E) of cells that had undergone proliferation was similar among 
cultures of LPS treated DC (and lower in immature DCs). Therefore, enhanced 
cross-presentation by DCs treated with NP-LPS, a variant that evades 
inflammatory endocytosis, leads to T cell tolerance rather than priming. Thus, 
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Figure 34. An LPS variant that prevents inflammatory endocytosis 
enhances cross-presentation and promotes T cell tolerance.  
DCs treated with LPS from P. gingivalis or E. coli (100 ng/ml; 16-18 hr) or media 
alone were pulsed with bbOVA for 1hr and co-cultured with CTV labeled OT-I 
cells. T cell proliferation and viability were assessed by flow cytometry after 72 
hr. (A) Representative scatter plots for CTV dilution versus Live Dead staining. 
Three gated regions are shown: dead T cells that did not proliferate (R1), live 
proliferating T cells (R2), and T cells that underwent activation induced cell death 
(R3). Bar graphs show the percentage of cells in R1 (B), R2 (C), and R2 + R3 
(D). The absolute numbers of live and dead T cells that underwent proliferation 
(R2 + R3) are shown in (E). Data represent the mean ± SD of triplicate samples 





LPS structure regulates the activity endocytic pathway: phagosome 
maturation and antigen internalization 
 We next investigated whether LPS structure dictates the efficiency of T cell 
priming. E. coli LPS (and other TLR ligands) enhance the efficiency of cross-
priming by delaying phagosomal antigen degradation, thereby preserving 
peptides for optimal T cell activation. Therefore, we characterized the 
degradative capacity of phagosomes in immature and LPS treated DCs using 
bbOVA and single organelle-based flow cytometry (Figure 35A&B) (Savina et al. 
2010). This technique allows for kinetic analysis of OVA degradation exclusively 
in phagocytosed beads. In immature DCs, bead phagocytosis led to the 
progressive degradation of OVA over 120’. When DCs were treated with E. coli 
LPS, very few phagosomes with low OVA amounts appeared over time, 
consistent with delayed antigen degradation. In contrast, no delay in OVA 
degradation was observed when DCs were treated with P. gingivalis LPS 
species. These results suggest that cross-priming is less efficient in DCs treated 
with 4P- and 5P-LPS when compared to cells treated with E. coli LPS, despite 
the fact that these variants induce similar T cell proliferative responses in cross-




























































Figure 35. LPS structure modulates the rate of phagosomal antigen 
degradation.  
DCs were treated with P. gingivalis or E. coli LPS (100 ng/ml) or media alone for 
16-18 hr before phagocytosis of bbOVA. Phagosomal degradation of OVA was 
analyzed by flow cytometry after different chase periods. (A) Representative 
histograms are shown for each time point and condition. (B) A graphical 
representation of pooled results from two of three independent experiments is 
shown. Percent degradation was calculated by measuring the amount of 





Delayed antigen degradation in maturing DCs is the combined result of physical 
sequestration of phagosomes and lysosomes and a global decrease in the rate 
of vesicular traffic along the endocytic axis. As a consequence, DCs lose their 
capacity to internalize antigens as they mature into efficient APCs. To determine 
whether enhanced cross-priming by DCs treated with 4P- and 5P-LPS could be 
explained by increased antigen uptake, we assessed the endocytic activity of 
immature and LPS treated DCs. Whereas immature DCs avidly internalized 
antigens by phagocytosis (Figure 36A), macropinocytosis (Figure 36B), and 
endocytosis (Figure 36C), all of these activities were significantly reduced in DCs 
treated with E. coli LPS. In contrast, phagocytosis was slightly enhanced in DCs 
treated with all P. gingivalis LPS species as compared to immature DCs, and 
macropinocytosis was unaltered. Interestingly, endocytosis was significantly 
reduced in DCs treated with 4P- and 5P-LPS when compared to immature DCs, 
but was unaltered in DCs treated with the NP-LPS variant (Figure 36C), 
correlating with the TLR4-dependent endosomal signaling characteristics of 
these three LPS variants. These results show that DCs treated with P. gingivalis 
LPS species retain their antigen sampling function, (and more specifically actin –
dependent forms of endocytosis) and suggest that increased antigen uptake can 
compensate for the fact that phagosomal antigens are degraded at an 
accelerated rate. Indeed, a reduction in T cell activation was observed in DCs 
treated with 4P- and 5P-LPS, but only at limiting concentrations of antigen 




capacity to internalize antigens, delayed degradation allows for efficient cross-
priming from a limited antigen depot. In contrast, DCs treated with P. gingivalis 
LPS degrade internalized antigen at accelerated rate but retain their antigen 
sampling function and can prime T cells with similar efficiency when antigen is in 
excess. Collectively, these results reveal that P. gingivalis LPS induces a 
program of DC maturation that allows for constitutive antigen uptake and cross-




























































































































Figure 36. LPS structure regulates the endocytic activity of DCs.  
DCs were treated with the indicated LPS variants (100 ng/ml) or media alone for 
16-18 hr. Phagocytosis (A; bbOVA), macropinocytosis (B; LY), and endocytosis 
(C; DQ-OVA) were assessed by flow cytometry. Results are expressed as 
percent activity relative to media treated immature DCs. Data represent the mean 
± SD of triplicate samples from one representative of three independent 












































Figure 37. DCs treated with P. gingivalis LPS species cross-prime T cells 
less efficiently when antigen is limiting.   
DCs were treated with the indicated LPS variants (100 ng/ml) or media alone for 
16-18 hr and then co-cultured with CTV-labeled OT-I T cells in the presence of a 
limiting dose of soluble OVA (40 µg/ml). The absolute number of proliferating T 
cells was determined by flow cytometry after 72 hr. Data represent the mean ± 





IFNβ exerts regulatory input on the endocytic pathway following E. coli LPS 
stimulation and enhances the efficiency of CD8 T cell priming  
Our results support that notion that TLR4 signaling from endosomes regulates 
the endocytic pathway, to optimize the efficiency of T cell priming and improve 
host defense. To identify factors involved, we first considered the role of IFNs. 
During the immune response to viruses, IFN-alpha (IFNa) enhances cross-
priming of CD8+ T cells by delaying antigen degradation (Spadaro et al. 2012). 
We reasoned that IFNβ works in an analogous manner to promote enhanced 
cross-priming by E. coli LPS and could account for differences in efficiency 
observed with P. gingivalis LPS. To address this, we first generated DCs from 
IFNβ-deficient mice. IFNβ deficiency did not impair the differentiation of bone 
marrow precursors into DCs, or alter their cell-surface phenotype (Figure 38A). 
Although E. coli LPS induced cytokine production was moderately impaired 
(Figure 38B), the phenotypic maturation of Ifnb-/- DCs was largely unaffected 



















































































































































































































































































































































































































































































































































































Figure 38. Phenotypic analysis of IFNβ-deficient DCs and assessment of 
immune responses to LPS and other microbial ligands. 
(A) DCs generated from WT and Ifnb-/- mice were analyzed for surface 
expression of CD11c, CD11b, DC-SIGN, MHC-I, and MHC-II by flow cytometry. 
(B) WT and Ifnb-/- DCs were treated with E. coli LPS (100 ng/ml), Pam3CysK4 
(1µg/ml), or media alone for 18 hr. Levels of TNF, IL-6, and IL-12p70 in cell 
culture supernatants were determined by ELISA. (C) WT and Ifnb-/- DCs were 
treated with E. coli LPS (100 ng/ml), CpG DNA (1 µM) Pam3CysK4 (1µg/ml), or 
media alone for 18 hr. Surface expression of co-stimulatory molecules (CD40, 
CD80, and CD86) and MHC complexes were analyzed by flow cytometry. 
Results are expressed as fold change in surface expression (MFI) relative to 
media treated controls. Data represent the mean ± SD of triplicate samples from 





To determine whether IFNβ mediates the LPS-induced delay in antigen 
degradation, we assessed the proteolytic activity of phagosomes in E. coli LPS 
stimulated WT and Ifnb-/- DCs (Figure 39). Stimulation with E. coli LPS 
significantly delayed phagosomal degradation of OVA in WT DCs when 
compared to unstimulated controls but failed to do so in Ifnb-/- DCs. Moreover, 
the LPS induced reduction in the rate of phagocytosis (Figure 40A), 
macropinocytosis (Figure 40B), and endocytosis (Figure 40C) were abolished in 
Ifnb-/- cells. In fact, a significant increase in phagocytic activity was observed in 
Ifnb-/- DCs stimulated with E. coli LPS relative to unstimulated controls, mirroring 
the phenotype observed in WT DCs treated with P. gingivalis LPS. These results 
suggested that IFNβ delays the rate of vesicular traffic along the endocytic axis, 
thereby reducing both the rate of antigen uptake and its subsequent degradation. 
Accordingly, treatment of DCs with recombinant IFNβ led to a reduction in all 
forms of endocytic uptake (Figure 41A-C), delayed phagosomal antigen 
degradation (Figure 41D), and induced changes to cell morphology (Figure 41E) 
comparably to LPS stimulation. Therefore, IFNβ regulates the endocytic pathway 
of DCs following LPS stimulation, and controls the rate of antigen transport along 
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Figure 39. IFNβ mediates the LPS-induced delay in the rate of phagosomal 
antigen degradation. 
WT and Ifnb-/- DCs were treated with E. coli LPS (100 ng/ml) or media alone for 
16-18 hr before phagocytosis of bbOVA. Phagosomal degradation of OVA was 
analyzed by single organelle-based flow cytometry after different chase periods. 
Representative histograms depict OVA staining on beads for each time point and 
condition. A graphical representation of pooled results from two of three 
independent experiments is included.  Percent degradation was calculated by 

















































































Figure 40. IFNβ reduces the endocytic activity of DCs following LPS 
treatment.  
WT and Ifnb-/- DCs were treated with E. coli LPS (100 ng/ml) or media alone for 
16-18 hr. Phagocytosis (B; bbOVA), macropinocytosis (C; LY), and endocytosis 
(D; DQ-OVA) were assessed by flow cytometry. The results are expressed as 
percent activity relative to media treated immature DCs. Data represent the mean 
± SD of triplicate samples from one representative of three independent 
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Figure 41. IFNβ controls the rate of antigen transport along the endocytic 
axis in DCs thereby reducing antigen uptake and delaying degradation.  
(A) DCs were treated with E. coli LPS (100 ng/ml), rmIFNβ (50 U/ml) or media 
alone for 16-18 hr before phagocytosis of bbOVA. Phagosomal degradation of 
OVA was analyzed by flow cytometry after different chase periods. (B-D) DCs 
were treated with E. coli LPS (100 ng/ml), rmIFNβ (50 U/ml) or media alone for 
16-18 hr. Phagocytosis (B; bbOVA), macropinocytosis (C; LY), and endocytosis 
(D; DQ-OVA) were assessed by flow cytometry. Results are expressed as 
percent activity relative to media treated immature DCs. (E) Light scattering 
properties of DCs treated with E. coli LPS (100 ng/ml), rmIFNβ (50 U/ml) or 
media alone for 16-18 hr as assessed by flow cytometry. Error bars represent 





We next examined the role of IFNβ in LPS-induced cross-presentation. LPS 
treatment increased the efficiency of cross-presentation for both sOVA and 
bbOVA in WT and Ifnb-/- DCs (Figure 42A). However, robust T cell proliferation 
(Figure 42B) and cytokine secretion (Figure 42C) were only observed in 
response to LPS treated WT and not Ifnb-/- DCs. These results indicate that IFNβ 
is dispensable for the LPS-induced increase in the efficiency of cross-
presentation but necessary for optimal CD8+ T cell priming. Note that, like WT 
DCs treated with P. gingivalis LPS, E. coli LPS treated Ifnb-/- DCs retain their 
antigen sampling function (take up more antigen) and cross-prime less efficiently.  
We observed comparable T cell responses when LPS treated WT and Ifnb-/- DCs 
were pulsed with the processed SIINFEKL peptide (Figure 42D,E), suggesting 
that impaired cross-priming is due to defects in phagosomal functions rather than 
differences in co-stimulation or MHC-I surface levels. Indeed, IFNβ was 
dispensable for E. coli LPS induced MHC-I expression (Figure 38C). We 
conclude that IFNβ regulates the endocytic pathway following LPS stimulation, to 
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Figure 42. IFNβ is essential for E. coli LPS-induced cross-priming but not 
cross-presentation.  
(A-C) Cross-presentation of sOVA, bbOVA, or the SIINFEKL peptide by 
immature and E. coli LPS-treated WT or Ifnb-/- DCs. DCs treated with E. coli LPS 
(100 ng/ml; 16-18 hr) or media alone were pulsed with sOVA, bbOVA, or the 
SIINFEKL peptide (0.01 ng/ml) and then co-cultured with CTV labeled OT-I T 
cells. The frequency (A) and absolute number (B, D) of proliferating T cells was 
determined by flow cytometry after 72 hrs. (C, E) IL-2 and IFNγ secretion by OT-I 
cells in 18 hr culture supernatants as measured by ELISA. (D&E) WT and Ifnb-/- 
DCs treated with E. coli LPS (100 ng/ml; 16-18 hr) or media alone were pulsed 
with the SIINFEKL peptide (0.01 ng/ml) and co-cultured with CTV labeled T cells. 
(D) The absolute number of proliferating T cells was determined by flow 
cytometry after 72 hrs. (E) IL-2 and IFNγ secretion by OT-I cells as determined 





To determine whether IFNβ contributes to the differential ability of LPS variants 
to promote cross-priming, we treated WT and Ifnb-/- DCs with P. gingivalis LPS 
species or E. coli LPS (100 ng/ml;16-18 hr) and assessed cross-presentation of 
sOVA to OT-I T cells.  As shown in Figure 43A, treatment with P. gingivalis LPS 
species or E. coli LPS enhanced cross-presentation of SIINFEKL from sOVA in 
both WT and Ifnb-/- DCs. Ifnb-/- DCs treated with 4P-, 5P-, or E. coli LPS were 
significantly impaired in their ability to support OT-I T cell proliferation, when 
compared to similarly treated WT DCs (Figure 43B). In contrast, both WT and 
Ifnb-/- DCs induced similar T cell responses when treated with NP-LPS, a variant 
that evades inflammatory endocytosis and ifnb induction. These results 
demonstrate that IFNb contributes to the differential capacity of LPS variants to 
promote cross-priming by DCs. For both genotypes, T cell priming was most 
efficient when DCs were treated with E. coli LPS. Notably, 4P-LPS, which 
potently accelerated the CD14-dependent endocytosis pathway and 
preferentially activates signaling from endosomes, was superior to 5P-LPS in 
promoting cross-priming by Ifnb-/- DCs. This suggests that other aspects of 


































































































































Figure 43. IFNβ contributes to the differentially capacity of LPS variants to 
promote cross-priming by DCs.  
(A-C) Cross-presentation of sOVA by immature and LPS-treated WT or Ifnb-/- 
DCs. DCs treated with E. coli LPS (100 ng/ml; 16-18 hr) or media alone were 
pulsed with graded doses of sOVA for 1 hr and then co-cultured with CTV 
labeled OT-I T cells. The frequency (A) and absolute number (B) of live 
proliferating T cells was determined by flow cytometry after 72 hrs. Data 
represent the mean ± SD of triplicate samples from one representative of two 





In this chapter, we demonstrated that modification of lipid A structure influences 
the strength of TLR4 signaling and preferential adapter usage by altering 
interactions with the TLR4 complex. Both NP- and 5P-LPS were similarly 
recognized by CD14 and promoted its endocytosis. The activities of these 
variants were discriminated by MD-2, based upon their capacity to dimerize this 
receptor. NP-LPS failed to dimerize TLR4 and prevented its selection as cargo 
for inflammatory endocytosis, thus evading TLR4 signaling from both the plasma 
membrane and from endosomes. 4P-LPS was a weaker inducer of TLR4/MD-2 
dimerization and MyD88-dependent signaling when compared to 5P-LPS, but 
potently accelerated the CD14 endocytosis pathway and induced a similar 
degree of TRIF-dependent signaling. P. gingivalis LPS species were weak TLR4 
agonists when compared to E. coli LPS. The transcriptional activities of these 
LPS variants correlated with their ability to induce the expression of co-
stimulatory molecules and inflammatory cytokine production.   
 
Surprisingly, we found that LPS treatment enhanced the efficiency of cross-
presentation independent of its ability to induce canonical TLR4 signaling. 
Enhanced cross-presentation required CD14-dependent endocytosis. As CD14 
lacks a transmembrane domain and intrinsic signaling capacity, the data suggest 
that LPS needs to be internalized in order to influence antigen presentation. We 




that inflammatory endocytosis was necessary to promote T cell priming. NP-LPS, 
a variant that evades TLR4 endocytosis, enhanced the efficiency of cross-
presentation and promoted T cell tolerance. Moreover, the capacity of LPS 
variants to promote TLR4 signaling from endosomes correlated with the 
efficiency of T cell priming and IFN played a key regulatory role in this regard. 
Our results suggest that IFN induced a global decrease in the rate of endocytic 
traffic, which reduced antigen uptake and delayed phagosomal degradation, 
thereby preserving peptides for efficient T cell activation. When compared to E. 
coli LPS, DCs treated with 4P- and 5P-LPS weakly activated TRIF signaling, 
degraded phagosomal antigens at an accelerated rate, and primed T cells less 
efficiently. However, these DCs retain their endocytic activity, inducing a program 
of DC maturation that allows for constitutive antigen uptake and cross-priming. Of 
note, although cross-priming seemed to be only modestly reduced in cells treated 
with 4P- and 5P-LPS, it is important to bear in mind that this is an in vitro assay 
and that we are using purified antigen together with transgenic T cells specific for 
that antigen. In a more physiological setting, where antigen is limiting and 
specific T cells are rare, the decrease in the efficiency of cross-priming would 
likely be more apparent. These results indicate that LPS structure influences 
TLR4 signaling, and signaling exerts regulatory input on the endocytic pathway. 
Taken together, our findings demonstrate that, by modifying LPS structure, P. 
gingivalis can direct the host immune system toward tolerance or immunity, as 




Chapter 5. Lipid A modifications regulate innate and adaptive immune 
responses to Gram-negative bacteria  
Introduction 
LPS can exist within soluble micelles or in association with the bacterial 
membrane, and might enter cells through different pathways, depending on the 
cargo properties. The mechanisms of TLR4 endocytosis can also be diverse, and 
have been shown to exhibit cell type specificity. In macrophages, the means by 
which TLR4 is selected as cargo for endocytosis is universal and always requires 
CD14, regardless of the mode of LPS entry. In DCs, the requirement for CD14 in 
TLR4 endocytosis can be bypassed with phagocytic cargo, presumably due to 
non-specific receptor uptake during phagocytosis (Zanoni et al. 2011, 14). In the 
previous chapter, we demonstrated that the endocytosis of TLR4 is a critical 
determinant of the nature and quality of T cell immune responses elicited by 
DCs. We found that modification of LPS structure regulates endosomal TLR4 
signaling and controls the efficiency of cross-priming by DCs. In this chapter, we 
employ P. gingivalis lipid A mutant strains to understand how alterations in the 
cargo property (soluble LPS versus bacteria) and route of uptake (endocytosis 
versus phagocytosis) influences the detection of LPS variants by the TLR4 
complex in DCs. We describe an alternate pathway for TLR4 internalization that 
is activated independently of CD14 during phagocytosis of Gram-negative 




this pathway. Finally, we determine the impact of lipid A modifications on cross-
presentation of microbial antigens. 
 
Recognition of P. gingivalis lipid A variant strains by the TLR4 complex and 
down stream signaling in DCs 
Previous studies have established that the requirement for CD14 in TLR4 
endocytosis could be bypassed with phagocytic cargo in DCs. Indeed, whereas 
E. coli LPS failed to induce TLR4 endocytosis in Cd14-/- DCs, these cells 
internalized TLR4 comparably to WT DCs when treated with whole E. coli 
(Figure 44). We thus wondered whether alterations in the cargo property (soluble 
LPS versus intact bacteria) and route of uptake (endocytosis versus 
phagocytosis) could influence the detection of LPS variants by the TLR4 
complex. To address this, we examined TLR4 internalization in DCs treated with 
P. gingivalis strains or E. coli (Figure 45A). As compared to E. coli, Pg-5P 
triggered modest levels of TLR4 endocytosis. TLR4 endocytosis proceeded less 
efficiently in DCs treated with Pg-4P relative to Pg-5P, and was barely detectable 
in cells treated with Pg-NP. These results mirror those observed with soluble 
LPS, indicating that alterations in the cargo property cannot restore TLR4 
endocytosis for intrinsically under-acylated LPS variants. However, unlike LPS, 
TLR4 endocytosis proceeded independently of CD14 during phagocytosis of 
Gram-negative bacteria. Moreover, the magnitude and kinetics of TLR4 




The same trend in results was obtained when TLR4/MD-2 dimerization were 
examined (Figure 45B). To further explore the mechanism underlying cargo-
dependent discrepancies in TLR4 endocytosis, we first tested whether it is due to 
differential binding and uptake of P. gingivalis strains by DCs. Flow cytometry 
analysis using fluorescently labeled bacteria revealed that all P. gingivalis strains 
were internalized similarly by DCs (Figure 46). These data reveal that there is 
ligand specificity to this pathway for TLR4 endocytosis and that it operates 





































Figure 44. TLR4 internalization proceeds independently of CD14 during 
phagocytosis of Gram-negative bacteria.     
(A) WT and Cd14-/- DCs were treated with media, E. coli LPS (100 ng/ml), or 
intact E. coli (MOI 10) for 18 hr and surface levels of TLR4 were examined by 
flow cytometry. Data represent the mean ± SD of triplicate samples from one 



















































































Figure 45.  P. gingivalis evades TLR4 internalization via expression of 
immune evasive (silent/antagonistic) lipid A variants.   
WT and Cd14-/- DCs were treated with P. gingivalis strains or E. coli (MOI 10) for 
0, 30, 60, or 90 min. TLR4 internalization (A) and dimerization (B) were 
determined by flow cytometry. Data represent the mean ± SD of triplicate 


















































































































Figure 46. Modification of lipid A does not impact phagocytic uptake of P. 
gingivalis strains by DCs.  
DCs were treated with FITC-labeled P. gingivalis strains (MOI 10) and bacterial 
uptake was assessed by flow cytometry at the indicated times. The upper panel 
shows the results of Trypan Blue quenching, demonstrating that the majority of 




A cargo-dependent requirement for CD14 in TLR4 endocytosis has implications 
for the activity of lipid A variants, particularly Pg-4P. To investigate this, we 
stimulated DCs with P. gingivalis strains and measured IFNβ production. Pg-NP 
and Pg-4P elicited low levels of IFNβ over a wide range of doses, whereas Pg-5P 
induced robust IFNβ secretion, comparable to E. coli  (Figure 47A). We 
observed a similar pattern of ifnb expression in WT and Cd14-/- DCs treated with 
P. gingivalis strains (Figure 47B). IFNβ production was TLR4-dependent (Figure 
47A) and required the signaling contributions of both MyD88 (Figure 47C) and 
TRIF (Figure 47D). Strain-dependent discrepancies in IFNβ production could not 
be attributed to differences in DC viability (Figure 48A), inflammasome-
dependent IL-1 secretion (Figure 48B) or bacterial survival (data not shown). 
These results are in contrast to those obtained with purified LPS, where 4P-LPS 
induced similar or higher expression of ifnb relative to 5P-LPS (depending on the 
dose), and NP-LPS was the weak inducer (Figure 49A). This trend in TLR4 
activation could be recapitulated in HEK293 cells expressing recombinant 




























































































































































Figure 47. P. gingivalis evades TLR4-dependent IFNβ induction via 
expression of immune evasive (silent/antagonistic) lipid A variants. 
(A) WT and Tlr4-/- DCs were treated with increasing doses (MOI 10, 25, 50, and 
100) of P. gingivalis strains or E. coli for 18 hr. Levels of IFNβ in culture 
supernatants were determined by ELISA. (B) WT and Cd14 -/- DCs were treated 
with P. gingivalis strains (MOI 10) or E. coli LPS (100 ng/ml) for 2 hr. Ifnb mRNA 
expression was examined by qPCR. (C,D) WT, MyD88-/- (C) and Trif-/- (D) DCs 
were treated with increasing doses (MOI 10, 25, 50, and 100) of P. gingivalis 
strains or E. coli for 18 hr. Levels of IFNβ in culture supernatants were 
determined by ELISA. Bars represent the mean ± SD of triplicate samples from 
one representative of three independent experiments. *p <0.05 relative to 
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Figure 48. Modification of lipid A does not substantially influence 
inflammasome dependent IL-1β secretion or DC viability.  
(A) WT and Tlr4-/- DCs were stimulated with increasing doses (MOI 10, 25, 50, 
and 100) of the indicated P. gingivalis strains or E. coli for 18 hr. Levels of IL-1β 
in culture supernatants were determined by ELISA. (B) DCs were stimulated with 
the indicated P. gingivalis strains at the indicated MOIs. Cell death was 
monitored by propidium iodide incorporation over the course of 16 hr. DCs pre-
treated with E. coli LPS (100ng/ml; 2hr) and then exposed to ATP (5mM) were 
































































Figure 49. Cargo-dependent recognition of lipid A variants can be 
recapitulated in HEK cells expressing recombinant huCD14/TLR4-MD2. 
HEK293 cells expressing murine CD14, TLR4/MD-2, and an NF-kB inducible 
SEAP reporter gene were stimulated with graded doses of LPS (A) or intact 
bacteria (B) for 16 hr. SEAP activity in culture supernatants was determined 
using a fluorescence based assay. Data represent the mean ± SD of triplicate 




Role of lipid A modifications on MyD88- and TRIF-dependent signaling 
downstream of TLR4 
To better understand how lipid A modifications influence signaling downstream of 
TLR4, we examined MyD88 and TRIF-dependent gene expression in WT and 
Tlr4-/- DCs stimulated with P. gingivalis strains (Figure 50A). All P. gingivalis 
strains induced the expression of Il6 and Il1b, genes that require MyD88-
dependent signaling for their full induction. Of note, the expression of these 
genes was slightly higher in DCs treated with Pg-5P relative to Pg-NP and Pg-
4P, but this effect was independent of TLR4. In contrast to MyD88-dependent 
transcripts, only Pg-5P induced robust expression of the TRIF-dependent genes 
Ifnb and Cxcl10. MyD88-dependent gene expression was unaffected in Tlr4-/- 
DCs, whereas TRIF-dependent gene expression was abolished. These results 
indicate that lipid A modifications selectively impair TRIF-dependent gene 
expression. To further explore this possibility, we performed experiments in 
TRIF-deficient cells (Figure 50B). We reasoned that, if lipid A modifications 
preferentially disrupt TRIF-dependent gene expression, then gene expression in 
Trif-/- DCs should mirror results obtained with Tlr4-/- DCs. This prediction was 
correct. Expression of Il6 and Il1b were unaffected in TRIF-deficient DCs when 
compared to WT cells, whereas Ifnb and Cxcl10 were diminished. We next 
examined gene expression in MyD88-/- DCs (Figure 50C), which only permit 
signaling via the TRIF pathway. Similar to results obtained with WT cells, only 




Pg-NP and Pg-4P failed to induce the expression of Il6 and Il1b in MyD88-/- cells, 
whereas induction of these genes was detectable in cells treated with Pg-5P, 









































































































































































































































Figure 50. Expression of immunologically silent or antagonistic lipid A 
variants impairs TRIF-dependent transcriptional responses downstream of 
TLR4.  
WT, Tlr4-/-(A), Trif-/- (B), and Myd88-/- (C) DCs were stimulated with the indicated 
P. gingivalis strains (MOI 10) for 2 hr. Relative expression of Il1b, Il6, Ifnb, and 
Cxcl10 was analyzed by qPCR using actb as an endogenous. Results are 
expressed as fold induction over media control. Data represent the mean ± SD of 




When gene expression was examined at a later time point, induction of Il6 was 
reduced in both Tlr4-/- and Trif-/- DCs compared to WT cells, and this was 
observed for all P. gingivalis strains, independently of the lipid A species 
expressed (Figure 51A). Impaired IL-6 production by Tlr4-/- cells was also 
detected at the protein level in response to all strains, and a similar trend in 
results was obtained when other pro-inflammatory cytokines were tested, 
including TNF and IL-12p70 (Figure 51B). The observation that TLR4 and TRIF 
are required for Il6 expression only at late time points is consistent with the 
notion that TRIF-dependent signaling stabilizes inflammatory cytokine expression 
induced by MyD88 (Yamamoto et al. 2003). To determine whether IFNβ plays a 
role in this process, experiments were performed in IFNβ-deficient DCs. As 
shown in Figure 51B, Ifnb-/- DCs phenocopy Tlr4-/- cells for impaired TNF, IL-6, 
and IL-12p70 production. In contrast, both Ifnb-/- and Tlr4-/- DCs responded 
comparably to WT cells when stimulated with the TLR2 ligand Pam3CysK4, 
demonstrating that neither of these genotypes is inherently impaired in innate 
immune responses (Figure 51C). Thus, the overall reduction in inflammatory 
cytokine production observed in Tlr4-/- DCs likely reflects the absence of 
autocrine IFNβ signaling rather than a direct contribution of the TLR4-MyD88 
pathway. Collectively, these results demonstrate that lipid A modifications evade 























































































































































































































































Figure 51. Role of TLR4 and IFNβ in P. gingivalis-induced inflammatory 
cytokine production.  
(A) WT, Tlr4-/-, Trif-/-, and Myd88-/- DCs were stimulated with P. gingivalis strains 
(MOI 10) for 5 hr. Relative expression of Ifnb, and Il6 was analyzed by qPCR 
using actb as an endogenous. Data represent the mean ± SD of triplicate 
samples from one representative of three independent experiments. (B) WT, 
Tlr4-/-, and Ifnb-/- DCs were stimulated with P. gingivalis strains (MOI 10) or media 
alone for 18 hr. Levels of TNF, IL-6, and IL-12p70 in cell culture supernatants 
were determined by ELISA. (C) WT, Tlr4-/-, and Ifnb-/- DCs were stimulated with 
E. coli  LPS (100 ng/ml), Pam3CysK4 (1µg/ml), or media alone for 18 hr. Levels 
of TNF, IL-6, and IL-12p70 in cell culture supernatants were determined by 
ELISA. Data represent the mean ± SD of triplicate samples from one 





Both MyD88 and TRIF-dependent pathways activate NF-kB and MAPKs 
downstream of TLR4 (Hirotani et al. 2005). To examine the influence of lipid A 
modifications on the activation of MAPKs pathways, we assessed 
phosphorylation of ERK, JNK, and p38 in DCs stimulated with P. gingivalis 
strains (Figure 52). Lipid A dependent evasion of all MAPK was observed in cells 
stimulated with wild-type strain Pg-NP as compared to Pg-5P. In contrast, Pg-4P 
phenocopied the wild-type strain for its ability to evade MAPK activation. The 
same trend in results was observed when examining NF-kB activation using 
pp65 levels as the read out. These data indicate that modification of lipid A 

























Figure 52. Expression of immunologically silent or antagonistic lipid A 
impairs NF-kB and MAPK activation in DCs.  
WT DCs were stimulated with P. gingivalis strains (MOI 10) for 0, 30, or 60 min. 
Total and phosphorylated p38, ERK1/2, JNK, and p65 in whole cell lysates were 
detected by Western blot analysis. Results are representative of three 




Given that lipid A modifications preferentially disrupt TRIF-dependent gene 
expression, we hypothesized that they would inhibit TRIF-dependent activation of 
NF-kB and MAPKs. To address this, we examined NF-kB and MAPK activation in 
WT, TLR4-, MyD88-, and TRIF-deficient cells using phosphorylation of p65 and 
p38 as readouts. To facilitate high-throughput analysis of multiple genotypes, 
phosphorylation events were assessed by in-cell Western blot (Figure 53). 
Consistent with results obtained with conventional Western blot analysis, 
activation of p65 and p38 was increased in WT DCs treated with Pg-5P relative 
to Pg-NP or Pg-4P. Whereas lipid A dependent differences in NF-kB and MAPKs 
were evident in MyD88-deficient DCs, all P. gingivalis strains induced similar 
responses in TLR4- and TRIF-deficient cells. Therefore, these results 
demonstrate that lipid A modifications inhibit TRIF-dependent activation of NF-kB 



































































































































































































































Figure 53. Expression of immunologically silent or antagonistic lipid A 
impairs TRIF-dependent activation of NF-kB and MAPKs. 
WT, Myd88-/-, Trif-/-, and Tlr4-/- DCs were stimulated with the indicated P. 
gingivalis strains (MOI 10) for 0, 30, 60, or 90’ min. Phosphorylation of p38 (A) or 
p65 (B) detected by in-cell Western blot analysis. Expression levels were 
normalize to actin and are expressed as fold induction relative to unstimulated 
controls. Results from one of two independent experiments are shown. *p <0.05; 




After microbial internalization, intracellular stores of TLR4 are recruited to 
phagosomes containing Gram-negative bacteria forming a signaling platform that 
mediates activation of IRF3 and transcription of ifnb (Husebye et al. 2010; 
Mantegazza et al. 2012). In human monocytes, lipid A modifications employed by 
Y. pestis evade this response (Husebye et al. 2010).  To determine whether 
modification of lipid A structure influences signaling from intracellular 
compartments, we treated DCs with P. gingivalis strains and monitored ifnb 
mRNA levels over a time course (Figure 54A). E. coli  LPS was used as a 
control to distinguish the early phases of signaling that result from surface 
internalized TLR4 from later stages of phagosomal signaling. In addition, use of 
this control allowed us to discriminate between signaling from endosomes 
(CD14-dependent) and phagosomes (CD14-independent). Ifnb expression 
peaked 2 hr after stimulation with E. coli LPS, and rapidly returned to baseline by 
4-5 hr. In DCs treated with P. gingivalis strains, ifnb mRNA levels reached an 
initial peak at 2 hr and were sustained over the next hour. A larger secondary 
peak was observed at 5 hr before mRNA levels dropped and returned to baseline 
by 8 hr.  These kinetics were identical for all three P. gingivalis strains, and ifnb 
expression was TLR4-dependent at both early and late time points (Figure 54B). 
While the magnitude of the response was similar in DCs treated with Pg-NP and 
Pg-4P, ifnb mRNA levels were significantly increased in cells treated with Pg-5P 
throughout the time course. In line with this, phosphorylation of IRF3 was 




not Tlr4-/- DCs (Figure 54C). Therefore, expression of immunologically silent or 
antagonistic lipid A structures equips P. gingivalis with the ability to evade 























































































































Figure 54. Expression of immunologically silent or antagonistic lipid A 
structures enables P. gingivalis to evade phagosomal TLR4 signaling and 
ifnb transcription.  
(A) WT DCs were treated with P. gingivalis strains (MOI 10) or E. coli LPS (100 
ng/ml) for 1, 2, 3, 5, and 8 hr. Relative Ifnb mRNA expression was examined by 
qPCR. Data are mean ± SD of duplicate cultures. (B) WT and Tlr4-/- DCs were 
treated with P. gingivalis strains (MOI 10) or E. coli LPS (100 ng/ml) for 2 or 5 hr. 
Relative Ifnb mRNA expression was examined by qPCR. (C) Immunoblot 
analysis of total and phosphorylated IRF3 in whole cell lysates from WT and Tlr4-
/- DCs treated or not with P. gingivalis strains (MOI 10) for 60 min. Data represent 








Role of lipid A modifications on P. gingivalis-induced DC maturation 
To determine the impact of microbial lipid A modifications on DC maturation, we 
stimulated DCs with P. gingivalis strains and examined the acquisition of 
maturation markers by flow cytometry. As shown in Figure 53, all P. gingivalis 
strains induced comparable surface expression of co-stimulatory molecules 
(CD40, CD80, CD86), co-inhibitory molecules (B7-H1, PDL-1), MHC complexes 
(MHC-I/MHC-II), and the lymph node homing receptor CCR7. P. gingivalis strains 
were as efficient as E. coli in inducing the expression of maturation markers. 
Thus, unlike results observed with purified P. gingivalis LPS, stimulation of DCs 
with whole bacteria induced the phenotypic maturation of DCs and this was 
independent of the lipid A species expressed. These data reveal that lipid A 






















































































Figure 55. Lipid A modifications do not influence P. gingivalis-induced co-
stimulatory molecules expression.  
WT DCs were stimulated with P. gingivalis strains (MOI 10), E. coli (MOI 10) or 
media alone for 18 hr. Surface expression of co-stimulatory molecules (CD40, 
CD80, CD86), co-inhibitory molecules (B7-H4, PD-L1), MHC complexes (MHC-I, 
MHC-II), and the lymph node homing receptor CCR7 was analyzed by flow 




We next examined whether TLR4 and IFNβ played a role in P. gingivalis induced 
DC maturation by using TLR4- and IFNβ-deficient DCs (Figure 56A-E). With the 
exception of CD86 (Figure 56C) and MHC-I (Figure 56D), the induction of 
maturation markers in TLR4- and IFNβ-deficient cells was comparable to that of 
WT DCs. The reduction in MHC-I and CD86 levels was observed with all P. 
gingivalis strains regardless of the lipid A species expressed and was more 
pronounced in Ifnb-/- DCs as compared to Tlr4-/- cells. The modest impairment in 
CD86 induction in Tlr4-/- cells could be partially rescued by increasing the dose of 
bacteria, but not in Ifnb-/- cells (data not shown). Both Tlr4-/- and Ifnb-/- DCs 
responded comparably to WT cells when treated with TLR2 or TLR9 ligands, 
demonstrating that these DCs are not generally defective in terms of their ability 
to mature in response to innate stimuli. As expected, Tlr4-/- DCs did not mature in 
response to E. coli LPS. IFNβ was also required for E. coli LPS induced CD86 
expression, but was dispensable for all other maturation markers tested. Taken 
together, these results demonstrate that neither TLR4 nor IFNβ is absolutely 
essential for P. gingivalis induced DC maturation. Of note, we observed 
differences in cellular morphology in WT DCs treated with Pg-5P as compared to 






















































































































































































































































































































































































































































































































































































Figure 56. Role of TLR4 and IFNβ in P. gingivalis-induced DC maturation.   
WT, Tlr4-/-, and Ifnb-/- DCs were treated with P. gingivalis strains (MOI 10) or 
media alone for 18 hr. Surface expression of CD40 (A), CD80 (B), CD86 (C), 
MHC-I (D), and MHC-II (E) was analyzed by flow cytometry (left). Cells 
stimulated with E. coli LPS (100 ng/ml), CpG DNA (TLR9; 1µM), a commercially 
available P. gingivalis LPS preparation from Invivogen (Pg LPS; 100 ng/ml), or 
Pam3CysK4 (TLR2; 1µg/ml) were included as ligand controls (right). Results are 
expressed as fold change in surface expression (MFI) relative to media treated 
cells. Data represent the mean ± SD of pooled results from two independent 









































































































































Figure 57. P. gingivalis lipid A modifications influence DC morphology via a 
TLR4- and IFNβ -dependent mechanism.  
WT, Tlr4-/-, and Ifnb-/- DCs were treated with P. gingivalis strains (MOI 10) or 
media alone for 18 hr. Light scattering properties were analyzed by flow 





Expression of immunologically silent or antagonistic lipid A impairs 
priming of pathogen-specific CD8 T cells  
In contrast to DCs that have been exposed to TLR ligands for several hours (as 
in Chapter 4), cross-presentation of phagocytosed Ag by immature DCs requires 
phagosome autonomous TLR signaling (Nair-Gupta et al. 2014). By delivering 
MHC-I molecules, TLR engagement remodels phagosomes to allow cross-
presentation of peptides derived from phagocytosed microbes (Nair-Gupta et al. 
2014). To determine whether alterations to LPS structure influence cross-
presentation of microbial antigens, we used heat-killed P. gingivalis strains 
coated with OVA as phagocytic cargo. We verified that OVA coating was 
comparable among strains (Figure 58A) and that the cargo properties of these 

























Figure 58. Flow cytometry analysis of OVA-coated P. gingivalis strains.  
(A) Heat-killed P. gingivalis strains (109/ml) were coated with 2 mg/ml of OVA 
overnight at 4 C on a rotating wheel. Bacteria were washed three times with PBS 
and stained with a 1/750 dilution of a polyclonal rabbit anti-OVA antibody 
followed by an Alexafluor647-conjugated anti-rabbit IgG. OVA coating was 
assessed by flow cytometry. OVA coated bacteria that were incubated with the 
secondary antibody alone were used as controls. (B) Light scattering properties 




We treated WT, Tlr4-/-, or Cd14-/- DCs with OVA-coated P. gingivalis strains and 
assessed cross-presentation to OT-I cells by upregulation of CD69 (Figure 59). 
Treatment of WT DCs with each strain led to a dose-dependent increase in the 
efficiency of cross-presentation. This increase was dependent on TLR4, as 
cross-presentation was impaired in Tlr4-/- DCs and did not improve with higher 
bacterial doses. Thus, although engagement of other innate receptors is 
sufficient to trigger co-stimulatory molecule expression in Tlr4-/- DCs, no other 
PRR can substitute for TLR4 to enable efficient cross-presentation of microbial 
peptides. Cross-presentation was not impaired in Cd14-/- DCs, indicating that the 
CD14-independent pathway is principally involved in generating ligands for CD8 
T cells from phagocytosed bacteria. As expected, WT, Tlr4-/-, and Cd14-/- DCs 
were equally capable of activating OT-I cells when provided with the processed 
























































Figure 59. TLR4 engagement selects microbial antigens for presentation by 
MHC class I molecules, regardless of the lipid A structure.  
Cross-presentation of SIINFEKL from OVA-coated P. gingivalis strains by WT, 
Tlr4-/-, and Cd14-/- DCs. Cells were pulsed with OVA-coated P. gingivalis strains 
(MOI 10, 25, or 50) or SIINFEKL peptide (0.01 ng/ml) for 4.5 hr and then co-
cultured with OT-I T cells for 18 hr. CD69 expression on OT-I cells was analyzed 
by flow cytometry. Error bars represent the mean ± SD of triplicate samples from 
one representative of three independent experiments. *p <0.05 relative to 




Prior studies demonstrated that delivery of MHC-I molecules to phagosomes 
containing TLR ligands is MyD88-dependent (Nair-Gupta et al. 2014). 
Accordingly, cross-presentation was selectively impaired in Myd88-/-and not Trif-/- 
DCs (Figure 60). Because both MyD88 and TRIF were required for IFNb 
production, these findings rule out a role for this cytokine in cross-presentation 
(but not cross-priming), a conclusion supported by results obtained using soluble 
LPS, as well as published work (Nair-Gupta et al. 2014). In contrast to 
phagocytosed antigen, WT, Trif-/-, and Myd88-/- DCs presented the SIINFEKL 


































































Figure 60. MyD88 but not TRIF is critical for cross-presentation of peptides 
derived from phagocytosed bacteria.  
Cross-presentation of SIINFEKL from OVA-coated P. gingivalis strains by WT, 
Myd88-/-, and Trif-/- DCs. Cells were pulsed with OVA-coated P. gingivalis strains 
(MOI 10 or 25) or SIINFEKL peptide (0.01 ng/ml) for 4.5 hr and then co-cultured 
with OT-I T cells for 18 hr. CD69 expression on OT-I cells was analyzed by flow 
cytometry. Error bars represent the mean ± SD of triplicate samples from one 
representative of three independent experiments. *p <0.05 relative to similarly 




Our results indicate that lipid A modifications do not substantially impact cross-
presentation of microbial antigens at the level of peptide-MHC-I complex 
formation (signal 1). We next examined whether modification of lipid A structure 
influences the outcome of antigen presentation by DCs (signal 2). To address 
this possibility, we measured cytokine production by OT-I cells following co-
culture with WT, Tlr4-/-, or Cd14-/- DCs that had been pulsed with OVA-coated P. 
gingivalis strains. Although phagocytosis of all P. gingivalis strains promoted 
cross-presentation, only DCs treated with Pg-5P could effectively prime OT-I 
cells and induce the secretion of IL-2 (Figure 61A) and IFNγ (Figure 61B). T cell 
priming required TLR4 but not CD14. Therefore, expression of immunologically 































































Figure 61. Expression of immunologically silent or antagonistic lipid A 
impairs CD8 T cell activation by cross-presented microbial peptides 
WT, Tlr4-/-, and Cd14-/- DCs were pulsed with OVA-coated P. gingivalis strains 
(MOI 10, 25, or 50) or SIINFEKL peptide (0.01 ng/ml) for 4.5 hr and then co-
cultured with OT-I T cells for 18 hr. IL-2 (A) and IFNγ (B) secretion by OT-I cells 
was measured by ELISA. Bars represent the mean ± SD of triplicate samples 
from one representative of three independent experiments. *p <0.05, relative to 
similarly treated WT DCs by two-way ANOVA; # p <0.05, versus WT DCs treated 




All P. gingivalis strains induced comparable expression of co-stimulatory 
molecules and a similar pattern of pro-inflammatory cytokine production in WT 
DCs, precluding a role for these factors in regulating CD8 T cell activation. By 
contrast, modification of lipid A structure strongly influenced TLR4 signaling from 
phagosomes and IFN production. Based on results obtained with soluble LPS, 
we reasoned that lipid A modifications influence immunogenicity by controlling 
the rate of endocytic traffic. To address this, we examined the degradative 
capacity of phagosomes in DCs treated with P. gingivalis strains or E. coli  
(Figure 62). When compared to DCs treated with E. coli or Pg-5P, cells treated 
with Pg-NP and Pg-4P degraded bbOVA at an accelerated rate. Notably, the 
delay in antigen degradation correlated with the extent to which these strains 
























































Figure 62. Lipid A structure modulates the kinetics of phagosomal antigen 
degradation following phagocytosis of Gram-negative bacteria.   
DCs were treated with P. gingivalis strains (MOI 10), E. coli  (MOI 10), or media 
alone for 16-18 hr before phagocytosis of bbOVA. Phagosomal degradation of 
OVA was assessed after different chase periods by flow cytometry. 
Representative histograms are shown for each time point and condition (upper 
panel). A graphical representation of pooled results from two of three 
independent is shown in the lower panel. Percent degradation was calculated by 




To determine whether accelerated degradation of phagosomal antigens 
coincides with increased antigen internalization, phagocytosis of bbOVA was 
examined in DCs treated with P. gingivalis strains or E. coli. DCs treated with E. 
coli and Pg-5P internalized bbOVA at a slower rate when compared with 
immature DCs (Figure 63A&B), and their overall phagocytic activity was also 
reduced (Figure 63C). In contrast, DCs treated with Pg-NP and Pg-4P retained 
the ability to take up bbOVA as efficiently as immature cells. To test other forms 
of antigen uptake, we examined endocytosis (Figure 63D) and macropinocytosis 
(Figure 63E). When compared to immature cells, endocytosis and 
macropinocytosis were reduced in DCs treated with bacteria. However, both of 
these activities were enhanced in DCs treated with Pg-NP and Pg-4P relative to 
DCs treated with E. coli or Pg-5P. Therefore, antigen internalization and 
degradation occur at an accelerated rate precisely in those DCs treated with P. 
gingivalis strains that failed to prime microbe specific T cells. These results 
suggest that differences in T cell activation to cross-presented microbial peptides 
are due to rapid degradation and extensive proteolysis of antigenic epitopes. 
Thus, by altering lipid A structure, host-adapted bacteria such as P. gingivalis, 
can modulate the endocytic activity of DCs and control the efficiency at which T 
































































































































































Figure 63. Lipid A structure regulates the endocytic activity of DCs 
following phagocytosis of Gram-negative bacteria.  
(A) WT DCs were treated with P. gingivalis strains (MOI 10), E. coli (MOI 10), or 
media alone for 16-18 hr. Phagocytic uptake of bbOVA (labeled with Alexa 647) 
in BMDCs was analyzed by flow cytometry after 15 min binding on ice followed 
by the indicated chase periods at 37°C. External beads were labeled with an 
OVA antibody followed by an Alexa 488-conjugated secondary antibody. Gates 
show the percentage of internalized beads. (B) Quantification of phagocytic 
uptake showing average percentage of internalized beads. Data represent the 
mean ± SD of triplicate samples from one representative of two independent 





In this chapter, we describe an alternate pathway for TLR4 internalization that 
proceeds independently of CD14 and is activated upon phagocytosis of Gram-
negative bacteria. Whereas CD14 was required for LPS-induced TLR4 
endocytosis, IFN induction, and cross-presentation, it was dispensable for all of 
these responses in DCs treated with Gram-negative bacteria. Kinetic analysis of 
ifnb gene expression revealed that this pathway is accompanied by a distinct 
phase of TLR4 signaling from phagosomes. Expression of immunologically silent 
and antagonistic lipid A enabled P. gingivalis to evade TRIF signaling including 
the activation of MAPK, NF-kB, IRF3, and downstream expression of TRIF-
dependent genes.   
 
In DCs, phagosomes that engage TLRs recruit MHC-I molecules to enable cross-
presentation of microbial peptides during infection (Nair-Gupta et al. 2014). In the 
case of Gram-negative bacteria, this process is dependent on TLR4 and MyD88 
(Nair-Gupta et al. 2014). Accordingly, both TLR4 and MyD88 were required for 
efficient cross-presentation of microbial antigens following phagocytosis of P. 
gingivalis strains. We observed a dose-dependent increase in the efficiency of 
cross-presentation for all bacterial strains, indicating that alteration of lipid A 
structure does not substantially impair cross-presentation of microbial peptides. 
However, only DCs treated with Pg-5P could efficiently prime T cells specific for 




antagonistic lipid A impaired priming of microbe-specific T cells. Therefore, 
similar to results obtained with soluble LPS, expression of modified lipid A on the 
surface of bacteria impacts the context in which microbial antigens are presented 
T cells, but not presentation of the antigen itself. Impaired T cell priming following 
phagocytosis of P. gingivalis strains expressing immunologically silent or 
antagonistic lipid A was not due to deficient co-stimulatory molecule expression 
or inflammatory cytokine production. Rather, it correlated with impaired IFN 
induction from phagosomes and an accelerated rate of endocytic traffic (antigen 
internalization and degradation). We propose that, by modifying their outermost 
membrane component, Gram-negative bacteria can control the endocytic activity 







Chapter 6. Alteration of lipid A structure modulates immune responses in 
vivo   
Introduction  
During Gram-negative bacterial infection, blood monocytes are rapidly mobilized 
to T cell areas in draining lymph nodes where they acquire powerful antigen-
capturing and presenting abilities, including the capacity for cross-presentation 
(Cheong et al. 2010). This migratory phenotype is induced in response to LPS 
and live or dead Gram-negative bacteria, but not Gram-positive bacteria or other 
TLR ligands (TLR1-9) (Cheong et al. 2010; van Helden et al. 2010). These 
moDCs become the dominant cell type for induction of effective T cell immunity 
and can be distinguished from other APCs in the lymph node by their expression 
of DC-SIGN (Cheong et al. 2010). Mobilization requires TLR4 and signaling 
through TRIF (Cheong et al. 2010; T. Kawai et al. 2001; De Trez et al. 2005). 
Through mobilization, DCs transport peripheral antigens to areas where naïve T 
cells are concentrated, so that they may locate rare T cell clones and promote 
their clonal expansion. In the beginning of this chapter, we utilize P. gingivalis 
strains in a subcutaneous infection model to determine the impact of lipid A 
modifications on DC mobilization to draining lymph nodes.  
 
Apart from its role in influencing T immunity, evasion of TRIF dependent 
signaling via expression of immunologically silent or antagonistic lipid A has 




induces the expression of chemokines that are important for immune cell 
recruitment to sites of pathogen invasion. In the final section of this chapter, we 
use P. gingivalis lipid A mutant strains in a model of acute peritonitis to determine 
the impact of lipid A modifications on immune cell recruitment and the induction 
of innate anti-microbial immunity in vivo.  
 
Expression of immune evasive lipid A (immunologically silent/antagonistic) 
disrupt DC mobilization to lymph nodes in vivo  
To determine whether lipid A modifications influence DC mobilization, groups of 
C57BL/6 mice (n=3) were infected with the different P. gingivalis strains (108 
CFU in 100 uL PBS) by subcutaneous injection (nape of the neck; Figure 64A). 
Mice treated with PBS alone served as vehicle controls.  After 24 hr, when moDC 
numbers in the lymph nodes peaks (Cheong et al. 2010), we sacrificed mice and 
harvested skin-draining lymph nodes and spleens for analysis of DC numbers by 
flow cytometry analysis.  Both the frequency (Figure 64B) and absolute number 
(Figure 64C) of DCs (Cd11c+MHC-IIhigh) was significantly increased in skin-
draining LNs from mice treated with Pg-5P when compared with vehicle-treated 
controls. In contrast, the frequency and number of DCs was unaltered in mice 
treated with Pg-NP and Pg-4P relative to controls. The frequency (Figure 64D) 
and number (Figure 64E) of DCs in the spleen was similar among all groups, 
excluding the possibility that DCs were inadvertently routed to this organ in mice 




immunologically silent or antagonistic lipid A structures enables P. gingivalis 
strains that evade TRIF signaling fail to mobilize DCs during infection in vivo, 
which may represent a critical strategy employed by bacteria to evade the 
adaptive immune system. However, additional experiments are required to 
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Figure 64. Expression of immune evasive lipid A (silent/antagonist) 
disrupts DC mobilization to skin draining lymph nodes following 
subcutaneous challenge with Gram-negative bacteria.   
(A) Schematic detailing experimental procedures for assessment of DC 
mobilization. Single cell suspensions prepared from skin-draining lymph nodes 
(B-D) or spleens (E-G) of mice treated with P. gingivalis strains (108) or PBS 
alone (s.c.) for 24 hr were analyzed for Cd11c and MHC-II expression by flow 
cytometry. (B, E) Representative scatter plots are shown for each treatment 
group. The frequency (C, F) and absolute number (D, G) of CD11c+MHC+ 
double positive cells. Data represent the mean ± SD from n=3 mice per group 





Expression of antagonistic lipid A impairs delays immune cell recruitment 
and promotes bacterial survival in vivo  
To determine the impact of lipid A modifications on the innate immune response 
to microbial infection in vivo, we used an acute peritonitis model. Mice were 
infected i.p. with P. gingivalis strains (5x107 CFU) and immune cell recruitment 
and bacterial survival were assessed after 6 or 24 hr. Mice injected with PBS 
were used as uninfected controls. In control mice, the majority of CD45+ 
leukocytes in the peritoneal cavity were CD11bhigh F4/80+ macrophages, with 
very few Ly6G+ neutrophils (Figure 65A). We observed a massive influx of 
CD45+cells into the peritoneal cavity at 6 hr post infection (Figure 65B), the 
majority of which were Ly6G+ neutrophils (Figure 65C). At the same time, 
macrophages numbers dropped precipitously (Figure 65D). Neutrophil 
recruitment was significantly impaired in mice treated with Pg-4P when compared 
to mice treated with Pg-NP and Pg-5P, and this correlated with increased 
bacterial survival (Figure 65E). After 24 hr, the number and distribution of 
immune cells in the peritoneal cavity was similar for mice treated with all three 
strains (Figure 65F-H). We were unable to recover viable bacteria at this point, 
indicating that mice had cleared the infection. We conclude that expression of 
antagonistic lipid A variants delays neutrophil recruitment and impairs bacterial 























































































































































































Figure 65. Expression of antagonistic lipid A delays neutrophil recruitment 
and impairs bacterial clearance in vivo.  
C57BL/6 mice were injected i.p. with 5x107 CFU  of the indicated P. gingivalis in 
500µL of PBS or PBS alone as a control (3-4 mice/group). After 6 or 24h, mice 
were euthanized and peritoneal exudate fluid was harvested by lavage for cell 
analysis by flow cytometry or bacterial CFU enumeration by plating. (A) 
Representative scatter plots depict the distribution of macrophages 
(CD11bhighLy6G-) and neutrophils (Ly6+CD11bint) in mice treated with PBS or P. 
gingivalis wild-type strain for 24 hr. Number of CD45+ leukocytes (B), neutrophils 
(C), and macrophages (D) per milliliter of peritoneal fluid from the indicated 
treatment groups at 6h post infection as determined by flow cytometry. (E) 
Recovered CFU counts per milliliter of peritoneal fluid as determined by plating at 
6 hr post infection. Number of CD45+ leukocytes (F), neutrophils (G), and 
macrophages (H) per milliliter of peritoneal fluid from the indicated treatment 






In this chapter, we used P. gingivalis strains expressing defined lipid A moieties 
to demonstrate that alteration of LPS structure impacts innate immune responses 
in vivo. We found that P. gingivalis expression of antagonistic lipid A delays 
neutrophil recruitment and impairs microbial clearance early following infection. 
Moreover, we show that P. gingivalis expression of immunologically silent or 
antagonistic lipid A disrupts DC mobilization in vivo. This has significant 
implications for the mechanisms by which commensal and pathogenic bacteria 
establish permanent niches within their host. How so? While modification of 
conserved microbial structures enables bacteria to evade innate immune 
responses, it cannot explain how microbes escape detection by the adaptive of 
immune system, which is capable of recognizing a nearly limitless number of 
antigens. Disruption of DC mobilization would prevent the selection of microbe-





Chapter 7. Discussion 
In this study, we used purified P. gingivalis LPS variants to understand how 
alterations to lipid A structure influence innate signaling and how this shapes 
cross-presentation by DC. We found that alteration of lipid A structure influences 
the strength of TLR4 signaling and preferential usage of downstream adaptors 
through differential interactions with the TLR4 complex. Both immunologically 
silent (NP-LPS) and TLR4 agonist (5P-LPS) LPS species were similarly 
recognized by CD14 and promoted its endocytosis. The activities of these 
variants were discriminated by MD-2. NP-LPS failed to induce TLR4/MD-2 
dimerization and prevented inflammatory endocytosis, thus evading signaling 
from both the plasma membrane and from endosomes. 5P-LPS induced 
TLR4/MD-2 dimerization and endocytosis, and elicited both MyD88- and TRIF-
dependent responses, but was a weaker inducer of these response when 
compared to E. coli LPS. 4P-LPS, a well-known antagonist of the TLR4/MD-2 
complex, was less efficient in inducing TLR4/MD-2 dimerization and MyD88 
signaling when compared to 5P-LPS. However, it potently accelerated the CD14-
dependent endocytosis pathway and comparably activated TRIF signaling.  
 
All P. gingivalis LPS species induced a program of DC maturation that allowed for 
constitutive antigen uptake and cross-presentation. Enhanced cross-presentation 
was independent of TLR4 agonist activity and required CD14. Moreover, the 




internalized antigens. NP-LPS, which did not induce TRIF-dependent signaling, 
enhanced cross-presentation and promoted T cell tolerance, whereas both 4P- 
and 5P-LPS induced cross-priming. These results show that, through the addition 
of a single phosphate to NP-LPS, P. gingivalis can direct the host immune system 
from tolerance to immunity. While treatment with E. coli LPS delayed phagosomal 
antigen degradation, DCs treated with P. gingivalis LPS species degraded 
antigens at an accelerated rate. Consequently, cross-priming proceeded less 
efficiently in these DCs. Delayed degradation and efficient cross-presentation by 
E. coli LPS treated DCs was shown to be mediated, at least in part, by 
downstream IFN production. We show that IFN treatment exerts regulatory input 
on the endocytic pathway to improve host defense. Specifically, IFN slowed 
antigen internalization and delayed its degradation for optimal T cell activation. 
Moreover, we demonstrated that differences in the efficiency of cross-priming 
among LPS variants could be attributed, at least in part, to differential IFN 
induction.  
 
We next examined how expression of divergent lipid A variants influenced 
immune responses to the bacterium and presentation of microbial antigens. We 
found that expression of immunological silent or antagonistic lipid A enabled P. 
gingivalis to evade TRIF-dependent signaling. Evasion of TRIF signaling was 
associated with accelerated antigen degradation and impaired priming of 




structures induced potent TRIF-dependent responses, delayed antigen 
degradation, and promoted the activation of microbe-specific T cells. Notably, the 
difference in immune responses were not due to impaired co-stimulatory 
molecule expression or cross-presentation of the antigen itself. Therefore, similar 
to results obtained with soluble LPS, alteration of lipid A structure on the bacterial 
surface influences the context in which antigens are presented to T cells. 
Notably, unlike soluble LPS, TLR4 endocytosis, TRIF signaling, and cross-
presentation all occurred independently of CD14 following uptake of Gram-
negative bacteria. 
 
Collective, these results show that, through the expression of NP-LPS and 4P-
LPS, P. gingivalis can induce the differentiation of DCs that constitutive tolerize or 
prime T cells, while preventing its own elimination by adaptive immune system. 
As the relative expression of NP-LPS and 4P-LPS is regulated by the clinical 
relevant nutrient hemin, we propose that modification of lipid A structure is a key 
mechanism by which P. gingivalis disrupts immune homeostasis and orchestrates 
dysbiotic inflammatory disease (Figure 66). Given that modification of lipid A is a 
fundamental feature of Gram-negative bacteria that stably colonize mammals, 
our findings likely represent a key mechanism by which host-adapted bacteria 
promote their active acceptance by the adaptive immune system. There is 
tremendous diversity in lipid A structure and species from different organisms are 





























































































































Figure 66. P. gingivalis evades detection by the adaptive immune system 
and disrupts immune homeostasis via expression of immune evasive lipid 
A (silent/antagonist) and manipulation of DC function.  
Expression of immunologically silent or antagonistic lipid A enables P. gingivalis 
to evade TRIF signaling in DCs. Evasion of TRIF signaling was associated with 
accelerated antigen degradation and impaired CD8 T cell activation by cross-
presented microbial peptides, thus facilitating evasion of pathogen-specific 
immunity. Soluble LPS from P. gingivalis induces a program of DC maturation 
that allows for constitutive antigen uptake and cross-presentation. In the wild-
type strain, the major species expressed is non-phosphorylated and 
immunologically silent. This species promotes cross-tolerance, which we propose 
leads to global immune suppression. In the presence of excess hemin, a clinical 
relevant nutrient, the activity of the lipid A 1-phosphatase is suppressed leading 
to the expression of antagonistic lipid A. In it’s soluble form, antagonistic lipid A 
promotes constitutive cross-priming, but when expressed on the surface of the 
bacterium, it impairs activation of microbe-specific T cells. In this way, P. 
gingivalis can shift the balance between the regulatory and effector arms of the 
immune system, all the while promoting its own survival. Expression of penta-
acylated lipid A structures by the agonist strain not only renders P. gingivalis 
susceptible to killing by CAMPs, it also results in the activation of pathogen-




their soluble form, penta-acylated LPS species also promoted constitutive cross-
priming. However, these species are only enriched in defined P. gingivalis 




CD14-dependent and –independent pathways for TRIF-mediated signaling 
Our results demonstrate a cargo-dependent role for CD14 in LPS-induced 
immune responses in DCs. Prior studies established that requirement for CD14 
could be bypassed with phagocytic cargo in DCs (Zanoni et al. 2011).  Our 
findings show that there is ligand specificity to this pathway for TLR4 
internalization and that it operates independently of CD14. While CD14 was 
required for LPS-induced TLR4 endocytosis, IFN expression, and cross-
presentation, it was dispensable for all of these responses in DCs treated with 
Gram-negative bacteria. Apart from a differential requirement for CD14, this 
alternate pathway for TRIF-mediated signaling could also be distinguished by its 
mutual reliance on both MyD88 and TRIF for IFN induction. We propose that the 
differential requirement for CD14 in TLR4-endocytosis and TRIF-signaling in 
response to LPS and Gram-negative bacteria underlies the divergent activity of 
4P-LPS. This variant is a well-known antagonist of the TLR4/MD-2 complex, and 
consistent with this, we found that it weakly activated MyD88-dependent 
signaling. However, it potently accelerated the CD14 endocytosis pathway and 
preferentially   less efficient in dimerize TLR4 when compared to 5P-LPS but it 
potently activated the CD14 endocytosis pathway and preferentially activated 
TRIF signaling. In their soluble form, both 4P-LPS and 5P-LPS activated 
endosomal TLR4 signaling and promoted T cell priming, whereas NP-LPS did 
not. When expressed on the surface of bacteria, only 5P-LPS induced robust 




antigens. The activities of NP-LPS and 5P-LPS, which were discriminated by 
MD-2, did not exhibit cargo-dependent discrepancies. Although our findings 
support a cargo dependent requirment for CD14 in LPS sensing, they do not 
exclude a role for this PRR in subsequent regulation of TLR4 signaling. These 
conclusions are supported by additional evidence, including (1) divergent 
responses to LPS and Gram-negative in CD14 mice (Moore et al. 2000); (2) 
CD14 binds LPS monomers and LPS on the surface of Gram-negative bacteria is 





Implications for lipid A modifications in the pathogenesis of P. gingivalis 
mediated periodontal disease and systemic immune pathologies  
Although it requires the presence of bacteria, periodontal disease is not an 
infection in the classical sense but rather results from a dysbiosis precipitated by 
alterations in immune function that disrupt host-microbe homeostasis 
(Hajishengallis, Darveau, and Curtis 2012). The transition from a healthy 
microbiota to a dysbiotic community has been attributed to colonization with 
keystone pathogens (Hajishengallis, Darveau, and Curtis 2012). These 
pathogens initially subvert the host immune system leading to outgrowth of a 
dysbiotic microbiota, in which pathobionts promote aberrant host immune 
responses that drive destruction of tissues supporting the teeth (Darveau 2010). 
Inflammation and dysbiosis reinforce each other because inflammatory products 
of tissue damage, such as hemin from blood cells, feed the dysbiotic microbiota 
leading to a self-perpetuating cycle (Hajishengallis 2015). Like many other 
chronic diseases, periodontal disease is characterized by intermittent periods of 
remission and relapse.  
 
P. gingivalis is regarded as a keystone pathogen that orchestrates periodontal 
disease by remodeling the normal commensal microbiota into a dysbiotic one 
(Hajishengallis, Darveau, and Curtis 2012).  We propose that P. gingivalis lipid A 
species are crucial to the initiation and propagation of inappropriate inflammatory 




maturation of DCs, LPS from P. gingivalis induces a program of DC maturation 
that allows for constitutive antigen uptake and cross-presentation. Depending on 
the lipid A species that is expressed, this leads to constitutive T cell priming or 
tolerance. In the wild-type strain, the major lipid A species expressed was the 
immunologically silent tetra-acylated, non-phosphorylated variant (NP-LPS) 
which induced T cell tolerance.  We propose that this is the initial disease trigger, 
which drives global immune suppression and leads to the outgrowth of a 
dysbiotic microbial community. Studies in mouse models are consistent with this 
idea, where P. gingivalis has been shown to initially subvert the host immune 
system promoting its own survival and the elevating the overall microbial load. 
One of the inflammatory products of tissue breakdown is hemin, a component of 
red blood cells. When P. gingivalis is grown in the presence of excess hemin, the 
activity of the lipid A 1-phosphatase is suppressed, leading to the expression of 
tetra-acylated, mono-phosphorylated lipid (4P-LPS) which acts as a TLR4 
antagonist (Al-Qutub et al. 2006). When DCs were treated with this LPS variant, 
they induced constitutive cross-priming. We propose this switch leads to chronic 
immune activation and tissue destruction.  DCs treated with P. gingivalis LPS 
prime T cells with lower efficiency, providing an explanation for the low-grade 
inflammation that is the hallmark of P. gingivalis mediated disease. The activated 
T cells might be specific for commensal organisms, which could explain the loss 
of beneficial microbes. In this scenario, only other inflammophilic organisms with 




composition.  Notably, when expressed on the surface of the bacterium both NP-
LPS and 4P-LPS prevented the activation of pathogen-specific T cells. This 
would allow P. gingivalis to shift the balance between regulatory and effector 
immune responses, all the while promoting its own survival. We propose that 
hemin-dependent alterations in lipid A structure underlie the intermittent periods 
of remission and relapse that are characteristic of periodontal disease (Al-Qutub 
et al. 2006; Coats et al. 2009). Interestingly, waves of chronic inflammation are 
also a feature of many other inflammatory and autoimmune diseases, such as 
rheumatoid arthritis and multiple sclerosis. This leads to the alarming notion that 
keystone pathogens may underlie many chronic conditions.  
 
In addition to local immunopathology, P. gingivalis is implicated as a risk factor 
for numerous systemic diseases characterized by misdirected immune 
responses (Hajishengallis 2015). The aberrant activity induced by P. gingivalis 
LPS could on one hand, lead to a break in host tolerance to self-antigens or 
commensal bacteria, and on the other hand, induce global immune suppression. 
It is therefore not surprising that this organism is associated with diseases 
propagated by immunosuppression, such as cancer (Ahn, Segers, and Hayes 
2012; Tezal et al. 2009; Whitmore and Lamont 2014), as well as inflammatory 
diseases such as atherosclerosis, RA, and diabetes (Gibson and Genco 2007; 
Hayashi et al. 2011; Slocum et al. 2014; Hayashi et al. 2012; Levine 2013; 




translocation of LPS into the circulation, which is plausible given the low 
biological activity P. gingivalis LPS. In support of this hypothesis, a recent report 
found that DCs isolated from P. gingivalis infected mice constitutively prime T 
cells at both local and systemic sites (Mizraji et al. 2017).  
 
LPS as the key to the hygiene hypothesis 
Somatic recombination creates a diverse lymphocyte repertoire capable of 
specifically recognizing and responding to countless antigens. This provides an 
obvious advantage in terms of host defense against rapidly evolving 
microorganisms. However, by using randomly generated receptors that cannot 
reliably discriminate between self and non-self, adaptive immunity carries a 
significant risk of inappropriate immune reactivity (Steinman and Nussenzweig 
2002). Indeed, the advantages that accompanied the evolution of adaptive 
immunity came at a steep price, which is evident today more than ever. 
Autoimmune, allergic, and inflammatory diseases are reaching epidemic 
proportions in the industrialized world. Since the 1950’s, rates of asthma, celiac 
disease, type 1 diabetes, and multiple sclerosis have increased by 300% or more 
(Rubio-Tapia et al. 2009; Grimaldi et al. 2007; Podar et al. 2001). Malfunctioning 
of the adaptive immune system drives pathology in these conditions, particularly 
the T cell arm. This results in misdirected immune responses toward self-, 
environmental, or commensal-derived antigens. The mere presence of an 




T cell needs to be instructed by a DC to carry out its effector function. DCs 
orchestrate immune responses according to innate signals they receive from 
their microenvironment. What then might explain the soaring rates of immune-
mediated disorders in industrialized societies?   
 
In 1989, David Strachan formulated the hygiene hypothesis to explain the 
increased incidence of allergic and atopic disease in the western world (Strachan 
1989). He postulated that increased sanitation and reduced microbial exposures 
led to defects in immune tolerance. Over the years, this hypothesis has evolved 
to include the diverse communities of microorganisms that colonize the barrier 
surfaces of the body (Scudellari 2017; Round and Palm 2018). Commensal 
bacteria play a critical role in the development and homeostasis of the 
mammalian immune system (Ivanov and Honda 2012). They provide innate 
signals that educate the antigen-specific immune system, acting as endogenous 
adjuvants that regulate steady state immune function (Belkaid and Hand 2014). A 
healthy dialogue between host and resident microbes ensures optimal immunity 
to pathogens, while maintaining tolerance to self- and innocuous antigens 
(Belkaid and Harrison 2017). The observation that humans with immune-
mediated diseases house altered microbial communities suggests that 
pathogenesis might arise from improper training of the immune system by 





Until recently, a cogent hypothesis for how microbes might increase the risk of 
aberrant immune responses had not been put forth. A new study found that 
children with microbiotas that produce poorly immunogenic LPS are at risk for 
autoimmune and allergic disease (Vatanen et al. 2016). Specifically, Bacteroides 
doreii, which has previously been associated type I diabetes (T1D), was enriched 
in the microbiota of children with T1D autoantibodies, and its abundance 
correlated with antibody titers (Vatanen et al. 2016). The authors found that B. 
doreii LPS failed to elicit substantial cytokine production from DCs and inhibited 
cell activation by E. coli LPS, thus functioning as TLR4 antagonist (Vatanen et al. 
2016). They concluded that, “LPS from B. doreii inhibits the establishment of 
endotoxin tolerance and thus increases the risk of aberrant immune responses.” 
A flaw in this conclusion is that endotoxin tolerance is an innate immune 
phenomenon, whereas allergic and autoimmune diseases are driven by adaptive 
immune responses to self- and innocuous environmental antigens. The 
antagonistic lipid A expressed by B. doreii is nearly identical to the antagonist 
expressed by P. gingivalis, down to the last carbon including the number and 
positioning of phosphates and the acyl chain length, number, and distribution. 
Moreover, recent studies have shown that DCs isolated from P. gingivalis 
infected mice constitutively prime T cells of irrelevant specificity (Mizraji et al. 
2017). These observations suggest that the lipid A structures expressed by these 
organisms exhibit a distinct type of activity that increases the risk of aberrant 




structures represent the archetypal molecules of commensal bacteria that 









































































Figure 67. The antagonistic lipid A species synthesized by P. gingivalis and 
B. doreii. 
The antagonistic lipid A variants produced by P. gingivalis and B. doreii are both 
tetra-acylated bearing a phosphate at the C-1 position. The positioning and 
carbon length are nearly identical. We propose that these are the archetypical 




CD14 sits at the apex of adaptive immune responses to LPS 
Through chemical or biological modification of lipid A, the therapeutic benefits of 
this LPS derivative can be harnessed while limiting its toxicity (Needham et al. 
2013). MPLA is a well-known TRIF-biased adjuvant with properties that have 
perplexed the scientific community for decades (Mata-Haro et al. 2007; Casella 
and Mitchell 2008). The chemically detoxified compound is 1000 times less toxic 
than its derivative (Qureshi, Takayama, and Ribi 1982). MPLA is a weak inducer 
of TLR4/MD-2 dimerization, NF-kB/MAPK activation, and poorly stimulates pro-
inflammatory responses when compared to canonical lipid A (Casella and 
Mitchell 2013). And yet, it has been shown to be as effective or better in inducing 
T cell clonal expansion and Th1 responses (Thompson et al. 2005). These 
findings alone make it abundantly clear that the classical model of TLR4/MD-2 
dimerization cannot explain how this LPS derivative retains its potent immune 
adjuvant activity. It has been shown that, not only is MPLA TRIF biased, but it 
can induce the expression of TRIF-dependent genes at lower concentrations 
than canonical lipid A. In this report, we demonstrate similar properties for 4P-
LPS. This LPS variant is a well known TLR4/MD-2 antagonist. Like MPLA, it is a 
weak inducer of TLR4/MD-2 dimerization compared to its parental derivative (5P-
LPS). Furthermore, we demonstrate that it stimulates the expression of TRIF-
dependent genes at lower doses than 5P-LPS, and our results reveal a plausible 
underlying mechanism: an unusually high affinity for CD14. 4P-LPS potently 




transport TLR4 to endosomes where TRIF signaling can occur (Kagan et al. 
2008; Zanoni et al. 2011).  CD14 not only promotes TLR4 endocytosis, it also 
delivers LPS to MD-2, which can explain the ability of 4P-LPS to potently inhibit 
binding and cytokine production by stronger TLR4 agonists. Notably, MPLA has 
also been shown to function as an antagonist for endotoxic form of lipid A 
(Casella and Mitchell 2008). This suggests that the likely mechanism of action for 
therapeutically useful TRIF-biased immune adjuvants is a high affinity for CD14. 
Although more work will be needed to verify this conclusion, these findings may 
have major implications for the rational design of safe and effective immune 
system modulators. 
 
On the topic of CD14, a major finding of this work is that this LPS co-receptor sits 
at the apex of adaptive immune responses to LPS. We found that treatment of 
DCs with LPS from E. coli , P. gingivalis , and B. thetaiotomicron dramatically 
enhanced cross-presentation of peptides derived from antigens internalize by 
endocytosis or phagocytosis. Moreover, despite the fact that these LPS variants 
range in TLR4 agonist activity from silent to highly stimulatory, they all 
comparably enhanced cross-presentation and this required CD14. What do we 
propose is the underlying mechanism? The internalization and storage of LPS 
molecules. Mammalian cells have been shown to internalize and retain large 
quantities of LPS, and this process requires membrane CD14. We propose that 




subsequently accumulate on vesicles containing incoming cargoes. By 
sequestering microbial ligands, the DC retains information about the type of 
pathogen it has encountered and tailors phagosome maturation and antigen 
presentation accordingly. This explains why the effects of TLR engagement on 
phagosome maturation and antigen presentation are autonomous within the first 
few hours but then become global after prolonged exposure to microbial ligands 
(Alloatti et al. 2016). This hypothesis also explains our results with different lipid 
A variants. Even though all LPS species enhanced the efficiency of cross-
presentation, the subsequent immune response that was elicited was tailored to 
the type of LPS the DC had been exposed to. For instance, DCs treated with NP-
LPS cross-presented peptides as efficiently as E. coli LPS treated DCs but 
tolerized rather primed T cells.  
 
Another potential underlying reason for the key role of CD14 is that it is required 
to induce calcium flux and NFAT activation in response to LPS (Zanoni et al. 
2009). This process occurs selectively in DCs and not macrophages, and 
together with NF-kB, drives the expression of genes that are critical for adaptive 
immunity (Zanoni et al. 2009). These include IL-2, Nur77, and mPGES1 (Tan and 
Kagan 2014). IL-2 is a necessary growth factor for naïve T cell activation, 
whereas Nur77 is crucial for regulating DC life span after LPS stimulation (Tan 




efficient delivery of antigen to lymph nodes draining infected tissues (Zanoni et 





Chapter 8. Future Directions 
P. gingivalis lipid A variants as a therapeutic tool for immune system 
modulation  
The ability to elicit immunogenic antigen presentation in tumors is a critical 
determinant of successful cancer immunotherapy. To create a self-sustaining 
immune response, tumor antigens need to be cross-presented to activate a 
patient’s own T cells. Cross-presentation is enhanced during DC maturation and 
then down-modulated in fully mature cells (Gil-Torregrosa et al. 2004; Alloatti et 
al. 2016), providing a relatively narrow window for the induction of effective 
immune responses.  Developmental control of cross-presentation, coupled with 
the fact that DCs in the tumor microenvironment are profoundly dysfunctional, 
poses a significant challenge for immunotherapy (Sharma et al. 2018). Tumor 
antigens are abundant in the tumor microenvironment, and the fact that DCs 
treated with P. gingivalis LPS species retain their antigen sampling function is 
beneficial in this case, as it would allow for a wide variety of tumor-specific T cells 
to be activated, as opposed to vaccination with a single antigen. MPLA has been 
shown to be an effective adjuvant for cancer immunotherapy, and as discussed 
previously, we suspect that 4P-LPS has a similar mechanism of action and may 
also be therapeutically useful.  
 
Diseases caused by dysregulated immune activation, including autoimmune 




been recent advances in treatment, notably the development of anti-TNF 
biologics, therapies to date induce non-specific immunosuppression resulting in 
potentially severe side effects. A major advance in treatment of autoimmune 
syndromes would be the development of antigen-specific immune therapies- i.e. 
strategies to induce immune tolerance. We propose that bacteria expressing 
immunologically silent lipid A and an antigen of interest could be used to induce 
antigen specific tolerance in transplantation, allergy, or autoimmune disease. It is 
noteworthy that NP-LPS uncoupled the endocytosis of TLR4 from that of CD14 
and promoted T cell tolerance. Oxidized host lipids also uncouple the 
endocytosis of TLR4 and CD14 and fail to induce inflammatory gene expression, 
including the LPS mimetic oxPAPC (Zanoni et al. 2017). We propose that these 
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